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ABSTRACT 
  Over the recent years, the incidence of diabetes has significantly increased. Use 
of preventive services and treatment with oral antidiabetic drugs (OAD) has 
remained cornerstone in the management of type 2 diabetes (T2DM). Despite strong 
evidence that treating diabetes using these disease management strategies 
decreases morbidity, mortality and complications, glycemic control as well as other 
diabetes related outcomes remain unsatisfactory. The prevalence of diabetes in the 
United States has grown vastly in proportion over the last few years with the 
American Diabets Association estimating that 9.3% of the population suffered from 
diabetes in the year 2012. These estimates are expected to increase in the future 
with the World Health Organization (WHO) estimating that 366 billion people (4.4%) 
will have diabetes. Diabetes places a greater clinical as well as economic burden on 
the patients as well as the health care system. 
The presence of comorbid depression is frequent in people suffering from 
diabetes and can cause health outcomes in patients with diabetes. Poor adherence 
and persistence to diabetic medications resulting from the occurrence of adverse 
events is a cause of poor health as well as economic outcomes. There is a continuing 
need to evaluate the associations between comorbidities as well as common 
complications of medication treatment in persons with diabetes and examine how 
they influence health behavior. Evidence regarding differences in the utilization of 
preventive care services in diabetic patients with and without comorbid depression is 
scant. Similarly, the factors that predispose an individual to hypoglycemia as well as 
  
the association between hypoglycemic episodes and persistence to OAD therapy, 
specifically sulfonylureas, has rarely been quantified retrospectively. This dissertation 
utilizes the manuscript format and has four fold objectives: 
1. To review the current literature regarding the role of hypoglycemia and 
comorbid depression in the diabetes and examine their impact on clinical 
and economic aspects of diabetes management;  
2. To quantify the effect of comorbid depression on the rates of preventive 
care service use in a nationally representative population of US adults; 
3. To identify significant predictors and estimate the costs associated with the 
occurrence of hypoglycemia in the inpatient and outpatient settings. 
4. To evaluate the association between the development of hypoglycemia and 
persistence to oral sulfonylurea therapy in patients newly initiated on this 
class of OAD medications. 
In order to review the literature regarding the effect of hypoglycemia and comorbid 
depression and diabetes, we utilized various biomedical and psychological databases. 
We analyzed the effect of comorbid depression as a principal risk factor associated 
with use of ADA recommended preventive services in patients with diabetes using 
the Medical Expenditure Panels Survey Data. A logistic regression was performed to 
achieve this objective and all the relevant confounders were controlled for in order 
to achieve the results. Claims data provided by the Blue Cross and Blue Shield of 
Rhode Island was utilized to assess the relationship between hypoglycemia and 
persistence to sulfonylurea medication as well as outline the predictors and costs of 
  
hypoglycemia. A time-varying Cox proportional hazards regression model was utilized 
to compare the hazard rate of medication discontinuation in diabetic patients that 
were exposed to hypoglycemic events, compared to those that were unexposed. A 
predictive modelling approach was utilized to highlight the factors associated with 
hypoglycemia. 
While the impact of comorbid depression and diabetes was significant both clinically 
and economically, it was seen that the extent of preventive care service use was 
comparable for diabetic patients with and without comorbid depression but 
suboptimal in general thus indicating major gaps in the implementation of ADA 
recommended preventive care practices. While depression was not significantly 
associated with increased use of the recommended diabetes preventive care 
services, other sociodemographic factors were seen to contribute. Moreover, though 
no significant association between events of hypoglycemia and subsequent 
discontinuation sulfonylurea medication was illustrated, we demonstrated several 
clinical factors to have a profound impact on the risk of developing hypoglycemic 
episodes.
 v 
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To the reader: This dissertation utilizes the manuscript format, and is composed 
of four chapters relating to the evaluation of the role of hypoglycemia & comorbid               
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1.1 Diabetes  
Diabetes is a chronic metabolic disorder of characterized by different pathways. It 
results in hyperglycemia with an abnormality in the body’s capability to convert 
glucose (sugar) to energy. Type 2 diabetes (T2DM) is the most frequent subtype of 
diabetes since it accounts for up to 90% of all cases of diabetes worldwide.1 Diabetes 
is the seventh leading cause of death in the United States.2,3 Diabetes is the most 
significant cause of macrovascular and microvascular complications.4,5 Patients with 
diabetes have a lower quality of life as compared to people of the same age group 
without diabetes and it is even lower in cases of diabetes complications and disease 
progression.6-8  
Recent estimates put the prevalence of diabetes for individuals aged 20 to 74 
worldwide at 6.4% in 2010, and it is estimated that the prevalence would increase to 
7.7% (439 million patients) by the year 2030.9 It is one of the most prevalent, 
debilitating, and costly chronic conditions, both nationally as well as globally, 
resulting in substantial mortality, morbidity, and economic burden.4,5,10 During the 
last 20 years, the prevalence of diabetes has increased dramatically in many parts of 
the world and the disease is now a worldwide public health problem. The World 
Health Organization estimates that the total number of people with diabetes is 
projected to rise from 171 million in 2000 to 366 million in 2030.11 According to the 
American Diabetes Association (ADA), the prevalence of diabetes in the United States 
was about 9.3% in the year 2012 with 29.1 million people diagnosed with this 
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disorder according to the Centers for Disease Control (CDC), which was significantly 
higher than the 25.8 million (8.3%)reported in previous years.12,13 In addition to this, 
another 7 million people are estimated to be suffering from undiagnosed diabetes 
and 86 million are estimated to suffer from prediabetes.14 The CDC estimates that 
among U.S. residents aged 65 years and older, 10.9 million, or 26.9%, had diabetes in 
2010.15 This number is projected to rise rapidly with the ageing of the population and 
the corresponding increase in the prevalence of chronic conditions.2,16,17 Danaei et al. 
in a study to estimate the undiagnosed diabetes prevalence as a function of a set of 
health system and sociodemographic variables, found that prevalence of diabetes in 
the U.S. was 13.7% among men and 11.7% among women ≥ 30 years.18 Previous 
studies have noted major cultural and racial variations in the prevalence of 
T2DM.13,19,20 According to the ADA, 12.6% non-Hispanic blacks have T2DM compared 
to 7.1% non-Hispanic whites in the United States, with the highest prevalence of 
diabetes found in the southern states.13,21  
In a recent study by the ADA to estimate the total economic cost of diabetes for the 
United States, it was demonstrated that in the year 2007 the economic burden was 
estimated to be $174, approximately 1 of 8 dollars spent on medical care, as 
compared with $98 billion in 1997.10,22,23  In the same year, the approximate total 
cost for treating diabetes was $232 billion. Moreover, the total costs of diabetes had 
increased to $245 billion with $176 billion attributable to direct medical costs and 
$69 billion to lost productivity.10 After adjusting for population age and sex 
differences, average medical expenditures among people with diagnosed diabetes 
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were 2.3 times higher than those in the absence of diabetes.10 Literature suggests 
that a high degree of health care resource use can be attributed to diabetes namely 
hospital inpatient days (25.7%), nursing/residential facility days (33.3%), prescription 
medications, and visits to the physician, emergency room, hospital outpatient etc. 
Previous research suggests that these estimates are higher in cases of uncontrolled 
diabetes and diabetes with complications.10 
The increasing prevalence of the disease and thereby its economic as well as social 
impact emphasizes the importance of effective diabetes prevention and care. 
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1.2 Use of Preventive Services in Diabetes 
Apart from being a major cause of heart disease and stroke, diabetes poses an 
increased risk of cardiovascular, peripheral arterial and cerebrovascular diseases.24-26 
Previous studies also note a much higher proportion of non-traumatic lower limb 
amputations, kidney failure and blindness in diabetic patients.26 A number of studies 
have concluded that timely utilization of medical and preventive care is an ideal 
practice for the management of diabetes.27,28 These services can be vital in the 
incidence and progression of any diabetes specific complications.29 Controlling blood 
glucose, blood pressure, and LDL cholesterol levels can reduce the microvascular 
complications like eye, kidney, and nerve diseases as well as macrovascular 
complications like heart attack, stroke, and lower-extremity amputations. For 
example, Litzeman et al. in a blinded, randomized, controlled trial of patients in an 
academic general medicine practice setting found that better foot care in patients 
with diabetes were likely to have reduced prevalence of lower extremity clinical 
disease.28 One of the principal preventive services in patients with diabetes is the 
testing the A1C which might demonstrate the patient’s blood glucose levels. 
Similarly, routine eye exams diagnose symptoms of diabetes related eye disease and 
this early detection is usually instrumental in preventing the progression this disease. 
Comprehensive foot care programs include assessment and treatment of feet of the 
diabetes patient and can help reduce amputation rates. Other preventive tests 
include timely immunization against pneumococcal disease and influenza as well as 
regular blood pressure and medical checks.   
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1.3 Depression  
Major depressive disorder (MDD) is a grave and recurrent condition affecting around 
121 million people worldwide. The World Health Organization (WHO) recognizes 
depression as the fourth leading cause of disease burden associated with non-fatal 
health outcomes and a leading cause of disability around the world.30 It has been 
widely reported in the literature that depression is often underdiagnosed and under 
treated.30,31 Even though the scenario with respect to treatment rates has been 
positively changing in the past decade, many patients still suffer from symptoms of 
depression.32 Gonzalez et al. in a study of a large national sample found that majority 
of the people suffering from depression did not get the guideline recommended 
degree of care and large disparities existed based on various factors like race and 
ethnicity.33  
Kessler et al. in a study using the National Comorbidity Survey Replication (NCSR) 
suggested that in the United States, the lifetime prevalence of depression was 16.2% 
and the 12-month prevalence was 6.6%.32 Bromet and colleagues, in a study 
conducted in in over 18 countries reported that the average lifetime prevalence of 
depression was 14.6% in high-income countries and 11.1% in middle to low income 
countries.34 Mathers et al. in a study projecting mortality and burden of disease by 
cause to year 2030 found that depression was predicted to hold the second position 
among diseases contributing to the global burden of diseases by 2030 , and there has 
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been a 37% increase in disability-adjusted life years of  depression from the year 
1990 to 2010.35  
Evidence from studies suggests apart from being a major cause of morbidity, 
mortality and disability, MDD is responsible for higher economic costs by means of 
health care resource use as well as indirect costs including workplace absenteeism, 
diminished, or lost work productivity and increased use of healthcare resources.6,36-38 
This economic burden of depression has been evaluated in several studies nationally 
as well as worldwide. For example, Greenberg et al. estimated the burden of 
depression in the United States to be $104 billion divided as $33 billion (31%) in 
medical care; $6 billion (7%) in mortality due to suicide; and $65 billion (62%) in 
workplace productivity losses.39 It has also been noted that the costs of depression 
increased from $77.4 billion in the year 2000 to $83.1 billion in the year 2010.40 
Similarly, Luppa et al. in a systematic review of cost of illness studies of depression 
estimated that the average annual costs per case ranged from $1000 to $2500 for 
direct costs, from $2000 to $3700 for morbidity costs and from $200 to $400 for 
mortality costs.41 Working people with depression have a lower degree of 
productivity in terms of higher rates of absenteeism and reduced on-the-job output 
and can lead to disability.42-44 Greenberg et al. noted that lost productivity accounted 
for more than 60% of the total social economic burden of depression in the US in 
2000, which was estimated at $52.9 billion.39 Stewart et al. in a study of employed 
individuals, who participated in the American Productivity Audit, reported that 
people with depression lost 5.6 hours of productive work every week.45 Pratt et al. 
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examined data from Data from the National Health and Nutrition Examination Survey 
(NHANES) and concluded that 80% of people with depression reported some level of 
functional impairment because of their depression, and 27% reported serious 
difficulties in work and home life.44 
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1.4 Comorbidity of Diabetes and Depression 
A large body of literature has highlighted the association between diabetes and 
depression.46-48 The essential finding in the aforementioned analyses has been that 
that diabetes and depression co-occur frequently with the presence of once 
condition significantly increasing the likelihood of patient suffering from the 
other.48,49 A systematic review by Roy and colleagues suggested that prognosis of 
comorbid depression in patients with diabetes, in terms of its clinical and societal 
implications, is worse for either condition in comparison to when they occur 
individually.50  
1.4.1 A Bi-Directional Relationship between Diabetes and Depression 
In a review of literature Egede et al. noted that previous research indicated a 
complex relationship between diabetes and depression because the temporality of 
this association is not clear.6 There is a growing body of evidence, which suggests 
that there exists a bidirectional relationship between these two chronic disorders.51 
Moreover, several physiological and behavioral mechanisms have been studied to 
explain this possible link between diabetes and depression. Mezuk et al. in a meta-
analysis of studies from 1950 to 2007 of diabetes and depression, established that 
people with depression had a 60% increased risk of developing diabetes compared to 
non-depressed patients while people with diabetes had a 15% increased risk of 
developing depression compared to non-diabetics.52 Pan et al. studied women over a 
10 year period and found that the relative risk for T2DM in women with depressed 
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mood  was higher as compared to those who were non depressed (OR 1.17; 95% CI 
1.05–1.30).53 Studies have found incidence of depression as a modifiable 
independent risk factor in the onset of diabetes.54-56 Golden et al. performed a 
longitudinal study depressive symptoms at baseline were associated with an 
increased incidence of T2DM at follow-up over a 3-year period; an increased risk for 
developing depressive symptoms over the 3-year period was associated with treated 
T2DM, but conversely baseline impaired fasting glucose and untreated T2DM were 
associated with reduced risk for depression.51 The increased risk of developing 
diabetes might be due to the negative physiologic effects of depression on glucose 
metabolism as well as neuroendocrine and autonomic nervous systems.54 Similarly, 
diabetes can also act as a precursor to depression through various clinical and 
psychological mechanisms.50 Poor metabolic control and increasing complications as 
a result of diabetes may result in or further worsen depression and lessen response 
to antidepressant treatment.6,50 For example In a study of 1,586 older adults from 
the Rancho Bernardo study, Palinkas et al. reported that there was a 3.7- fold 
increase in odds of depression in those with a prior diagnosis of diabetes.57 Thus, as 
suggested in a recent meta-analysis, there is lack of concrete information supporting 
the direction of relationship between diabetes and depression with there being 
clinical and epidemiological support for both hypotheses.58  
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1.4.2 Prevalence of Depression in Diabetes 
It is well documented that depression is significantly higher in patients with diabetes 
as compared to the general population.48,59 Anderson et al. and Egede et al. found 
that the odds of suffering from depression among patients with diabetes are two fold 
as compared to the patients without diabetes.47,49 Ali et al. in a systematic literature 
review in order to estimate the prevalence of clinically relevant depression in adults 
with T2DM had similar results with odds of suffering from comorbid depression being 
nearly twice among diabetic patients (OR = 1.6, 95% CI 1.5–1.7).48,60 These findings of 
diabetic population being more likely to suffer from depression have been reaffirmed 
by World Mental Health Surveys, which indicate an elevated risk of mood (OR=1.38) 
and anxiety disorders (OR=1.20) in patients with diabetes compared with persons 
without diabetes.60 The reported prevalence of depression in patients with diabetes 
varies widely due to an array of factors but most studies estimate that 10 -30% of 
individuals with diabetes suffer from various forms comorbid depression with some 
studies indicating that the rates may be as high as 39%.47,49,61,62 Li et al. examined 
data from the 2006 Behavioral Risk Factor Surveillance System (BRFSS), a 
standardized telephone survey of U.S. adults aged 18 and older and found that the 
age adjusted rate of depression was 8.3%.63 In a second study by the same authors 
investigating the prevalence of undiagnosed depression among individuals with 
diabetes found the adjusted and unadjusted prevalence of undiagnosed depression 
to be 8.7% and 9.2%, respectively.64 Maraldi and colleagues, in a secondary analysis 
from the Health ABC study, a prospective cohort (n=3,075) of community-dwelling 
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adults who are aged between  70 and 79 years, found an increased risk of depressed 
mood among people with diabetes.65 D Groot et al. found that the lifetime 
prevalence rates of major depression among patients with diabetes to range from 
14.4% to 39% which are approximately three times higher than the rates in general 
population.66 A population-based epidemiologic study conducted to determine the 
behavioral and clinical characteristics of diabetes associated with depression found 
that 501 of 4,193 study participants (12%) met Diagnostic and Statistical Manual of 
Mental Disorders–Fourth Edition (DSM-IV), criteria for MDD and 357 participants 
(8.5%) met criteria for minor depression (10-7,8).67 Ali et al. also found that the 
prevalence of depression was significantly higher among patients with T2DM (17.6%) 
than those without diabetes (9.8%).48 
1.4.3 Clinical Implications Of Comorbid Diabetes And Depression 
The clinical implications of occurrence of comorbid depression in patients with 
diabetes are of serious concern since it is associated with poorer diabetes 
outcomes.48,68 Apart from having a negative impact on the physical, mental and social 
wellbeing of the diabetic patients, it might also have implication on quality of life, 
rates of mortality and morbidity.49 Studies have shown that depression is associated 
with a higher number of diabetes complications and can exacerbate the severity of 
these complications.50,52,54,69 A meta-analysis by De Groot and colleagues 
demonstrated a clinically significant relation between depression and several diabetic 
complications like retinopathy, nephropathy, neuropathy, sexual dysfunction, and 
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macrovascular complications.66 Lustman et al. found that depressive symptoms in 
patients are associated with decreased glycemic control.70 Richardson et al. assessed 
the longitudinal effects of comorbid depression on glycemic control and observed 
that depression was associated with persistently higher A1C levels over the time 
period.71 Moreover, Katon et al. in a study of 4,225 patients from nine primary care 
clinics of a nonprofit health maintenance organization found that patients with MDD 
and diabetes, with or without evidence of cardiovascular disease, were 1.5 to 2 times 
as likely as nondepressed patients with diabetes to have ≥3 cardiac risk factors.72 In 
another study of 10,704 Medicare beneficiaries in the U.S, Katon et al. reported that 
beneficiaries with diabetes and comorbid depression had a 36–38% increased risk for 
all-cause mortality over a 2-year period.73 In a study of 10,025 patients from the 
NHANES I Epidemiologic Follow-up Study, Egede et al. found that hazard rates for all-
cause mortality for individuals who had diabetes and depression were 2.50 (95% CI 
2.04–3.08) compared with those without diabetes or depression and concluded that 
comorbid depression is associated with a significantly higher risk of death.74 
1.4.4 Quality Of Life In Patients With Diabetes And Comorbid Depression 
In addition, it is increasingly evidenced in the literature that presence of comorbid 
depression in diabetes is significantly associated with deterioration of various quality-
of-life indices such as physical, mental, and social functioning.75-77 For example, in a 
study investigating the effects of depression on the quality of life in type II DM 
patients with and without current major depressive episode diagnosed according to 
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DSM-IV criteria, Eren et al. found a significant decline in quality of life in individuals 
with comorbid depression and diabetes.78 Various instruments have been used in 
studies which have proved treatments and complications in patients with comorbid 
depression and diabetes adversely affect the quality of life of these patients.76  
1.4.5 Health Care Resource Use In Patients With Diabetes And Comorbid Depression 
Previous studies evaluating health care expenditures and utilization have found 
comorbid depression and diabetes are associated with higher direct and indirect 
health care costs due to greater use of resources,  lost work time and disability. 49,79-
81 Simon et al. in a study assessing the relative contributions of diabetes 
complications, depression and comorbid medical disorders to health service costs in 
adults with diabetes, found that the health care costs were 70% higher in individuals 
with comorbid depression and diabetes.82 Analyzing a nationally representative 
survey in the United Kingdom, Das-Munshi et al. found an increased use of health 
care resources among diabetic patients with depression in the form of higher 
frequency of hospital admissions and physician visits.83 Finkelstein et al. found that 
treatment of depression was associated with greater use of inpatient and outpatient 
medical services.81 Himelhoch et al. found that a diagnosis of depression was 
associated with greater use of acute care services (emergency department and 
inpatient care) among Medicare beneficiaries with diabetes and other chronic 
medical conditions.84 Using Medical Expenditure Panel Survey (MEPS) data, Egede et 
al. found that self-reported history of depression was associated with higher total 
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health service costs ($247,000,000 vs. $55,000,000, P value < 0.0001)among 
respondents with diabetes.49 In a sample of 367 health maintenance organization 
members with diabetes, Ciechanowski et al. found that higher Hopkins Symptom 
Checklist depression scores were associated with significantly higher health service 
costs, with severe depression accounting for up to 86% higher costs.80 In a study of 
55,972 adults with diabetes, Le et al. found that patient with diabetes and depression 
had higher diabetes-related medical costs ($3,264) than patients with diabetes alone 
($1,297). They also found that depressed patients with diabetes had higher total 
medical costs ($19,298) than patients without depression ($4,819).6 Egede et al. 
found that adults with diabetes and depression were more likely to miss more than 7 
workdays in any given year.85 
1.4.6 Self Care Behaviors In Patients With Diabetes And Comorbid Depression 
Self-care behaviors are of highly critical in the management of diabetes since patients 
with comorbid depression and diabetes are at a higher risk for worse health 
outcomes as compared to individuals with a single disorder.86 Clinical management 
guidelines stress the importance of self-care behaviors in diabetes including 
adherence to dietary recommendations, diabetic knowledge, adequate physical 
activity and exercise, smoking cessation, adherence to prescribed medication and 
other therapies and timely monitoring of blood glucose.55 Previous research indicates 
that patients with comorbid depression and diabetes have lower rates of adherence 
to these patient initiated components of diabetes care.66,87 For example, in a study 
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examining the impact of depression on adherence to oral hypoglycemic agents 
(OHAs) of patients identified from a Medicaid claims database using Medication 
Possession Ratio (MPR), Kalsekar et al. indicated that patients with depression had 3-
6% lower adherence to OHAs compared with patients without depression.88 There is 
also evidence to suggest lower adherence rates to other medication regimens as a 
result of co-existing depression in diabetes.55 Apart from non-adherence to 
medications, higher body mass index (BMI) and tobacco use are concerning aspects 
of poor self-care behaviors since they might cause insulin resistance and increased 
morbidity in patients with diabetes.67 Gonzalez et al. in a study examining the 
relationship between comorbid depression and diabetes self-care behaviors noted 
that controlling for relevant covariates, patients with comorbid depression and 
diabetes reported significantly fewer rates of adherence to a full range of self-care 
behaviors along with a 2.3-fold increase in the likelihood of missing medication 
doses.89 
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1.5 Oral Hypoglycemic Agents And Goals Of Therapy 
Previous research has identified some of the principal goals of oral antidiabetic 
therapy. ADA proposes a glycated hemoglobin (A1C) level of less than 7% and 
preprandial blood glucose level of 80–120 mg/dL, a bedtime blood glucose level of 
100–140 mg/dL.90,91  
Garber et al. and Grant et al. have demonstrated that oral hypoglycemic agents 
(OHAs) were effective in lowering A1C by 1–2%.92,93 Achieving lower A1C levels has 
demonstrated a significant beneficial impact on reducing diabetes related micro and 
macro vascular complications including retinopathy, nephropathy and neuropathy.94-
97 Results of the U.K. Prospective Diabetes Study (UKPDS) suggested that for every 
percentage-point reduction in A1C, it is possible to achieve a 22% to 35% reduction in 
microvascular complications.97,98 However, previous literature does not clearly define 
the advantages of intensive therapy to achieve lower A1C levels while reducing 
macrovascular and microvascular complications.99 With these goals in mind, the 
selection of a particular agent is based on factors such as clinical and biochemical 
characteristics of patient, safety concerns, severity of diabetes as well as the 
available therapeutic options. Recent advances in research have presented clinicians 
with a plethora of oral medications which are effective in controlling hyperglycemia 
associated with T2DM as well as managing diabetic complications, thus making the 
decision making process complex. Moreover, most of the patients  require 2 or more 
medications to achieve the desired glycemic control over a period of time.100 In 2011, 
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there were 8 classes of oral medications approved by the FDA for treating T2DM such 
as – biguanides, sulfonylureas, meglitinides, thiazolidinediones (glitazones), alpha-
glucosidase inhibitors, DPP-4 inhibitors, bile acid sequestrants, dopamine-2 
agonists91,101. Mann et al. using a series of cross sectional surveys, reported that the 
proportion of US adults who took 2 classes of medications was 35% with an increase 
of  6% to 14% in the number of patients who took 3 or more classes of medication.102 
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1.6 Hypoglycemia in T2DM  
Hypoglycemia is one of the most common as well as dangerous side effects of T2DM 
therapy. Even though it is well proven in evidence that tighter glycemic control may 
be instrumental in reducing the risk of other serious complications of T2DM like 
retinopathy, neuropathy, and nephropathy, it can also present an additional risk of 
severe hypoglycemia. In many T2DM patients, hypoglycemia is responsible for 
recurrent morbidity and at times, can be a cause of mortality thereby creating a 
barrier to the long term benefits of optimal glycemic control.103 Cryer et al. in a 
comprehensive review of literature mentioned that though there is no concrete 
evidence with respect to the frequency of hypoglycemic episodes in T2DM patients, 
the rates of severe episodes requiring medical attention in patients on intensive 
insulin therapy varied from 3 to 73 episodes per 100 patient-years, which was about 
10% of those in Type 1 Diabetes.103-105 The United Kingdom Prospective Database 
Study (UKPDS) reported that 2.4% of patients using metformin, 3.3% of patients 
using a sulfonylurea, and 11.2% of patients using insulin reported incidents of severe 
hypoglycemia requiring medical attention over the 6 years of follow up period with 
hypoglycemia becoming a limiting factor to glycemic control over a period of time.106 
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1.7 Persistence to OADs in T2DM  
Medication persistence or conforming to the recommendation of continuing 
treatment for the prescribed length of time is an important issue in the long term 
management diabetes considering the chronic nature of the disease and the nature 
of the treatment regimen intended to achieve the desired glycemic targets.107 
Cramer et al. in a review of literature to determine the extent to which patients fail 
to comply with the doses of medications prescribed for diabetes noted that the rates 
for treatment persistence ranged from 16 to 80% when the patients continued taking 
their medications for at least 6-24 months. The authors noted that the 
methodologies followed by the researchers varied in that the cross-overs to an 
alternative OHA or insulin might not have been counted as discontinuation.108 
Bocuzzi et al. conducted a retrospective analysis of a large administrative pharmacy 
claims database, using data on continuously pharmacy benefit-eligible members 
prescribed OHAs, reported that the 12-month persistence rate for the OHA cohort 
was low, ranging from 31% for alpha-glucosidase inhibitors to 60% for metformin.109 
Guénette et al. studied the 1-year treatment persistence and compliance of new oral 
antidiabetic drug (OAD) users and found that 79.3% of the cohort members persisted 
with the therapy during their first year of antidiabetic treatment.110 In another 
literature review, Cramer et al. reported that 45% of the individuals who newly 
initiated oral antidiabetic therapy were non adherent to the regimen and almost 33% 
of the patients discontinued their therapies in 12 months.108 Other past studies have 
reported persistence estimates for oral antidiabetic medications from a low of 15% 
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to a high of 76% with the variations attributed to differences in methodologies, 
definitions of persistence as well as length of the follow up periods. Non-persistence 
with therapy most often leads to failure in meeting glycemic goal thus leading to 
avoidable undesirable adverse health outcomes.111 
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1.8 Conclusions 
It is clear from the above literature review that issues with diabetes management are 
highly prevalent and are significantly associated with negative health and economic 
outcomes. The coexistence of diabetes and depression also results in compromised 
self-care behaviors which are essential in the management of both the diseases 
especially diabetes. Of greater importance among the self-care behaviors is the 
suboptimal utilization of preventive care services since these are particularly 
essential in preventing the complications in diabetes. Similarly, medication 
persistence and hypoglycemia are issues affecting the achievement of desired 
glycemic goals. There is a need to develop strategies to address both patient and 
other health care related factors in order to increase the potential effectiveness of 
disease management in diabetes. A multifactorial approach might be essential to 
counter the adverse health effects of comorbid diseases as well as adverse effects of 
diabetic medications in patients with diabetes. 
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2.1 Background and Significance 
The American Diabetes Association (ADA) publishes Clinical practice guidelines for 
persons with diabetes annually. These guidelines are evidenced based and are 
intended to improve the quality of care for patients with diabetes.112 Evidence from 
previous research has been instrumental in the development of several clinical 
practice guidelines that are intended to improve the quality of care for diabetes 
patients112. These recommendations suggests that adherence to these recommended 
guidelines is likely to have a positive impact on the morbidity and mortality related to 
diabetes thereby reducing the clinical as well as economic burden of diabetes as well 
as improving the management of diabetes.12,27,28,113,114  
Despite this knowledge, the use of the clinical preventive services in the U.S. adult 
population is suboptimal and is quite variable.115 For example, The Healthy People 
2020 initiative, reported low levels of use of multiple clinical preventive services for 
diabetes as well as other diseases.116 Previous research suggests the use of 
preventative services ranges from 10% to 85%, depending on the particular 
service.117 Evidence from population-based studies in various settings also indicates 
that there is a significant difference between reported levels of use of preventive 
care practices among people with diabetes and the degree of recommended use for 
optimal level of care.118 This discrepancy might be primarily attributed to the effects 
of race/ethnicity, income, health insurance coverage, and comorbidities.119-121 For 
example, Pu et al., in a study to explore potential mediators linking race/ethnic 
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disparities to reduced receipt of preventive care found that patients were less likely 
to receive diabetes preventive care if they were younger in age, Hispanic, resided in 
rural areas, had lower family income and were uninsured.12  
While implementing preventive care measure on a population scale can be costly, the 
potential long-term health benefits can certainly offset the healthcare expenditures 
over time. To date, many published studies of preventive care services focused solely 
on individuals who are diagnosed with diabetes alone.113,122 However, preliminary 
data suggests that comorbid depression may have an effect on use of preventive 
services among other treatment recommendations persons with diabetes.49,112,123,124 
There is a paucity of conclusive research concerning use of diabetes specific 
preventive care service in patients suffering from comorbid depression and diabetes 
with some studies yielding an increased rate of receipt of diabetes preventive 
care49,125,126 while others indicating lower degree of use82,127,128 or no significant 
association.129,130 For example, Lin et al. conducted a study of 4,463 patients in a 
large health maintenance organization to assess whether diabetes self-care, 
medication adherence, and use of preventive services were associated with 
depressive illness.112 This study did not find an association between major depression 
and receipt of preventive services for diabetes. In contrast, in a study of 4,398 adult 
health plan members with diabetes conducted by Simon et al, reported that 
depression was associated with lower visit rates for preventive services.82 Given the 
conflicting evidence on the use of preventive services in patients with both diabetes 
and depression and the need for improvement in the levels of preventive service use, 
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we sought to quantify the effect of comorbid depression on rates of preventive 
service utilization.70,131 For our study, we focused on five important preventive 
services, including: 1) A1C testing; 2) Diabetic Foot Exam; 3) Lipid check; 4) Influenza 
Vaccination; 5) Dilated Eye Exam; 6) Routine Medical Checkup. 
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2.2 Methods 
2.2.1. Study Design and Data source 
To achieve the aims of our project, we conducted a retrospective cohort study 
among adult patients (18 years of age or older) with diabetes. Our study utilized 
components of the Medical Expenditure Panel Survey (MEPS), a publicly available 
dataset collected by the Agency for Healthcare Research and Quality (AHRQ).132,133 
MEPS is a large-scale nationally representative survey of U.S. non-institutionalized 
population, medical providers, and employers. The MEPS utilizes a national 
probability-sampling scheme and collects household and individual-level data on 
medical service utilization information and can be used for cross-sectional or 
longitudinal analysis.134-137 The data set is unique in terms of its sample size, 
composition and provides a set of variables, which are hypothesized to influence the 
receipt of diabetes preventive care. The MEPS sampling frame is drawn from a 
subsample of households included in the previous year’s National Health Interview 
Survey (NHIS) conducted by the National Center for Health Statistics (NCHS).137 The 
MEPS sample design includes stratification, clustering, multiple stages of selection, 
and over sampling of certain racial and ethnic minority populations.136,137 
To achieve the aims of the MEPS, AHRQ employs an overlapping panel designs 
(Appendix 2.2) approach to identify preliminary contacts followed by interviews 
during five separate in-person rounds with purposeful oversampling of certain groups 
(e.g., low income, racial minorities).138 A new panel of sample households is selected 
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each year, and data for each panel are collected during two consecutive calendar 
years. The overlapping design of the MEPS provides information on the same people 
several times during the year, allowing for repeated observation analyses.139 To 
account for the complex design and sampling scheme of the MEPS, sampling weights 
are published for each survey which when utilized adjusts for the complex survey 
design and survey nonresponse. In addition, the weights allow extrapolation to 
reflect rates of medical service utilization in the US general population as derived 
from the Current Population Survey.133,136,137,140 
In addition to the overarching design of the survey, the MEPS collects several types of 
data that are useful for conducting healthcare research. There are three principal 
components of the survey; the Household Component (HC), the Insurance 
Component (IC), and the Medical Provider Component (MPC).141  For this study, we 
included the HC and several sub-surveys that were useful for our analyses. The 
household component (HC) file of MEPS, considered the core survey, collects 
demographic characteristics, health conditions, self-rated health status, medical 
services use, access to care, satisfaction with care, health insurance coverage status, 
and income for each person surveyed for a period of two years.136,139 During 
interviews, all participants are also questioned regarding healthcare use services and 
medical and mental health treatment including prescription drugs and mental health 
counseling. Within the HC, the Medical Conditions (MC) file reports information on 
health conditions and procedures reported by respondents during the survey. The 
medical conditions and procedures reported by the household component 
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respondent are recorded by the interviewer as verbatim text, which is then coded by 
professional coders to fully specified International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes, including medical condition and V 
codes.142 However, to preserve confidentiality, the MEPS data includes only 3-digit 
ICD-9 CM codes in the publicly available research files. To foster data analyses, the 
MEPS data provide Clinical Classification Codes (CCCs), derived by using the Clinical 
Classifications Software (CCS) disease categorization scheme which aggregates ICD-9-
CM codes into clinically meaningful categories, grouping similar conditions into one 
CCC. To minimize underreporting of medical conditions and procedures, the 
interviewers use a variety of techniques.137    
Since we were primarily interested in assessing the use of preventive care in patients 
with comorbid depression and diabetes the preventive services for diabetes, we 
specifically utilized the Diabetes Care Survey (DCS) supplement.143 The DCS a special 
self-administered paper-and-pencil questionnaire fielded Rounds 3 and 5. 
Households received a DCS based on their response to question regarding a health 
professional communicating with the individual that he or she has diabetes. The DCS 
specifically collects information regarding the diabetes related medical care that is 
received by the patients, including medications and previous diagnostic tests 
including the receipt of preventive services by the individual in the recent past. 
Linking this survey, administered once a year over two years, with the household 
components enables a complete examination of the diabetes related health care 
received by the patient.136  
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2.2.2 Study Cohort 
To gain adequate sample size and construct an analytical study cohort for our 
analyses, we selected data for individuals from households in Panels 12, 13, 14, 15, 
16 coinciding to MEPS survey years of 2008-2011. Data for each year was constructed 
based on six rounds of interviews, rounds 1-3 for the panel that was initiated that 
year and rounds 3-5 for the panel that was initiated in the previous year. Information 
attained in each round of the interviews pertains to a specific frame of time known as 
reference period. Thus, the study reference period begins from 1st January 2008 for 
panel 12 round 5 and ends on 31st December 2011, which is the end of the last 
reference period. Table 2.1 provides an overview of the panels and rounds from 
which the study cohort was selected with respect to the year. Within these included 
years, we focused on all respondents aged 18 years or older, who self-reported a 
diagnosis of diabetes with a positive sampling weight.   
2.2.3 Cohort Eligibility-Identification Of Diabetes 
We defined the inclusion criterion for the study sample as the presence of diabetes in 
individuals, with or without comorbid depression. We identified diabetes-using 
patient self-report in answering to survey question regarding diabetes, where 
respondents were asked, “Have you ever been told by a doctor that you have 
diabetes ?”.143   If the individual responded affirmatively, we considered them eligible 
for entry into the final cohort. Individuals who were aged 17 years or younger and 
those who responded “not sure,” “don't know,” “refused” or “missing.” were 
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considered ineligible59. Similarly, we excluded cases of gestational diabetes. During 
the process of this survey, every person who reported to have received a diagnosis of 
diabetes was further asked to complete the DCS. In previous studies, Richard et al. 
and Dismuke et al. have utilized similar procedures to recognize diabetic population 
in this dataset to investigate the racial disparities in the quality of diabetes care and 
association between major depression, number of depressive symptoms and 
personal income among the diabetic population respectively.68,139 
2.2.4 Exposure Definition-Comorbid Depression 
To conduct our retrospective cohort study, we created two groups, 1) those with 
comorbid depression, and 2) those without comorbid depression.  We identified 
study participants with depression using individual’s self-reports as well as diagnosis 
codes captured on the MC survey. As part of the MC survey, the two-item, Patient 
Health Questionnaire (PHQ-2) is collected from participants. The PHQ-2 is a 
previously validated instrument to identify depression. The PHQ-2 was designed to 
report the feelings of depressed mood and anhedonia in patients over the past 2 
weeks, with the scores ranging from 0 ("not at all") to 3 ("nearly every day") for each 
criterion. Kroenke et al. reported that the PHQ-2 has a 83% sensitivity and 92% 
specificity for identifying major depression.144,145 Utilizing this information, we 
identified survey respondents with a score of ≥3 on the PHQ-2 as having comorbid 
depression. To comprehensively identify persons with depression and taking into 
account some respondents may have not demonstrated signs of depression at the 
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time of survey (e.g. symptoms managed with antidepressant medication); we further 
identified individuals who had reported ICD-9 CM codes 311, 296 or a CC code 657 or 
both. Egede et al. suggested that for approximately 70% of the MEPS population in 
the year 1996, ICD 9 CM code 311 was appropriate.49 Kim et al. in a study to assess 
the impact of workplace injury on depression and identify the potential risk factors 
associated with post-injury depression in the US working population, used ICD 9 CM 
codes 296 and 311 to identify depression in the study population.146 Similarly, 
Bhattacharya et al. identified depression using the CCC 657 to examine the excess 
risk of chronic physical conditions associated with depression.147 Frayne and 
colleagues developed an algorithm to identify the patients with depression, which 
utilizes a more inclusive set of codes, namely 296 and 311.148 
The prevalence of depression in the final study cohort was 25.8% with 1,208 patients 
suffering from depression as identified by the self-reported PHQ-2, ICD 9 CM/CC 
codes or both. Of the 4,668 identified respondents, 731 had a score of 3 or higher on 
the depression scale. Of these, 288 had an ICD 9 CM/ CC code for depression while 
443 respondents did not record an ICD 9 CM/ CC code for depression. Out of the 
3,937 respondents who did not have a score of 3 or higher on the depression scale, 
477 respondents (12.1%) had an ICD 9 CM/ CC code for depression and therefore we 
classified them as having comorbid depression. Thus, the final sample for inclusion 
included 1,208 persons with depression and 3,460 persons without depression. 
Figure 2.1 outlines the process of selecting the patients with diabetes and comorbid 
depression.   
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2.2.5 Outcome: Use of Preventive Services in the Past Year 
The main outcome variable of this study was the suggested use of diabetes 
preventive care services according to the ADA guidelines. The self-reported receipt of 
seven recommended diabetes-specific preventative services was examined within 
the past year using the DCS, based on the inclusion in the MEPS and consistent with 
the guidelines of the national organizations.91 For this study, the seven outcomes of 
focus were annual receipt of:  
1. Hemoglobin A1C (A1C) testing 
2. Foot exam 
3. Dilated eye exam 
4. Influenza vaccination 
5. Cholesterol testing 
6. Blood pressure screening 
7. Physical exam 
   
For information regarding the frequency testing of the hemoglobin A1C, the 
individuals were asked about the number of times a doctor, nurse or other health 
professional checked their blood for A1C in the past year. In contrast, questions with 
reference to the remaining preventive care services were constructed in a manner 
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which asked the respondent to report the last time they underwent a preventive 
service in the recent past (alternatives restricted to same year, past year, year before 
past year, not in the past 2 years and never had the preventive service). Using this 
information, we created seven binary outcome variables for each of the self-reported 
preventive health care utilization over the prior year. Table 2.2 summarizes the MEPS 
questions asking about use of these services, the coding scheme for the receipt or no 
receipt of these services and the ADA recommendations  for the services.91 During 
the study, respondents with missing data reported for any of the preventive services 
were considered ineligible for further analyses.  
2.2.6 Identification of Potentially Confounding Factors 
Based on the available literature, we identified and evaluated a set of socio-
demographic characteristics that was associated with differences in the use of 
preventive care services in patients with comorbid depression and diabetes. The 
variables describing demographic status of the person were constructed as per the 
self-reported status of the person on the 31st of December of the survey year. These 
variables are updated in every round of data collection. Since the DCS was a cross-
sectional survey, the variables represented current status only. In our study analyses, 
some categories of the variables were merged and reconstructed to have a 
preferable distribution of the population within these categories. These factors 
included age (18–34 years, 35-49 years, 50-64 years and 65 and above), gender (male 
versus female), marital status (married, widowed/divorced/separated and never 
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married), race/ethnicity (Hispanic, White non-Hispanic, black non-Hispanic and 
others), income level based on the federal poverty line (FPL) (poor/near poor [<125% 
FPL], low income [125% -<200% of FPL], middle income [200%-<400 of FPL] and high 
income [>400% of FPL]), educational status (less than a high school degree, high 
school degree, advanced education and others), perceived health status (excellent or 
very good, good and others), health insurance status (private insurance coverage, 
public insurance coverage only, uninsured), insulin use (Yes versus No), Metropolitan 
Statistical Area (MSA; MSA versus Non-MSA), employment status (Employed versus 
not employed), Body Mass Index (BMI; underweight [BMI <18.5], normal weight [BMI 
≥18.5 and ≤24.9], overweight [BMI ≥25.0 and ≤29.9] and obesity [BMI ≥30.0 ]) and 
smoking status (Yes versus No). 
2.2.7 Identification of Comorbidities 
Based on the available literature, we identified and evaluated a set of socio-
demographic characteristics that was associated with differences in the use of 
preventive care services in patients with comorbid depression and diabetes. The 
variables describing demographic status of the person were constructed as per the 
self-reported status of the person on the 31st of December of the survey year. These 
variables are updated in every round of data collection. Since the DCS was a cross-
sectional survey, the variables represented current status only.15 In our study 
analyses, some categories of the variables were merged and reconstructed to have a 
preferable distribution of the population within these categories.138  
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Comorbidities were defined by using the patients’ clinical records in the medical 
conditions file. The CCCs were used to identify presence of clinically relevant 
comorbidities. The methodology defined by Machlin et al. was used to select 
comorbidities based on sample size considerations and relevance to association with 
use of preventive care services.149 Single or multiple CCCs were chosen to define each 
comorbidity and the presence of each comorbidity was recorded as a dichotomous 
variable. Appendix 2.3 provides more detailed information on the identified 
comorbidities including the CCCs that utilized to ascertain each of the comorbidities. 
2.2.8 Statistical Analysis 
As we conducted a retrospective cohort study, we conducted all analyses comparing 
the two created exposure groups, those with comorbid depression (n= 1,208) and 
those without comorbid depression (n= 3,460). We first checked for comparability in 
background characteristics of the two groups focusing on age, gender, comorbidity 
conditions, and other aforementioned socio-demographic factors. This was done to 
understand and profile the study population and identify potentially confounding 
factors between the two groups. We generated descriptive statistics within each of 
the groups including means and standard deviations for continuous variables and 
percentages were reported for categorical variables. We examined differences 
between the two exposure groups using the Pearson's chi-square test or Fisher exact 
test for categorical variables and T tests for continuous variables.  
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After baseline comparison of the two exposure groups, we next assessed the 
prevalence of use of preventive care service use in the diabetic population with and 
without depression. Percentages were reported to compare the use of preventive 
services between diabetic individuals with and without depression. To further 
quantify the effect of comorbid depression on use of preventive services after 
controlling for confounding, we employed logistic regression modeling.  We 
identified potentially confounding variables that varied between the two exposure 
groups (during bivariate analyses). In addition to these, variables of known clinical 
importance (age, gender race/ethnicity) were selected as potential confounders.  
Initially, we constructed unadjusted odds ratios for use of preventive care services in 
diabetic patients with and without comorbid depression. Then, we used a series of 
multivariate logistic regression models to determine the independent effect of 
comorbid depression on the use of preventive services. Controlling for all the 
aforementioned patient level covariates that might influence the use of preventive 
services, we calculated the adjusted odds of receiving at least 2 A1C tests, a diabetic 
foot examination, an eye examination, an influenza vaccination, a blood cholesterol 
check and a routine medical checkup in the past year. Because of the complex survey 
design of the MEPS HC file, we used special diabetes weights from MEPS to compute 
robust standard errors of the estimates.150  
During the process of building the logistic regression models for each mentioned 
preventive care services individually, we used a non-computer generated stepwise 
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approach. Variables that were identified as potential confounders in the bivariate 
analysis were added to the model for each service sequentially in the order on the 
largest significant difference between the depressed and non-depressed groups with 
respect to the particular variable. Thus, nested models were fitted in an iterative, 
manual process using an inclusion threshold of a 10% change in the β estimate of the 
principal independent variable, comorbid depression (indicator of exposure group). 
Iterations continued in this manner until the most parsimonious model was fitted. At 
the end of this process, we added all the excluded variables back to the final model 
to assess the potential for residual confounding. This model with all the variables was 
compared to the final model constructed at the end of the stepwise process. We 
used the Akaike Information Criterion (AIC) at this step of the model building process 
since AIC is asymptotically equivalent to cross-validation and the bootstrap, two most 
popular validation methods. We conducted a Hosmer and Lemeshow Goodness-of-
Fit Test to examine the fit of the model as well as a likelihood ratio test to evaluate 
the final fitted model151-154. We further assessed multicollinearity in the model. For 
this purpose, we used the variation inflation factor (VIF), tolerance and eignevalues 
to make the decisions on exclusion of collinear variables. These were calculated 
utilizing a separate regression model and specifically using the VIF, TOL, and Collin 
options. If two variables were found collinear, we included the variable that was 
clinically more relevant to our analysis. All statistical tests were conducted with two-
tailed alpha 0.05. At the end of this process, we compared the models using the 
above procedures and selected the best fitting model. We then reported 
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multivariable (adjusted) odds ratios (AORs), including their respective 95% 
confidence intervals (95% CI). 
Due to the clustered and correlated nature of the survey data, analyses were 
conducted using SAS software, Version 9.3 (SAS Institute Inc., Cary, N.C.) and SAS 
callable SUDAAN, Release 9.0.1 (Research Triangle Institute, Research Triangle Park, 
N.C.) to account for complex survey design.155 This study was reviewed and approved 
as exempt by the University of Rhode Island’s Institutional Review Board. 
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2.3 Results 
2.3.1 Final Cohort 
Within the four years of MEPS data utilized for our analyses (2008-2011), we 
identified 138,030 survey respondents included in the dataset. Figure 4 describes the 
steps that were followed for the selection of final cohort of respondents. As per the 
recommended data estimations procedures, we did not consider respondents with 
non-positive person level weights for further analyses since only data for persons 
with a positive person-level weight can be used to make estimates for the civilian no 
institutionalized U.S. population. Further, we restricted the population to 
respondents who were above 17 years of age, who had responded “yes” to the 
question regarding diabetes and had a positive diabetes weight, which adjusts for 
DCS nonresponse and weights to the number of diabetics in the US civilian non- 
institutionalized population. This selection process resulted in the initial sample of 
7,780 respondents with diabetes. Out of this population, only the respondents who 
had information on all the required variables were selected for the study. Thus, the 
final sample for the study comprised of 4,468 respondents. This sample size 
represented 60% of the population that was eligible for the study.  
The prevalence of depression in the final study cohort was 25.78% with 1,208 
patients suffering from depression according to the self-reports of PHQ-2 or ICD 9 
CM/CC codes or both (Figure 2.1). Moreover, 288 patients had depression according 
to the PHQ score as well as ICD 9 CM/ CC code for depression while 443 respondents 
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did not record an ICD 9 CM/ CC code for depression even though they had a PHQ 
score 3 or more. Out of the 3,937 respondents who did not have a score of 3 or 
higher on the depression scale, 477 respondents had an ICD 9 CM/ CC code for 
depression and were considered as suffering from comorbid depression.  
2.3.3 Demographic and Clinical Characteristics of the Cohorts of Individuals With and 
Without Depression 
Table 2.3 presents an overview of the descriptive statistics of the final sample of 
individuals with diabetes and compares the demographics characteristics of the 
sample by depression status. With respect to depression status, those with existing 
comorbid depression were primarily between ages 50 and 64 (42.2%), females 
(59.2%), married (50.88%), high school graduates (49.1%) and non-Hispanic whites 
(72.7%). A high fraction of these respondents with depression had a fair or poor 
perceived health status (55.04%), private health insurance coverage (54.1%), did not 
use insulin (63.2%), resided in metro areas (78.6%), were not employed (65.2%), 
were overweight (87.1%), were nonsmokers (79.2%) and had a primary care 
physician (94.6%).  
Apart from a few variables (metro status, primary care provider status and insulin 
use), all the other variables demonstrated statistically significant differences with 
respect to the depression status among individuals with diabetes. With respect to the 
age groups, people with diabetes and comorbid depression were more likely to   be 
in the age groups 35-49 (17.8%) and 50-64 (42.2%) as compared to people without 
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comorbid depression (15.4% and 36.9% respectively p=0.002). In contrast, people 
without comorbid depression were more likely to be in the age group 65 and above 
(38.7% vs 30.7%). With respect to gender, the proportion of women in the comorbid 
depression group was higher as compared to those in the non-depressed group 
(59.2% vs 48.5%, p <0.001). Individuals with diabetes and depression were more 
likely to be unmarried as compared to people suffering from diabetes alone (49.1% 
vs 36.8%, p <0.001). In contrast, the percentage of people without comorbid 
depression and diabetes was significantly higher in the high income group as 
compared to the people with comorbid depression and diabetes (40.6% vs 25.9%, p 
<0.001). The prevalence of higher education was significantly lower in the 
respondents with comorbid depression and diabetes as compared to the 
respondents without comorbid depression (16.4% vs 23.3%, p = 0.001). With respect 
to the racial and ethnic distribution of the population, people with comorbid 
depression and diabetes are more likely to be non-Hispanic whites as compared to 
the diabetic people without depression (72.7% vs 66.8%, p=0.003). A significantly 
higher proportion of people with comorbid depression and diabetes reported being 
in fair or poor health status in contrast to the individuals with only diabetes (55.0% vs 
25.0%, p <0.001). In comparison to the individuals without depression, people with 
depression were more likely to have some form of public insurance (37.7% vs 25.7%, 
p < 0.001). There was a lower proportion of depressed people with current 
employment (34.5% vs 50.2%, p=0.001) and normal BMI status (10.2% vs 14.2%, p = 
0.013) in contrast to the non-depressed diabetic individuals. Respondents with 
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comorbid depression and diabetes were more likely to be smokers that the 
respondents with diabetes alone (18.6% vs 12.8%, p < 0.001). 
The prevalence of selected comorbidities was significantly higher in diabetes patients 
with comorbid depression as compared to the patients with diabetes alone. Table 2.4 
outlines the differences in the diabetic patients with and without comorbid with 
respect to the presence of clinically significant comorbidities. It could be seen that 
heart disease (16.4% vs 10.4%, p<0.001) and injury (16.1% vs 11.2%, p=0.005) were 
reported more frequently in diabetes patients with comorbid depression relative to 
patients suffering from diabetes alone. Similarly, back disorders (23.6% vs 15.2%, 
p<0.001), upper respiratory disorders (20.1% vs 14.1%, p=0.003) and thyroid 
disorders (17.3% vs 13.2%, p=0.023) had a higher prevalence in patients with 
comorbid depression and diabetes. Overall the most prevalent comorbidity for 
patients in the final cohort was hypertension, with patients suffering from comorbid 
depression and diabetes having a higher occurrence of hypertension than the 
patients with diabetes alone (78.6% vs 73.0%, p=0.004). Similarly, the reported rates 
for hyperlipidemia were high and differences between the diabetic patients with and 
without depression were remarkable (74.2% vs 67.9%, p=0.001). The occurrence of 
cerebrovascular disease (8.4% vs 4.9%, p=0.004), urinary tract infections (9.3% vs 
6.4%, p=0.037), headaches (11.6% vs 4.3%, p<0.001) and anemia (6.6% vs 4.2%, 
p=0.018) was also higher amongst the diabetic patients with comorbid depression. 
Differences in the rates of kidney disease (6.8% vs 6.6%, p=0.874) and eye disorders 
(10.1% vs 9.3%, p=0.554 were not significantly different in the diabetic patients with 
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and without comorbid depression. Similarly, the prevalence of epilepsy and 
convulsions (1.9% vs 0.9%, p=0.077), gall bladder disease (2.4% vs 2.1%, p=0.713), 
hernias (3.1% vs 2.3%, p=0.322) and osteoporosis (3.0% vs 2.8%, p=0.758) was 
relatively low and not significantly different between the two groups. In summary, 
the most frequently occurring comorbidities in the final cohort hypertension, 
hyperlipidemia, and back disorders while the least prevalent comorbidities were 
epilepsy and convulsions, gall bladder disease and osteoporosis. 
2.3.4 Prevalence of Use of Preventive Care Services In the Diabetic Population 
Table 2.5 describes the estimates of diabetes specific preventive care behaviors. In 
the final sample, about 79.1% of the people reported having undergone an A1C test 
in the previous year. Similarly, about 52.1% of the respondents reported having 
undergone an annual diabetic foot examination in the past 12 months while 65.8% of 
the sample reported having their blood cholesterol in the previous year. About 49.9% 
of the individuals with diabetes reported taking an influenza vaccine in the past year 
while 51.2% reported having a retinal eye examination performed during the past 
one year. Majority of the respondents indicated that they underwent a blood 
pressure check (96.8%) and a routine medical checkup (89.1%). 
Examining the trends in the use of these services, it could be seen that there were 
significant changes observed over the four years of data for some preventive care 
services. There was a steady increase in the rate of A1C testing, with 83.5% of the 
respondents reporting undergoing an A1C test in past year for data year 2011 as 
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compared to the 79.1% who disclosed testing for A1C in the last year for data year 
2008. Similar results could be seen for the diabetic foot exam, in which case the rate 
for testing in the past year rose from 49.8% in 2008 to 56.4% in 2011 representing a 
weighted increase of almost 7 percentage points. Rates for blood cholesterol checks 
progressed from data year 2008 (65.0%) to data year 2010 (73.4%) but exhibited a 
slight decline for the data year 2011 (72.9%). The number of respondents who 
reported taking an influenza vaccination also displayed an increase of approximately 
6% from data year 2008 (50.0%) to data year 2011 (56.3%). There was a significant 
rise in the number of people who reported having a retinal eye examination in the 
previous year with 49.2% respondents having undergone the test in data year 2008 
and 58.6% respondents having their eyes tested in data year 2011. 
Figure 2.3 describes the differences in the use of preventive services by presence or 
absence of comorbid depression. It was seen that people with comorbid depression 
(82.4%) had a higher rate of undergoing more than one A1C test in the previous year 
as compared to people without comorbid depression (80.4%). Similar results were 
found for annual diabetic foot exams (56.6% vs 52.3%), annual lipid check (71.1% vs 
68.8%), annual influenza vaccination (53.7% vs 52.7%) and blood pressure checks 
(98.1% vs 97.3%). In contrast, with respect to annual dilated eye examinations (52.3% 
vs 54.0%) and annual routine medical checkup (88.6% vs 90.6%), people without 
comorbid depression had a higher rate of receipt of these services. 
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2.3.5 Multivariable Modeling-the Effect Of Comorbid Depression On The Receipt Of 
Diabetes Preventive Care Services. 
 Crude and adjusted odds ratios with the 95% confidence intervals from multivariate 
logistic regression models describing the associations between presence of comorbid 
depression in diabetes and receipt of the preventive care services are described in 
Table 2.6. Among patients with diabetes, patients with depression were significantly 
more likely to receive >1 A1C tests in the previous year (Crude Odds Ratio [COR] 1.19; 
95% Confidence Interval [CI] = 1.01-1.44). However, after adjusting for confounding 
factors the receipt of A1C tests were not statistically significant (Adjusted Odds Ratio 
[AOR] = 1.03; 95% [CI] 0.83-1.28). Similarly, in unadjusted analyses, patients suffering 
from comorbid depression and diabetes are 20% more likely to receive an annual 
diabetic foot exam as compared to patients without comorbid depression (COR 
=1.20; 95% [CI] 1.01-1.44), which did not persist after adjustment  (AOR= 1.12; 95% 
[CI] 0.94-1.34). The unadjusted odds of patients with comorbid depression and 
diabetes receiving an annual lipid check were slightly higher than diabetic patients 
without depression (COR =1.11; 95% [CI] 0.94-1.32). These differences, however, 
were statistically insignificant. In adjusted analyses, depression had an insignificant 
association with the receipt of an annual lipid check in patients suffering from 
comorbid diabetes and depression (AOR= 1.07; 95% [CI] 0.88-1.30; p=0.47). The 
association between receipt of an annual influenza vaccination and presence of 
comorbid depression in diabetes was statistically insignificant in both unadjusted 
(COR =1.06; 95% [CI] 0.88-1.28; p=0.66) as well as adjusted analysis (AOR= 1.02; 95% 
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[CI] 0.83-1.25; p=0.87). Depression was not significantly associated to the receipt of 
an annual dilated eye examination in patients with diabetes. The odds of receiving an 
annual dilated eye exam was marginally lower for patients with comorbid depression 
and diabetes in both unadjusted (COR =0.94; 95% [CI] 0.79-1.11; p=0.45) and 
adjusted analyses (AOR= 0.93; 95% [CI] 0.76-1.12; p=0.44), but these differences 
were statistically insignificant after adjusting for confounding factors. 
Contrary to other preventive services, before adjusting for the specified confounders, 
people with comorbid depression and diabetes were less likely to receive a routine 
medical checkup as compared to the diabetic patients without depression (COR 
=0.80; 95% [CI] 0.63-0.99; p=0.04). However, similar to the results for other 
preventive services that were explored, these differences between people with and 
without depression were not significant after controlling for various socio-
demographic and clinical factors.  
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2.4 Discussion 
Using a nationally representative probability survey, we performed a study that had 2 
principal goals. The first was to examine patterns of preventive care service use 
among individuals with and without diabetes using data on non-institutionalized 
civilian US population. The second was to examine the relationship between the 
status of comorbid depression and receipt of diabetes specific preventive health 
practices. This study advances the current body of literature regarding the 
differences in the quality of preventive care in diabetic patients with and without 
comorbid depression by exploring the impact of depression as an independent factor 
on receipt of these services.  
The ADA recommends that diabetic patients have their blood A1C test done twice a 
year if their glycemic control is meeting its goals and quarterly in case of poor 
glycemic control or changes in diabetic management. The ADA further recommends 
diabetic patients to undergo certain other preventive care practices like diabetic foot 
exam, retinal eye exam, influenza vaccination, blood cholesterol check and a routine 
medical checkup annually.91,156 From the results of this study, we conclude that a 
significantly high percentage of the American diabetic population that was studied 
did not receive the recommended standard of care, thus highlighting the need and 
opportunity for improvement in the status of preventive care among adults with 
diabetes. For instance, nearly half of the study population did not receive a diabetic 
foot exam, influenza vaccination and dilated eye exam in the past year. In this study, 
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we observed that the levels of use of certain preventive services were considerably 
lower than those previously reported.22,116 For example, Harris et al. in a study of the 
Behavioral Risk Factor Surveillance System data examining the change in rates of 
adults with diabetes receiving 4 essential preventive care services found that the 
overall age adjusted rate of receiving all 4 preventive care services increased from 
10% in 1997 to 20% in 2007, but remained suboptimal. In the same study the 
proportion of adults receiving an annual foot examination was reported as 69% while 
that of receiving a pneumococcal vaccination was mush lower at 39%.157 Beckles et al 
assessed the use of preventive care services, concluding that most adults do not 
meet recommendations for standards of diabetes care with only 72% of the patients 
visiting a health care provider for diabetes care at least once, 61% having their feet 
inspected at least once, and 61% reporting having received a dilated eye exam.118 
Moreover, Pu at al reported that among diabetes patients, 74% received the 
recommended levels of A1C tests, compared to  65% getting a foot exam and an 63% 
receiving an eye exam.12 Moreover, based on a cross-sectional observational study 
conducted by Wang et al. using the Medical Expenditure Panel Survey (MEPS) from 
2005, the percentage of people receiving an annual diabetic foot exam, annual 
cholesterol check and annual influenza vaccination was demonstrated to be 74.3%, 
89.5%, 57.5%, respectively.22 Similarly, according to a study based on National Health 
and Nutrition Examination Survey (NHANES) and Behavioral Risk Factor Surveillance 
System survey (BRFSS), the proportions of annual foot exams (68.3%), annual 
cholesterol checks (84.6%), and annual influenza vaccinations (52.5%) were all 
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suboptimal. According to the Centers for Disease Control and Prevention (CDC), the 
age adjusted estimates of adults >18 years of age who reported receiving preventive 
care practices were 68.5% for receiving > 1 A1C test and 67.5%, 50.1% and 62.8% for 
an annual diabetic foot exam, influenza vaccination and dilated eye exam 
respectively.158 Gold et al. in a study of patients receiving care at Federally Qualified 
Health Centers (FQHCs) found that 32% of OCHIN (Our Community Health 
Information Network) patients with diabetes received a flu vaccination in 2005, 36% 
an LDL screening, 54% at least one HbA1c screening, and 21% a nephropathy 
screening. In our study, the proportions observed on these services were 81.0%, 
53.4%, 69.4%, and 53.5% respectively for >1 A1C tests, annual foot exam, annual 
cholesterol check, annual influenza vaccination and annual dilated eye examination 
in the previous year. This suboptimal use of preventive services is a major concern for 
policy makers since the benefits of implementing these services on reducing the 
mortality as well as micro- and macro-vascular complications of diabetes are well 
documented. It has also been reported widely in literature that timely receipt of foot 
care and eye examinations reduce the risk of foot complications by 50-60% and that 
of severe vision loss by approximately 60% in people with macular edema and 90% in 
people with proliferative retinopathy.156 Thus, it is imperative that strategies be 
designed to ensure effective mechanisms are in place to deliver preventive care that 
adheres to the standards recommended by the ADA.156  
Our study demonstrates that depression is not significantly associated with increased 
use of the recommended diabetes preventive care services. To our best knowledge, 
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this study adds substantially to the scarce literature that examines the effect of 
depression on the use of diabetes specific preventive care services. Other studies 
have yielded inconclusive findings with respect to differences in the utilization of 
preventive services in patients with and without depression.112,127,128,130,159 Before 
adjusting for clinically relevant covariates, presence of depression was associated 
with associated with the receipt of three diabetes specific quality of care indicators 
within the past year—an A1C measurement, a diabetic foot check, a retinal eye 
examination, with depressed people more likely to undergo the recommended levels 
of A1C testing and diabetic foot testing but less likely to undergo a retinal eye 
examination. However, after controlling for various demographic and health 
characteristics, we found that comorbid depression did not significantly influence the 
likelihood of receipt of these services. Our findings are consistent with some previous 
conducted studies that have concluded that presence of depression is not associated 
with higher use of preventive care services.124,128,156,160 Lin et al. found that major 
depression was mainly associated with patient-initiated behaviors that are difficult to 
maintain (e.g., exercise, diet, medication adherence) but not with preventive services 
for diabetes.112 Similarly, Egede et al. in a study to examine the effect of minor and 
major depression on self-care behaviors and quality of care among adults with 
diabetes, found no significant association between both major as well as minor 
depression and use of preventive care services like A1c testing (AORs 1.02, 95% 
CI[0.80 – 1.31] and 0.84, 95% CI [0.68 – 1.04] respectively) and diabetic foot exams 
(AORs 0.88, 95% CI [0.72 – 1.08] and 0.81, 95% CI [0.62 – 1.04] respectively).128 Desai 
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et al. studied the relationship between mental disorders and quality of diabetes care 
in a national sample of veterans and found that diabetic patients with or without 
depression did not differ significantly with respect to the receipt of A1C tests (AOR 
0.98, 95% CI [0.88 – 1.08]) and diabetic foot examinations (AOR 1.06, 95% CI [1.00 – 
1.12]).130 Similarly, Hutter et al. in a meta-analysis to review the impact of comorbid 
mental disorders on healthcare costs in persons with diabetes reported inconclusive 
evidence for differences in the use of retinal eye examinations.159 
The  results of our study are in contrast to some studies in the literature that 
conclude that coexisting major depression was associated with lower rates of 
preventive care service use in patients with diabetes and comorbid depression than 
in those without depression.112,128,159 For example, Jones et al. compared the use of 
preventive health services among diabetes patients with and without mental 
disorders during the years 1996 – 2001 and demonstrated a lower hazard ratio (HR) 
of A1C determinations (HR 0.92; 99.9% confidence interval [CI] 0.87-0.97) as well as 
cholesterol checks (HR 0.92; 99.9% CI 0.86-0.98) in patients with diabetes and mental 
disorders.127 Moreover Egede et al., after adjusting for clinically relevant covariates, 
individuals with minor and major depression were significantly less likely to receive a 
dilated eye examination (AORs 0.81, 95% CI [0.66 – 0.99] and ⁎ 0.70, 95% CI [0.54 – 
0.89] respectively) in the past year and a flu shot in the past 12 months with the 
latter significant only in patients with minor depression (AOR 0.79, 95% CI [0.65 – 
0.95]).128 Similarly, Simon et al. assessed the contribution of depression as one of the 
factors affecting health service costs in adults with diabetes and found that rate of 
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outpatient preventive care visits in patients with diabetes and depression was lower 
as compared to those without depression (SMD −0.09 [95% CI −0.16, −0.01]).82 
 The likely explanation for the non-significant results with respect to depression and 
receipt of preventive services is that various patient characteristics likely affect the 
rates of service receipt. In our study, depression was not found to be a significant 
factor increasing the frequency of A1C  testing. However, factors like age, race and 
ethnicity, income levels, BMI status, marital status, insulin use, presence of a primary 
care provider and comorbidities like hypertension, hyperlipidemia, and anemia were 
found to be significant predictors of A1C testing. These findings are similar to other 
studies analyzing the effects of patient characteristics on receipt of diabetes 
services.12,113 DeVeo et al. conducted a secondary analyses of data from 6,562 
diabetic individuals aged >17 years of age and found that the odds of receiving this 
test increased with increase in age and in people with higher incomes.138 Hu et al. 
found that both non-Hispanic black and other minority adults had a lower likelihood 
of reporting receiving a hemoglobin A1C measurement at least once in the past year 
compared with non-Hispanic white adults.15 He et al. concluded that primary care 
physicians and practice features seem to steer diabetes preventive services.24 In 
contrast, other studies do not find any significant association between these factors 
and annual testing for A1C.123 In our study, there no significant association was 
evident between depression and receipt of a diabetic foot exam after adjusting for 
various covariates. We observed several other vital patterns in the receipt of this 
test. Age, race and ethnicity, insulin use and comorbid hyperlipidemia were found to 
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be significant predictors of the likelihood of undergoing this test. Previous studies 
have shown some of these factors to be associated with odds of receipt of a diabetic 
foot exam annually.12,15,122,138 On the other hand, our results were in contrast to 
some studies that did not find a significant association between these 
sociodemographic characteristics and use of preventive services.118,139,161 In both 
unadjusted and adjusted analyses, depression was not significantly associated with 
receiving an annual lipid exam. In adjusted analyses, we uncovered associations 
between this preventive care service and some independent variables like age, race 
and ethnicity, insulin use as well as co-existence of hyperlipidemia. Various studies 
have found age to be significantly associated with the receipt of an annual 
cholesterol screening.12,15,138,162,163 With respect to the relationship between 
race/ethnicity and the likelihood of undergoing an annual lipid exam, our results are 
corroborated by some studies12,163 but are in contrast to results of others.15,138 
Although the effect of depression was insignificant on the likelihood of receiving an 
annual influenza vaccination, we found that in adjusted analyses age, race/ethnicity, 
insulin use, and comorbidities were significant predictors of a flu shot. Our findings 
suggesting that other factors (apart from depression) may be related to the lack of 
receipt of preventive services rather than depression itself. These findings are 
consistent with previous reports that provide an evidence of a strong association 
between these factors and receipt of the preventive service.119,138,163 After we 
controlled for the effects of all other sociodemographic covariates, depression was 
not found to significantly affect the receipt of an annual retinal eye examination. 
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However, as mentioned in the previous literature, we found that several covariates 
like age, educational status, smoking status, marital status, presence of primary care 
provider and comorbidities that we adjusted for in the multivariable logistic 
regressions, had a significant association with the receipt of a dilated eye 
examination. Richard et al. reported that elderly patients with college degrees were 
more likely to report receiving an eye examination compared to those who did not 
complete high school. Similarly, other studies have also concluded that age, marital 
status, comorbidities.15,118,138,161,162 Though depression was found to be insignificantly 
associated with a receipt of a routine medical checkup in the previous year, we found 
several demographic characteristics that affected the receipt of this recommend 
quality of care indicator, a finding supported by DeVeo et al. who found a significant 
association between routine medical check and factors like age, geographic region 
and income.138 
The findings of this study are unique and add to the body of literature regarding the 
impact of depression on diabetes specific preventive care services. It confirms that in 
a large population of non-institutionalized patients with diabetes, the overall rates of 
receiving diabetes specific preventive care services are sub-optimal. Though the self-
management of diabetes has been widely considered as having a beneficial effect on 
control of the disease, we found that major gaps in the use of ADA recommended 
preventive care practices persisted.118 Our findings suggest that, as reported earlier, 
there is a need for policy makers and physicians alike to place greater emphasis on 
diabetes preventive care practices.59 Many patient related factors contributing to 
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differing levels of health care use and overall health of patients were found 
significant in our analyses. Our findings could be vital in the management of diabetic 
patients with depression since it will allow researchers to focus on specific action 
areas that need greater importance and attention since they could affect these self-
care activities critical to health outcomes.59 It also highlights an insignificant 
association between presence of comorbid depression and adherence to ADA 
recommended levels of diabetes preventive care. Patients that suffered from 
depression in our study, though statistically insignificant, were marginally more likely 
to receive these recommended tests. This might be attributed to the higher 
frequency of visits to the physicians, since most of these are physician-initiated 
activities.164,165 Age, racial differences, insulin use, socioeconomic factors and access 
to care measured by presence of primary care physician emerged as principal factors 
related to use of diabetes specific preventive care services.  
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2.5 Limitations And Conclusions 
The interesting findings of this study should be viewed in context of some study 
limitations. Primarily, one limitation was the use of self-report in diagnosing both 
diabetes and depression and for identifying use of studied preventive services. As 
with all the observational studies that utilize self-reports in their design, the study 
had potential for recall bias. Further, MEPS does not provide information about 
several measures of diabetes severity.  For example, the MEPS does not collect 
information on the presence of micro albuminuria, serum cholesterol levels (LDL-C), 
or A1C levels in patients. It would be interesting to see if better quality of care results 
in better health outcomes as measured by these quality indicators.123 Undiagnosed 
diabetes as well as severe diabetes is known to be critical factors that affect diabetes 
care and outcomes. It was not possible to account for these factors.161 The issue of 
surveillance bias and measuring the disease severity were beyond the scope of the 
study. In case of this bias, stratification is often seen as a remedial measure. 
In conclusion, our study provides valuable insights into the differences in use of 
diabetes preventive services with evaluation of the effect of depression as a 
comorbid condition. The extent of use of preventative services was comparable for 
diabetic patients with and without comorbid depression but suboptimal overall. 
Many of the factors that were found significantly associated with the use of 
preventive services are modifiable and hence strategies and interventions focusing 
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on these could improve the outcomes in diabetes patients. This data also 
demonstrates the need to study effective management of depression in diabetic 
patients since depression potentially affects various self-care activities. Future 
research should focus on the underlying causes of this suboptimal use of preventive 
services as well as establishing a causal relationship between depression and self-
care behaviors.  
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Table 2.1: Distribution of Panels, Rounds, and Population for the Data Years 
Year Panels Rounds Total Population 
2008 
12 3,4,5 
33,066 
13 1,2,3 
2009 
13 3,4,5 
34,920 
14 1,2,3 
2010 
14 3,4,5 
31,228 
15 1,2,3 
2011 
15 3,4,5 
33,622 
16 1,2,3 
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Table 2.2: Preventive Services: ADA Recommendations, Survey Questions and 
Coding Schemesa 
Preventive 
Service 
ADA Recommendations Coding 
Scheme 
Survey Questions 
A1C Testing 
Perform the A1C test at 
least two times a year. 
(0,1) 
During 2007, how many 
times did a doctor, 
nurse, or other health 
professional check your 
blood for glycosylated 
hemoglobin or 
"hemoglobin A-one-C"? 
Dilated Eye 
Exam 
Perform an annual 
dilated eye exam. 
(0,1) 
Which of the following 
year(s) did you have an 
eye exam in which your 
pupils were dilated? 
This would have made 
you temporarily 
sensitive to bright light. 
Diabetic Foot 
Exam 
Perform an annual 
comprehensive foot 
examination. 
(0,1) 
Which of the following 
year(s) did a doctor or 
other health 
professional check your 
feet for any sores or 
irritations? 
Lipid Screening 
Perform an annual lipid 
screening examination. 
(0,1) 
Which of the following 
year(s) did you have 
your blood cholesterol 
checked? 
Influenza 
Vaccination 
Have an annual 
influenza vaccination. 
(0,1) 
Which of the following 
year(s) did you get a flu 
vaccination (shot or 
nasal spray)? 
Blood Pressure 
Check 
Blood pressure should 
be measured at each 
routine visit. 
(0,1) 
How long since last 
blood pressure check? 
Regular 
Medical 
Checkup 
Perform an annual 
medical checkup. 
(0,1) 
How long since last 
routine check-up by 
doctor or other health 
professional for 
assessing overall 
health? 
a: Adapted from Standards of medical care in diabetes91  & Diabetes Care Survey (DCS)143 
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Figure 2.1: Final Patient Selection To Stratify Patients With And Without Depression 
  
 
 
a: DCS Question: Have you ever been told by a doctor or other health professional that you 
have diabetes or sugar diabetes? 
b: Depression Scale: PHQ 2 (Patient Health Questionnaire 2). 
c: International Classification of Diseases, Ninth Revision, And Clinical Modification (ICD 9 CM 
Codes): 296, 311. 
d: Clinical Classification Code (CCC): 657. 
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Figure 2.2: Selection Of Final Study Population (Weighted) 
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Table 2.3: Demographic Characteristics of U.S. adults with Diabetes                        
(Aged >17, MEPS 2008-2011) Stratified By Depression Status 
 
DEPRESSION (+) DEPRESSION (-) 
P Value Variables
a Unwtd 
Freq 
(1,208) 
Wtd % Unwtd 
Freq 
(3,460) 
Wtd % 
Age 
    
0.002* 
17-34 41 2.9 163 3.9  
35-49 204 17.8 612 15.4  
50-64 513 42.2 1,264 36.9  
65 And Above 377 30.7 1,254 38.7  
Missing 73 6.2 167 4.9  
Gender 
    
<0.001* 
Male 440 40.7 1,625 51.4  
Female 768 59.2 1,835 48.5  
Marital Status 
    
<0.001* 
Married 591 50.8 2,028 63.1  
Widowed/Divorced/Separated 475 37.6 1,060 27.9  
Never Married 142 11.4 372 8.9  
Income Level 
    
<0.001* 
Poor/Near Poor 430 27.4 740 15.1  
Low Income 215 17.1 567 13.7  
Middle Income 330 29.6 1,083 30.5  
High Income 233 25.9 1,070 40.6  
Education Level 
    
0.001* 
Less Than High School 408 24.5 973 19.6  
High School 537 49.1 1,531 47.9  
Advanced Education 155 16.4 676 23.3  
Others 100 9.3 270 8.8  
Missing 8 0.5 10 0.2  
Race/Ethnicity 
    
0.003* 
Hispanic 276 12. 766 12.3  
White Non-Hispanic 658 72.7 1,563 66.8  
Black Non-Hispanic 208 9.8 818 13.9  
Others 66 4.8 313 6.7  
Perceived Health Status 
    
<0.001* 
Excellent/Very Good 147 13.3 986 30.4  
Good 361 31.5 1,478 44.5  
Fair/Poor 700 55.1 996 25.1  
Insurance Coverage 
    
<0.001* 
Any Private 552 54.0 2,072 67.1  
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Public Only 537 37.7 1,025 25.7  
Uninsured 119 8.2 363 7.1  
Insulin Use 
    
<0.001* 
Yes 434 36.6 929 27.1  
No 770 63.2 2,518 72.6  
Missing 4 0.1 13 0.3  
     
 
MSA Status 
    
0.029* 
Non MSA 246 21.3 587 17.6  
MSA 962 78.6 2,873 82.3  
Employment Status 
    
<0.001* 
Employed 367 34.5 1,698 50.2  
Not Employed 840 65.2 1,759 49.5  
Missing 1 0.1 3 0.1  
BMI Status 
    
0.013* 
Under /Normal 134 10.2 512 14.2  
Over 1,042 87.1 2,881 83.9  
Missing 32 2.5 67 1.7  
Smoking Status 
    
<0.001* 
Yes 222 18.6 425 12.1  
No 953 79.2 2,977 86.5  
Missing 33 2.1 58 1.3  
     
 
Primary Care Provider 
    
0.287 
Yes 1,131 94.6 3,168 93.2  
No 71 4.9 271 6.2  
Missing 6 0.4 21 0.4  
(+) : Prescence of Depression according to the PHQ-242 and/or ICD and CC Codes. 
(-)  : Absence of Depression according to the PHQ-242 and/or ICD and CC Codes. 
a: n(%) & the Cochran-Mantel-Haenszel statistic / Fischer’s Exact Test were used to compare categorical variables. 
*: Significance at p value 0.05 as derived from ChiSquare 
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Table 2.4: Comorbidities of U.S. adults with Diabetes                                                                 
(Aged >17, MEPS 2008-2011) Stratified By Depression Status 
Comorbidity 
Unwtd 
Frequency 
Wtd % 
Unwtd 
Frequen
cy 
Wtd % 
P value 
Diabetes W/O Coml.a 1,181 98.1 3,334 97.1 0.122 
Hypertension 956 78.6 2,497 73.1 0.004* 
Hyperlipidemia 889 74.2 2,286 67.9 0.001* 
Back Disorders 255 23.6 468 15.2 <0.001* 
Lower Resp. Disordersb 271 23.5 397 13.5 <0.001* 
Upper Resp. Disordersc 227 20.1 473 14.1 0.003* 
Thyroid Disorders 193 17.3 423 13.2 0.023* 
Heart Disease 203 16.4 322 10.4 <0.001* 
Injury 186 16.1 356 11.2 0.004* 
Headache 125 11.6 159 4.3 <0.001* 
Eye Disorders 106 10.1 285 9.3 0.554 
Urinary Tract Infections 105 9.3 194 6.4 0.037* 
Cerebrovascular 
Disease 
110 8.4 172 4.9 0.004* 
Kidney Disease 82 6.8 203 6.6 0.874 
Anemia/Deficiencies 84 6.6 147 4.2 0.018* 
Diabetes W. Compl.d 47 4.2 81 2.6 0.117* 
Hernias 38 3.1 61 2.3 0.032* 
Osteoporosis 35 3.1 97 2.8 0.758 
Gall Bladder Disease 25 2.4 57 2.1 0.713 
Epilepsy/Convulsions 19 1.9 41 0.9 0.077* 
Cancer 7 0.3 4 0.1 0.327 
Substance Abuse 2 0.1 14 0.4 0.051^ 
a: Diabetes without complications. 
b: Diabetes with complications. 
c: Lower respiratory disorders. 
d: Upper respiratory disorders. 
*: The Cochran-Mantel-Haenszel statistic was used to compare categorical variables. Significance at p value 0.05 
as derived from ChiSquare. 
^: The Fischer’s Exact Test was used to compare categorical variables. Significance at p value 0.05 as derived from 
Fishcer’s Exact Test. 
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Table 2.5 Frequency Of Preventive Care Service Use Stratified By Year                    
(2008 – 2011) 
 
 
Preventive 
Service 
Year Total 2008 2009 2010 2011 
Receip
t 
Unwtd Freq 
(WTD%) 
Unwtd Freq 
(WTD%) 
Unwtd Freq 
(WTD%) 
Unwtd Freq 
(WTD%) 
Unwtd Freq 
(WTD%) 
A1C Tests 
YES 3,689 (81.1) 867 (78.9) 946 (79.2) 891 (82.8) 985 (83.4) 
NO 979 (18.9) 254 (21.1) 279 (20.7) 215 (17.2) 231 (16.5) 
Diabetic  
Foot Check 
YES 2,433 (53.4) 533 (49.8) 619 (51.6) 599 (54.8) 682 (56.4) 
NO 2,235 (46.5) 588 (50.1) 606 (48.3) 507 (45.1) 534 (43.5) 
Lipid Check 
YES 3,073 (69.4) 695 (64.9) 775 (66.6) 757 (73.4) 846 (72.8) 
NO 1,595 (30.5) 426 (35.0) 450 (33.3) 349 (26.5) 370 (27.1) 
Influenza 
Vaccination 
YES 2,330 (53.1) 530 (50.1) 588 (51.5) 566 (54.4) 646 (56.2) 
NO 2,338 (46.9) 591 (49.9) 637 (48.4) 540 (45.5) 570 (43.7) 
Dilated Eye 
Exam 
YES 2,388 (53.5) 527 (49.2) 620 (51.4) 574 (55.1) 667 (58.6) 
NO 2,280 (46.4) 594 (50.7) 605 (48.5) 532 (44.9) 549 (41.3) 
Blood 
Pressure 
Check 
YES 4,517 (97.5) 1,086 (97.4) 1,184 (97.1) 1,074 (98.2) 1,173(97.6) 
NO 151    (2.4) 35   (2.5) 41   (2.8) 32   (1.7) 43  (2.3) 
Routine 
Medical 
Check 
YES 4,158  (90.1) 977 (87.9) 1,076 (88.6) 986 (90.6) 1,119 (93.1) 
NO 510    (9.8) 144 (12.1) 149 (11.3) 120   (9.4) 97 (6.9) 
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Figure 2.3: Comparing The Utilization Of Preventive Care Services In Diabetic 
Patients With And Without Depression 
(+): Presence of Depression 
(-):  Absence of Depression 
 75 
 
Table 2.6: Results Of The Multivariable Logistic Regression: Effect Of Comorbid 
Depression On The Receipt Of Diabetes Preventive Care Services. 
Preventiv
e 
Service 
Depressio
n Status 
Samp
le 
Size 
Crude 
Odds Ratios    
(95% CI) 
Adjusted 
Odds Ratios   
(95% CI) 
Adjusted For 
A1C 
Testing 
Non 
Depressed 
3,460 
1.00 
 (REF) 
1.00 
 (REF) 
Age, Gender, Race and 
Ethnicity 
Insulin use, Income level, 
Employment Status, Perceived 
health Status, BMI Status, 
Marital Status, Smoking Status, 
Primary Care Provider, 
Anemia, Back Disorders, 
Hyperlipidemia and 
Hypertension. 
Depressed 1,208 
1.19  
(1.01 – 1.44) 
1.03 
 (0.83 – 1.28) 
Diabetic 
Foot 
Exam 
Non 
Depressed 
3,460 
1.00 
 (REF)  
1.00 
 (REF) Age, Gender, Race and 
Ethnicity, Insulin Use, 
Perceived Health Status, 
Hyperlipidemia 
Depressed 1,208 
1.20  
(1.01 – 1.42) 
1.12  
(0.94 – 1.34) 
Lipid 
Check 
Non 
Depressed 
3,460 
1.00  
(REF) 
1.00  
(REF) 
Age, Gender, Race and 
Ethnicity, Income Level, Insulin 
Use, Educational Status, 
Perceived Health Status, 
Smoking Status, Marital 
Status,, 
Primary Care Physician, 
Hyperlipidemia, and 
Headaches. 
Depressed 1,208 
1.11 
 (0.94 – 1.32) 
1.07  
(0.88 – 1.30) 
Influenza 
Vaccination 
Non 
Depressed 
3,460 
1.00  
(REF) 
1.00  
(REF) 
Age, Gender, Race and 
Ethnicity, Insulin Use, Income 
Level, Perceived Health Status, 
Educational Status, 
Employment Status, Smoking 
Status,, Primary Care 
Physician, Headaches, Back 
Disorders, Upper Respiratory 
Disorders, Hypertension, 
Hernia and Hyperlipidemia. 
Depressed 1,208 
1.06 
 (0.88 – 1.28) 
1.02  
(0.83 – 1.25) 
Dilated Eye 
Exam 
Non 
Depressed 
3,460 
1.00  
(REF) 
1.00 
 (REF) 
Age, Gender, Race and 
Ethnicity, Income Status, 
Perceived Health Status, 
Educational Status, 
Employment Status, Insurance 
Status, 
Primary Care Provider, Marital 
Status, 
Hypertension, Hyperlipidemia 
and Back Disorders. 
Depressed 1,208 
0.94  
(0.79 – 1.11) 
0.93  
(0.76 – 1.12) 
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Routine 
Medical 
Checkup 
Non 
Depressed 
3,460 
1.00 
 (REF) 
1.00 
 (REF) 
Age, Gender, Race and 
Ethnicity, Income Status, 
Perceived Health Status, 
Educational Status, 
Employment Status, Back 
Disorders, Insurance Status, 
Primary Care Provider, 
Hypertension, Marital Status 
and Hyperlipidemia 
Depressed 1,208 
0.80 
 (0.63 – 0.99) 
0.81 
 (0.60 – 1.10) 
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3.1 Background 
Hypoglycemia is a serious complication that is associated with the treatment of 
diabetes resulting in a significant burden to the patients with diabetes.166While most 
hypoglycemic events are mild and self-managed, more severe hypoglycemic events 
require medical assistance and result in the development of serious complications. It 
is well documented that despite the variations in severity, hypoglycemia is known to 
cause negative health outcomes including increased morbidity, decreased quality of 
life, and rare occurrences of mortality in patients with diabetes.167 The most common 
symptoms associated with hypoglycemia include palpitations, trembling, sweating, 
hunger, and confusion.168 Long-term consequences of hypoglycemia include weight 
gain, cardiovascular diseases, and coma.167 Even though the symptoms and 
complications of diabetes differ among patients, a great degree of decline in 
cognitive and motor function as well as hormonal counter regulation has been 
previously documented.169 The fear of severe hypoglycemia requiring clinical 
assistance can seriously compromise the self-management of diabetes thereby 
causing the patients to prefer sub-optimal blood glucose control over incidents of 
hypoglycemia.170 
Though the estimates regarding the incidence of hypoglycemia in Type 2 Diabetes 
(T2DM) are varied, previous studies identify several factors associated with 
hypoglycemia.167,168,171-174 For example antidiabetic medications, particularly insulin 
and sulfonylureas (SUs), are among the principal risk factors for developing 
hypoglycemic events.175-178 This is concerning as intensive therapy with antidiabetic 
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drug agents is strongly associated with improvement in diabetes control including 
reducing the risk of developing micro- and macrovascular complications.95,179,180 
Similarly, many patient specific factors are also associated with the development of 
hypoglycemia. These factors include age and gender as well as physiological factors 
(e.g. chronic kidney disease and liver disease).177,181 Lastly, certain behaviors like 
continuity of physical exercise, intake of food and consumption of alcohol also 
increase the risk of hypoglycemia.168,173 
Apart from the clinical impact, hypoglycemia has also been shown to pose a 
significant financial burden to the patient as well as the health care system167,177,182. 
For example, Pelletier and colleagues estimated that the mean annual allowed 
charge for hypoglycemia was $345 (2007 US dollars).183 Similarly, Quilliam et al. 
estimated the rate and costs of hypoglycemia among working-age patients with type 
2 diabetes and found the total hypoglycemia costs accounted for 1.0% of all inpatient 
costs, 2.7% of ED costs, and 0.3% of outpatient costs. The mean costs for 
hypoglycemia visits were estimated to be $17,564 for an inpatient admission, $1387 
for an ED visit, and $394 for an outpatient visit. The authors concluded that 
hypoglycemia was associated with higher costs as compared to other diabetic and 
non-diabetic costs.184 These higher costs might be direct costs because of primary 
care visits, emergency room visits, hospitalizations etc. or indirect costs resulting 
from absence from work, disability, premature retirement and reduced 
productivity.185,186  
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The incidence and effects of hypoglycemia are more pronounced in insulin treated 
type 1 diabetes mellitus (T1DM). Hence, though the predictors and costs of 
hypoglycemia have been well outlined for T1DM, there is a paucity of research 
regarding the factors that cause hypoglycemia specifically in patients with type 2 
diabetes mellitus (T2DM). Moreover, due to the varied definitions of hypoglycemia 
operationalized in various studies and other methodological differences, findings 
from these studies often lack generalizability.  As the incidence rates of people 
suffering from diabetes will almost double by 2050, 2 more research on this 
devastating complication of antidiabetic treatment is warranted. Hypoglycemic 
events will continue to place a greater strain on the health care costs and resources.  
To expand on previously published studies, we conducted a cross sectional study of 
persons with T2DM using an insurance claims database to identify predictors and 
outline the costs of hypoglycemia treated in an outpatient or inpatient setting. 
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3.2 Methods 
3.2.1 Datasource  
For the purpose of our study, we used the Blue Cross and Blue Shield Of Rhode Island 
(BCBSRI) administrative claims data for the years 2009 - 2012. BCBSRI is a non-profit 
hospital service and medical service corporation covering more than 600,000 
members. In the data extract used for our analyses, all the members had at least one 
International Classification of Disease-9 (ICD-9) code for diabetes (ICD-9 250.XX) 
between 2009 and 2012. To achieve the aims of our study, we utilized three 
administrative files, including: eligibility files, medical claims (inpatient and 
outpatient) and pharmacy claims.  The enrollment file included age, gender as well as 
the start and end dates for enrollment in the health plan. Similarly, the outpatient 
and inpatient files include diagnosis information (ICD-9 codes), Current Procedural 
Terminology (CPT) codes, admit and discharge dates as well as cost and copayment 
information. The medication claims dataset included prescription medications 
dispensed during the study period and included the National Drug Codes (NDC), drug 
product names, prescription quantity (number of units dispensed) and days supplied 
at the time of dispensing (e.g. 30 day supply of medication). Due to the 
comprehensive nature of the claims provided in the dataset, it can be assumed that 
this dataset provides a near complete picture of an individual’s health care.  
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3.2.2 Research design and study population 
Using the medical claims, inpatient and outpatient, as well as prescription claims, we 
conducted a cross sectional study. All the patients included in the dataset had a 
diagnosis of diabetes. As our interest was in factors associated with hypoglycemia in 
T2DM, we further excluded patients who had at least one claim for type 1 diabetes 
(ICD-9 250.X1 or 250.X3) or gestational diabetes (ICD-9-CM 648). 
3.2.3 Identification of Hypoglycemia 
The principal objective of our study was to identify independent predictors of 
hypoglycemia in T2DM. In order to identify hypoglycemia in the inpatient and 
outpatient medical settings, we used an algorithm designed by Ginde and 
colleagues187.  Within this algorithm, specific codes related to hypoglycemia (251.0 
251.1 251.2 270.3 775.0 775.6 962.3) are first directly classified as a hypoglycemic 
event. Secondarily, additional instances of hypoglycemia are identified using ICD- 9 
code of 250.8 in the absence of other contributing diagnoses (ICD -9 259.8, 272.7, 
681.XX, 682.XX, 686.9X, 707.1-707.9, 709.3, 730.0-730.2, or 731.8).  This algorithm is 
well validated and demonstrated a positive predictive value of 89% for detecting 
hypoglycemia visits.187 As all episodes of hypoglycemia identified in our study 
required medical intervention, we considered these events as serious and thus will 
utilize this terminology in the presentation of our results.  Using this information, we 
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created two groups, those with at least one serious hypoglycemic event (n=1243) and 
those who did not have a serious hypoglycemic event (n=28,128). 
2.4 Identification of Independent Predictors 
We assessed the relevant demographic characteristics of the sample population 
including age (18-34, 35-49, 50-64, 65 and above) and gender. We used the 
Charlson’s Comorbidity Index in order to examine the composite impact of the 
burden of comorbid diseases on the risk of having a hypoglycemic event. In addition, 
we also defined the prevalence of specific individual comorbidities predictors of 
hypoglycemia using the Elixhauser Comorbidity Index. Previous studies have 
identified other diabetes micro- and macrovascular complications that might be 
predictive of hypoglycemia in patients. We also identified the presence of these 
complications as well as other diseases like influenza and pneumonia, which can 
potentially to increase the likelihood of a hypoglycemic event.183,188,189 In case of an 
overlap of the conditions, we considered the condition defined under one set of 
comorbidities preferably in the order of elixhauser comorbidity index, micro and 
macrovascular complications and other diseases. 
3.2.5 Characterizing The Use Of Medications 
We use a combination of National Drug Codes (NDC) and drug product names in 
order to identify the use of both diabetic and non-diabetic medications that might 
have an association with the incidence of hypoglycemia. Among the antidiabetic 
medications, we specifically identified the use of all the major classes of oral 
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antidiabetic medications including biguanides, sulfonylureas (SUs), a-glucosidase 
inhibitors, DPP-4 inhibitors (DPP), meglitinides , thiazolidinediones (TZDs) as well as 
insulin. With respect to the other medications, we identified use of other  
medications previously suggested to cause hypoglycemia: angiotensin-converting 
enzyme (ACE) inhibitors, allopurinol, angiotensin II receptor blockers (ARBs), 
benzodiazepines, b-blockers, fibrates, fluoroquinolones, nonsteroidal 
antiinflammatory drugs (NSAIDs), trimethoprim, and warfarin.173,190-192  
3.2.6 Estimating Costs 
In order to examine the medical costs for hypoglycemia, we used the total allowed 
amount paid for the services for both inpatient and outpatient encounters. In 
addition to the measurement of total costs, we also stratified the costs into 3 
mutually exclusive groups namely costs related to hypoglycemia as identified using 
the Ginde algorithm;187 costs related to other diabetes-related claims as identified by 
primary ICD-9 250.XX); and costs related to all other claims. We classified all the 
episodes occurring on the same day as a single episode of care. All the costs were 
adjusted to 2012 equivalents (final year of available data) using the regional 
Consumer Price Index medical care expenditure category in order to make accurate 
comparison of costs across all study years. 
3.2.7 Statistical Analyses 
We created two groups for comparison in our study, those with a serious 
hypoglycemic event and those without.  We compared the prevalence of the selected 
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covariates among the patients with or without any hypoglycemic events by 
examining the frequencies and thereafter using the Cochran-Mantel-Haenszel 
statistic for categorical variables and Student's t-test for continuous variables. We 
then selected all the variables with a p-value of less than 0.25 in these preliminary 
bivariate analyses. We then developed a predictive logistic regression model using 
the variables identified in the above process, initially fitting a preliminary model 
containing all of the above variables and then further refining it using a manual 
iterative process of refinement. During this process, we sequentially excluded 
variables that were not contributing significantly to the model (Wald p-value >0.10) 
and thus were potentially not associated with hypoglycemia. Further, we carried out 
likelihood ratio testing in order to confirm the exclusion. After identifying a working 
model with all of the relevant predictors included, we further assessed 
multicollinearity in the model. For this purpose, we used the variation inflation factor 
(VIF), and Eigen values to make the decisions on exclusion of collinear variables. 
These were calculated utilizing a separate regression model and specifically using the 
VIF, TOL, and Collin options. If two variables were found collinear, we included the 
variable that was clinically more relevant to our analysis. We tested all two-way 
interactions between the independent variables in a stepwise process that was 
similar to the one used to in order to build the initial model (using likelihood ratio 
testing for confirmation). We retained each interaction term if it was significant and 
continued this process until all interaction terms were either removed from the 
model, or retained if found significant. We used AIC (the Akaike Information 
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Criterion) and Hosmer-Lemeshow test to assess goodness of fit at all steps of building 
the final model. At the end of this process we then reported multivariable (adjusted) 
odds ratios (AORs), including their respective 95% confidence intervals (95% CI). For 
the cost analyses, we conducted Student t-tests to compare mean costs across the 
created cost subgroups. All statistical tests were conducted with a 2-tailed alpha of 
0.05. All analyses were performed using SAS software version 9.3 (SAS Institute Inc., 
Cary, NC). This study was reviewed and approved as exempt by the University of 
Rhode Island’s Institutional Review Board.  
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3.3 Results 
3.3.1 Demographics 
The initial dataset of patients with diabetes was compromised of 36,954 individuals 
identified as having diabetes (ICD-9 250.xx).  After excluding the patients with type 1 
diabetes or gestational diabetes (n=7,240) as well as patients below the age of 18 
(n=343), our final analytic sample included 29,371 patients with T2DM. Among the 
eligible sample, 1,243 (4.2%) patients experienced a serious hypoglycemic event over 
the three-year period while 28,128 (95.7%) patients did not have any reported 
hypoglycemic events. The demographic characteristics of the study sample stratified 
by the presence of serious hypoglycemia are described in Table 3.1. Overall, the 
mean age was 61.4 years and was slightly higher in the patients with serious 
hypoglycemic events as compared to those who did not (65.3 Vs 61.2, respectively). 
When divided into specific age groups, it could be seen that that 46.7% (580 patients) 
of the hypoglycemic group had an age above 65 years in comparison to the 9,716 
patients(46.7%) in the non-hypoglycemic group (χ2: 80.62, p-value: <0.001). 
Moreover, the observed gender distribution was similar across both groups with the 
proportion of females being lower in both hypoglycemic (567 patients, 45.6%) and 
non-hypoglycemic groups (13,275 patients, 47.2%) 
3.3.2 Clinical Characteristics 
Comparison of clinical characteristics in patients with or without serious 
hypoglycemia revealed a higher prevalence of comorbidities in the hypoglycemic 
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group (Table 3.2). Overall, the Charlson’s comorbidity score describing the burden of 
other diseases was found to be higher in the hypoglycemic group (mean = 2.97 +/- 
1.18) than the non-hypoglycemic group (mean=2.15 +/- 1.20; t=36.22; p value 
<0.001). When divided into separate groups, it was found that 250 patients in the 
hypoglycemic group (20.1%) and 12,690 patients in the non-hypoglycemic group 
(45.1%) had a score of 0 indicating a higher percentage of patients in the non-
hypoglycemic group did not suffer from any comorbidities. In contrast, 607 patients 
in the hypoglycemic group (48.8%) and 6,160 patients from the non-hypoglycemic 
group (21.9%) had a score of greater than 3, indicating a greater proportion of 
patients in the hypoglycemic group suffering a higher burden of comorbidities 
(X2=566.30; p-value: <0.001). Table 3.3 also provides more detail on individual 
comorbidities (as identified using the Elixhauser Comorbidity Index).193 The most 
commonly observed comorbidities had a higher prevalence in the hypoglycemic 
group as opposed to the non-hypoglycemic group. For example,  congestive heart 
failure (28.3% vs 8.0%, χ2: 353.31, P value <0.001), cardiac arrhythmias (26% vs 13%, 
χ2: 170.5, p value: <0.001), valvular disease (13.4% vs 7.4%, χ2: 60.79, χ2: 60.79 p 
value <0.001), peripheral vascular disorders (27.8% vs 11.6%, χ2: 289.3, p value: 
<0.001), hypertension uncomplicated (61.85%), chronic pulmonary disease (66.3% vs 
61.6%, χ2: 11.24, p value: 0.0008), hypothyroidism (16.7% vs 13.3%, χ2: 11.43, p 
value: 0.0007), solid tumor without metastasis (16.0% vs 10.5%, χ2: 36.22, p value: 
<0.001)and depression (19.7% vs 13.7%, χ2: 2339.59, p value: <0.001). Some of the 
least frequent comorbidities also displayed a higher prevalence in the hypoglycemic 
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group. For example, paralysis (1.7% vs 0.4%, χ2: 43.03, p value <0.001), peptic ulcer 
disease excluding bleeding (1.5% vs 0.7%, χ2: 9.28 p value : 0.002), lymphoma (1.7% 
vs 0.9%, χ2: 7.83 p value: 0.005) and metastatic cancer (2.9% vs 1.3%, χ2: 20.86, p 
value: <0.001). Moreover, as seen in table 3.4the most prevalent macrovascular and 
microvascular complications of diabetes demonstrated higher prevalence in the 
hypoglycemic group. . For instance coronary artery disease (33.0% vs 18,7%, χ2: 
156.77, p value: <0.001),arrhythmias (15.7% vs 7.1%, χ2:126.45, p value: <0.001), 
stroke (7.5% vs 2.2, χ2: 98.32, p value: <0.001)peripheral vascular disease (36.2% vs 
15.4%, χ2: 380.37, p value: <0.001), diabetic retinopathy (20.8% vs 13.7%, χ2: 49.9, p 
value <0.001), diabetic neuropathy (5.7% vs 2.0%, χ2: 74.7, p value: <0.001) and 
ulcers (27.2% vs 5.3%, χ2: 969.8, p value: <0.001) were all observed to a higher 
degree in the hypoglycemic group. Among the other diseases that might contribute 
to the increased likelihood of having a hypoglycemic event, liver disorders (6.6% vs 
4.3%, χ2: 14.07, p value: 0.0002) were highly prevalent while Addison’s disease (1% 
vs 0.1%, χ2: 38.13, p value: <0.001) were rarely observed. The presence of these 
comorbidities was also significantly higher in the patients who had any events of 
hypoglycemia.  
3.3.3 Use of Medications 
The mean number of medications (SD) taken was higher in the patients in the 
hypoglycemic group (mean=15.31 +/- 12.21) as compared to those in the non-
hypoglycemic group (mean=10.97 +/- 9.63; t=56.78; p value 0.001). We further 
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assessed the use of diabetes and non-diabetes medications (Tables 3.5 - 3.7). Overall, 
the use of diabetic medications was common. Moreover, the use of these 
medications was significantly higher in the hypoglycemic group as compared to the 
non-hypoglycemic group. Specifically, 2,873 (9.5%) patients were using insulin with 
the use being significantly higher in the hypoglycemic group as compared to the non-
hypoglycemic group (24.14% vs 9.14%; χ2= 303.24; p-value: <0.001). The use of 
metformin (42.8%) was found to be high within the overall sample but comparable in 
the hypoglycemic and non-hypoglycemic groups (42.5% vs 42.8%). Furthermore, 
7,821 patients (26.6%), 2,881 patients (9.8%) and 2,458 (8.4%) patients were being 
prescribed sulfonylureas, TZDs and DPP respectively with the use being higher in 
patients in the hypoglycemic group.  More specifically, use of sulfonylureas (41.5% vs 
26.0%; χ2=147.17; p-value: <0.001), TZDs (11.6% vs 9.7%; χ2=4.62; p value: 0.03) and 
DPP-4 (9.7% vs 8.3%;  χ2=2.79; p value: 0.09) were more prevalent in those with 
serious hypoglycemia compared to those without. The use of other classes of 
diabetic medications like alpha glucosidase inhibitors (0.3%) and meglitinides (0.9%) 
was relatively rare and comparable in the hypoglycemic and non-hypoglycemic 
groups. Overall, it can be seen from Table 3.5 that 34.9% of the hypoglycemic group 
and 46.8% of the non-hypoglycemic group were not taking antidiabetic medication.  
 Similarly, as seen in Table 3.6, the prevalence of use of non-diabetic medications was 
also significantly higher in the hypoglycemic group as compared to the non-
hypoglycemic group. Furthermore, 11,097 patients and 7,888 patients were 
prescribed ACE inhibitors (44.2% in hypoglycemic group and 37.5% in non-
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hypoglycemic group; χ2=22.51; p value: <0.001) and beta-blockers (38.9% in 
hypoglycemic group and 26.3% in non-hypoglycemic group; χ2=96.44; p value: 
<0.001). Use of ARBs was more comparable between the two groups) 9.7% in 
hypoglycemia group versus 8.6% in non-hypoglycemia group). In contrast, use of 
other medications was much more common in those with hypoglycemia than those 
without hypoglycemia. For example warfarin (12.71% in hypoglycemic group and 
5.40% in non-hypoglycemic group; χ2=118; p value: <0.001), fluoroquinolones (33.1% 
in hypoglycemic group and 21.8% in non-hypoglycemic group; χ2=87.37; p value: 
<0.001), fibrates (8.6% in hypoglycemic group and 7.6% in non-hypoglycemic group; 
χ2=1.61; p value: 0.20) and NSAIDs (27.7% in hypoglycemic group and 28.5.% in non-
hypoglycemic group; χ2=0.37; p value: 0.53). Use of other evaluated agents was 
similar between the two groups and is presented in Table 3.6.    
3.3.4 Results Of Multivariable Logistic Regression 
The results of the multivariable logistic regression analyses are presented in Table 
3.7. While using the age group of 18 – 34 years as our reference, it was seen that 
with increasing age the relative likelihood of hypoglycemia generally decreased. For 
example, the AOR of patients aged 35 – 49 years was 22% lower (AOR 0.78; 95% CI 
0.51 to 1.18) while the AOR for patients aged 50 – 64 years decreased by 24% (AOR 
0.76; 95% CI 0.78 to 0.85). The lowest risk of a hypoglycemic event was found in the 
patients who were aged 65 or above (AOR 0.71; 95% CI 0.47 to 1.07). With respect to 
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gender, it could be seen that both male enrollees had a 4% higher but statistically 
insignificant relative rate of hypoglycemia (AOR 1.04; 95% CI 0.92 to 1.18).  
For other factors, there was an increased likelihood of severe hypoglycemia in 
patients with higher overall burden of disease as measured by the Charlson’s 
comorbidity index. As compared to patients with a comorbidity score of 0, patients 
with a comorbidity score of 1 were 38% (AOR 1.67; 95% CI 1.01 to 2.78) more likely 
to have a serious hypoglycemic event. Similarly, the relative risk of a serious 
hypoglycemic events in patients with a comorbidity score 2 (AOR 2.05; 95% CI 1.70) 
and those with a  3 or more (AOR 2.12; 95% CI 1.73 to 2.59) were more than twice 
that of patients with a comorbidity score of 0. In addition, presence of any claims for 
congestive heart failure (AOR 1.24; 95% CI 1.04 to 1.49), peripheral vascular disorders 
(AOR 1.19; 95% CI 1.02 to 1.40), paralysis (AOR 1.67; 95% CI 1.01 to 2.78), 
neurological disorders (AOR 1.52; 95% CI 1.22 to 1.89), obesity (AOR 1.30; 95% CI 
1.01 to 1.67), fluid and electrolyte disorders (AOR 1.31; 95% CI 1.09 to 1.57), 
deficiency anemia (AOR 1.37; 95% CI 1.13 to 1.67) and psychoses (AOR 1.60; 95% CI 
1.19 to 2.14) was associated with a higher relative rate of any serious hypoglycemic 
events. Among other macro-and microvascular complications of diabetes, claims for 
acute renal failure (AOR 1.67; 95% CI 1.01 to 2.78), ulcers (AOR 4.07; 95% CI 3.50 to 
4.72), amputations (AOR 2.73; 95% CI 1.26 to 5.91) and Addison’s disease (AOR 3.17; 
95% CI 1.64 to 6.14) displayed a significantly higher relative risk of hypoglycemia. In 
contrast, patients who suffered from hypertension demonstrated a 16% reduction in 
the relative rate for hypoglycemia events (AOR 0.84; 95% CI 0.74 to 0.97).  
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While evaluating the effect of medication use on the likelihood of hypoglycemic 
episodes, it was seen that patients who were using 4-7 unique drugs were least likely 
to suffer any hypoglycemic event (AOR 0.48; 95% CI 0.36 to 0.64). Similarly, patients 
using between 8 – 10 medications (AOR 0.59; 95% CI 0.44 to 0.80) as well as patients 
using more than 10 medications (AOR 0.66; 95% CI 0.56 to 0.79) had a 41% and 34% 
reduction in the risk of any hypoglycemia event. Most of the antidiabetic medications 
were associated with higher relative rates of hypoglycemia. Moreover, patients using 
insulin were more than twice as likely as those not using insulin to have any 
hypoglycemia related claims (AOR 2.20; 95% CI 1.88 to 2.56). Similarly, among the 
oral antidiabetic medications, sulfonylureas (AOR 1.71; 95% CI 1.49 to 1.97) and 
meglitinides (AOR 1.75; 95% CI 1.14 to 2.70) were associated with a 71% and 75% 
increased relative risk for a serious hypoglycemic events.  
3.3.5 Results Of Cost Analyses 
Table 3.8 presents the results of the costs analyses. We estimated that 0.5% of 
inpatient encounters were associated with hypoglycemia. Moreover, 6.9% of the 
inpatient visits were for other diabetes related outcomes while the remaining 92.6% 
of the visits were recorded for non-diabetes related care. Hypoglycemia related visits 
accounted for 0.7% of the total inpatient costs while non-hypoglycemia related 
diabetes costs accounted for 1.4%. The mean cost for inpatient visits for 
hypoglycemia was $1,514.60. In comparison, the mean cost for an inpatient visit for 
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non-hypoglycemia related diabetes outcomes and non-diabetes related outcomes 
was $232.71 and $1,171.60 respectively (p value <0.001). Similarly, hypoglycemia 
accounted for 0.2% of the total outpatient visits while non-hypoglycemia related 
outcomes and non-diabetes related outcomes were responsible for 14.4% and 54.4% 
of the outpatient visits respectively. In case of the outpatient visits, the estimated 
costs for hypoglycemia were 0.2% of the total costs while non-hypoglycemia related 
diabetes costs were 7.6% of the total outpatient costs. The mean cost of outpatient 
visits for hypoglycemia, non-hypoglycemia related diabetes outcomes and non-
diabetes related outcomes were $142.91, $83.93 and $182.63 respectively (p value 
<0.001).
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3.4 Discussion 
Our cross sectional study sought to identify the principal predictors of serious 
hypoglycemia (requiring inpatient or outpatient medical intervention) and estimate 
the related costs.  Within our analyses, we considered a range of demographic and 
clinical factors such as age, gender, comorbid diseases, as well as medication use as 
potential predictors in our analysis. Though there have been previous studies 
highlighting the risk factors for hypoglycemia in various settings (for example, solely 
in the emergency department), our results provide a comprehensive evaluation of 
serious hypoglycemic events requiring medical intervention.  Our study adds to the 
valuable literature thereby providing greater insights into management of 
hypoglycemia and health care resource use in patients with diabetes.  
Previous literature has found several clinical, physiological as well as drug related 
factors to have a significant impact on the rates of hypoglycemia in patients.190,194,195 
Some of the important predictors that we identified in our study were comorbidities 
including congestive heart failure, peripheral vascular disorders, hypertension, 
paralysis, neurological disorders, obesity, fluid and electrolyte disorders, anemia, 
psychoses, acute renal failure, ulcers, amputations, Addison’s disease as well as a 
combined Charlson’s comorbidity score. For example, in a case control study to 
analyze the clinical characteristics as well as risk factors that might be associated with 
hypoglycemia in non-diabetic hospitalized older adults, Shilo et al. found that low 
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plasma albumin level, liver disease, malignancy, and congestive heart failure were 
significant predictors of hypoglycemia.196 Similarly, Simeone et al., conducted a study 
to identify predictors of hypoglycemia-related emergency department and 
outpatient visits in patients with type 2 diabetes. They found that coronary artery 
disease (AOR 1.38; 95% CI 1.29 to 1.49), heart failure (AOR 1.70; 95% CI 1.49 to 1.93), 
peripheral vascular disease (AOR 1.80; 95% CI 1.60 to 2.02), arrhythmia (AOR 1.22; 
95% CI 1.04 to 1.44), and stroke (AOR 1.81; 95% CI 1.41 to 2.32) were all significantly 
increasing the risk of a hypoglycemic event with ulcer demonstrating a 6 fold increase 
in the likelihood of hypoglcyemia.173 Similarly, renal failure has also been shown to 
have a significant association with incidence of hypoglycemia.197 For example, Durán-
Nah and colleagues attempted to identify risk factors associated with symptomatic 
hypoglycemia and found a threefold increase in the rate of hypoglycemia in patients 
suffering from renal failure (AOR 3.0; 95% CI 1.20 to 7.70).198 Furthermore, our 
findings are also consistent with other studies, which have previously identified 
various macrovascular, microvascular, as well as other comorbidities as important 
risk factors for hypoglycemia.166,169,199,200 Our results were in contrast with some 
studies that have previously found a protective effect with an increase in the Body 
Mass Index (BMI).172,197,201 For example, while exploring the potential determinants 
for severe hypoglycemia 10,251 participants, Miller et al. found that BMI of 30 or 
higher resulted in a 35% reduction of hypoglycemia as compared to a BMI of less 
than 25 (Hazard Ratio[HR] 0.65, 95% CI 0.5 to 0.85). Possible reasons for this might 
be poor nutrition as well as irregular food intake. 
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With respect to other patient level factors like age, gender as well as certain 
comorbidities, we found that there was no significant association with the incidence 
of hypoglycemia. There has been contrasting evidence in literature regarding the risk 
of hypoglycemia associated with these factors. Age has been previously 
demonstrated to be a significant predictor of hypoglycemia. For example, the  
ACCORD and ADVANCE trials reported a 3% and 5% increase in risk for hypoglycemia 
with each additional year of age, respectively.178,200-203 Previous research suggests 
that along with the physiological changes that occur in the body with advancing age, 
other mechanisms that might contribute to incidence of hypoglycemia include 
decreased hypoglycemia awareness as well as decreased counter regulatory 
response to low blood glucose.175,204 However, in contrast some studies hypothesize 
age to have a protective effect with the risk of hypoglycemia decreasing with 
increasing age.173,198 Other studies demonstrate no association between age and 
hypoglycemia.166,205 In our study, we found a clinically significant (but non-statistically 
significant) trend towards a protective effect. While evaluating gender as a predictor, 
there have been conflicting results in literature. For example, studies including the 
ADVANCE trial demonstrated no significant association between gender and the 
likelihood of hypoglycemia.166,197,201On the other hand, the ACCORD trial, 
demonstrated a higher risk of a hypoglycemic event for women (Hazard Ratio= 1.21, 
95% CI 1.02 to 1.43).200 Some observational studies have provided evidence of a 
lower rate of hypoglycemia in females as compared to males.173,205 A possible 
explanation that is postulated for this gender variation in the incidence of 
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hypoglycemia is that even though women are more likely to use health care 
resources to a higher degree, it might be a result of a higher morbidity rate compared 
with men.206 On the other hand there are known physiological differences between 
males and females with a known relative reduction of counter regulatory responses 
in females that might also contribute to the incidence of hypoglycemia.173,207 
There has been considerable evidence that various treatment modalities might result 
in a higher propensity to suffer from hypoglycemia through various mechanisms like 
increase in insulin sensitivity.208 In our study, we found that a higher number of 
medications used by the patient increased the risk of hypoglycemia. This finding is 
corroborated by other studies, which provided similar evidence regarding 
polypharmacy.209,210 For example, Shorr et al in a study of 19,932 Tennessee 
Medicaid enrollees, aged 65 years or older found that patients using drugs from 5 or 
more therapeutic classes had a 30% increase in the likelihood of having a 
hypoglycemic event.211 With respect to oral antidiabetic medications, we found a 
significantly increased risk with insulin, sulfonlyureas and meglitinides. Even though 
tight glycemic control Is being increasingly recommended in clinical practice, this has 
shown to pre-dispose patients to an increased risk of hypoglycemia.208 For example, a 
prospectively planned group-level meta-analysis of various largescale trials 
demonstrated a two-fold increase in the risk of developing severe hypoglycemia in 
patients who were underwent intensive glucose lowering therapy.212 Similarly, both 
prospective trials and retrospective studies have consistently demonstrated the 
higher risk of hypoglycemia events with insulin.169,199,213-215 This risk however varies 
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with the patient’s medication regimen as well as the severity of the person’s 
diabetes.190 However, fear of hypoglycemia is known to prolong the initiation of 
insulin therapy in patients thereby seriously compromising the achievement of 
glycemic goals.216 Similarly, sulfonylureas have also traditionally been associated with 
an additional risk of hypoglycemia.169,190,215,217 For example, Bodmer et al. conducted 
a nested case control study to compare the risk of lactic acidosis and hypoglycemia 
among patients with type 2 diabetes using oral antidiabetic drugs and found that 
sulfonylureas had a substantially higher risk of causing hypoglycemia (AOR 2.79  95% 
CI 2.23–3.50).197 Literature suggests that meglitinides have a lower potential to cause 
hypoglycemia as compared to insulin and sulfonylureas.94 Interestingly, we found no 
significant association between the biguanide class of medications and incidence of 
hypoglycemia. There has been prior evidence of these drugs having a reduced 
hypoglycemic effect and hence are usually used as first line therapy. We did not find 
any association between the use of non-diabetic medications like allopurinol, 
warfarin, fibrates, NSAIDs, or B-blockers with severe hypoglycemia in multivariate 
analyses. The use drugs have previously shown an increase the likelihood of 
incidence of hypoglycemia.166,190,218 
Moreover, incidence of hypoglycemia has been associated with significant health 
care resource use as well as direct and indirect economic burden in previous 
literature.184,208,219,220 Due to under reporting of hypoglycemia itself, these cost 
estimates are often underestimated. In our study, hypoglycemia related visits were 
accountable for 0.7% and 0.2% of the total costs for inpatient and outpatient visits 
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respectively. Our results might differ from results described in other studies due to 
variations in the methods to measure costs as well as definitions of hypoglycemia. 
For example, we calculated the cost estimates based on total amount that was paid 
for the services, which included the copay amounts. Heaton et al. in a study to 
determine the incidence and economic cost of hypoglycemia in patients with 
diabetes taking insulin found that mean cost per episode was $1,186 (range, $181-
$4,924) or $7.04 per patient per month.221 On the other hand, Quilliam et al. while 
investigating the incidence rate and costs of hypoglycemia in patients with T2DM 
estimated the mean costs per encounter for inpatient and outpatient visits for 
hypoglycemia to be $17,564.25 and $ 393.64 respectively.184 Similarly, in a series of 
studies conducted in three European countries, the average cost per hypoglycemic 
event was found to be €537–688.222,223 It was interesting to note that most of the 
hypoglycemia cost studies have been performed in patients who are being treated 
with insulin with there being a scarcity of information on patients who are being 
treated with non-insulin therapies. 
Even though, the study provides valuable insights into the predictors and costs of 
hypoglycemia in inpatient and outpatient settings, there are some inherent 
limitations to our study. Since our data represents a regional health plan, the results 
might not be generalizable to all patients with T2DM. Secondly, as with other studies, 
our diagnoses of hypoglycemia only represents the most severe cases for which 
medical assistance was necessary since only these may be considered as reliable 
events.174,190,224 The true rates of hypoglycemia may be considerably higher than our 
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estimates. Moreover, we could not elucidate the effects of certain clinical as 
demographic aspects like blood glucose levels and race/ethnicity that are vital in the 
progression of diabetes. Lastly, due to the cross sectional design of the study, 
consideration of previous hypoglycemic events was beyond the scope of the study.   
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3.5 Conclusions 
Hypoglycemia is the principal and often underreported limiting factor in the 
management of patients with T2DM. Considering the clinical and economic 
implications of hypoglycemia, we conducted a cross sectional study to identify the 
predictors and estimate the costs of a comprehensive definition of severe 
hypoglycemia. Our study confirms that specific comorbidities as well as diabetic and 
non-diabetic treatment modalities are significantly predictive of hypoglycemic 
episodes. The cost estimates also provide evidence of the significant economic 
burden associated with hypoglycemia. The inpatient episodes related to 
hypoglycemia incur a much larger financial burden as compared to the outpatient 
episodes of hypoglycemia.  Considering the clinical burden of hypoglycemia, reducing 
the incidence of this adverse event in diabetic patients will have a significant impact 
on improvement of the quality of life of patients. 
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Figure 3.1 : Final Patient Selection Flowchart 
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Table 3.1: Demographic Characteristics of the study population Stratified by the 
Hypoglycemia 
 
Demographic 
Characteristic 
Hypoglycemia 
(n=1243)(%) 
No Hypoglycemia 
(n=28,128)(%) 
Chi-Sq 
Value 
P Value 
Agea 
18 - 34 29   (2.33) 808   (2.87) 
80.62 <0.001* 
35 - 49 137 (11.02) 4,469 (15.89) 
50 - 64 497 (37.38) 13,135 (46.70) 
65 And Above 580 (46.66) 9,716 (34.54) 
Gendera 
Male 676 (54.38) 13,275 (47.19) 
49.86 0.27 
Female 567 (45.62) 14,853 (52.81) 
a: The Cochran-Mantel-Haenszel statistic was used to compare categorical variables. 
*: Significant at p value 0.05 
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Table 3.2: Prevalence of Comorbidities as Measured by the Charlson Cormobidity 
Index Stratified by the Presence of Serious Hypoglycemic Events 
 
Demographic 
Characteristic 
Hypoglycemia 
(n=1243) 
No Hypoglycemia 
(n=28,128) 
Test 
Statistic 
Value 
P Value 
Charlson’s Comorbidity Index (Categorical Variable)a 
Cat 1 (0)+ 250 (20.11) 12,690 (45.12) 
529.82 <0.001* 
Cat 2 (1)+  136 (10.94) 4,409 (15.67) 
Cat 3 (2)+ 250 (20.11) 4,869 (17.31) 
Cat 4 (3 and 
above)+ 
607 (48.83) 6,160 (21.90) 
Charlson’s Comorbidity Index (Continous Variable)b 
Score 3.14 + (2.86) 1.50 + (2.03) 36.22 <0.001 
+: Category (Score). 
a: n(%) & the Cochran-Mantel-Haenszel statistic was used to compare categorical variables. 
b: Mean + (Standard Deviation) & a paired t-test was used to compare continuous variables. 
*: Significant at p value 0.05  as derived from Chi-square or T test. 
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Table 3.3: Prevalence of Elixhauser Comorbidity Conditions Stratified by the 
Presence of Serious Hypoglycemic Events 
Elixhauser Comorbidity Indexa 
Hypoglycemia 
(n=1,243) 
No 
Hypoglycemia 
(n = 28,128) 
Chi-Sq. 
Value 
P Value 
AIDS/HIV 3   (0.24) 37   (0.13)   1.05 0.3043 
Alcohol Abuse 28   (2.25) 361   (1.28) 8.55 0.0034* 
Blood Loss Anemia 28   (2.25) 339   (1.21) 10.58 0.0011* 
Cardiac Arrhythmias 324 (26.07) 3,682 (13.09)      170.15 <0.001* 
Chronic Pulmonary Disease 326 (26.23)   5,092 (18.10)      52.22 <0.001* 
Coagulopathy 56   (4.51) 532   (1.89) 41.45 <0.001* 
Congestive Heart Failure 290 (23.33) 2253   (8.01)      353.31 <0.001* 
Deficiency Anemia 156 (12.55) 1,607   (5.71) 98.62 <0.001* 
Depression 245 (19.71) 3,853 (13.70)      35.84 <0.001* 
Diabetes Complicated 1,034 (83.19) 6,317 (22.46) 2339.5 <0.001* 
Diabetes Uncomplicated 1,121 (90.19) 25,172 (89.49)    0.61 0.4343 
Drug Abuse 20    (1.61) 230    (0.82)  8.83 0.0030* 
Fluid And Electrolyte Disorders 230 (18.50) 1191   (6.79) 241.52 <0.001* 
Hypertension, Complicated 106   (8.53) 1190   (4.23)         52.11 <0.001* 
Hypertension, Uncomplicated 825 (66.37)   17,341 (61.65) 11.24 0.0008* 
Hypothyroidism 208 (16.73) 3,764 (13.38) 11.43 0.0007* 
Liver Disease 114   (9.17) 1,732   (6.16) 18.35 <0.001* 
Lymphoma 22   (1.77) 271   (0.96) 7.83 0.0051* 
Solid tumor without metastasis 199 (16.01) 2,979 (10.59) 36.22 <0.001* 
Metastatic Cancer 37   (2.98) 391  ( 1.39)  20.86 <0.001* 
Obesity 79   (6.36) 1,388   (4.93) 5.06 0.0244* 
Other Neurological Disorders 133 (10.70) 1,059   (3.76)   147.03 <0.001* 
Paralysis 22   (1.77) 124   (0.44) 43.03 <0.001* 
Peptic Ulcer Disease Excluding 
Bleeding 
19   (1.53) 211   (0.75)    9.28 0.0023* 
Peripheral Vascular Disorders 346 (27.84)   3,272 (11.63) 289.36 <0.001* 
Psychoses 70   (5.63) 469   (1.67) 103.84 <0.001* 
Pulmonary Circulation Disorders 65   (5.23) 700   (2.49) 35.24 <0.001* 
Renal Failure 199 (16.21) 1,224  (4.35) 350.93 <0.001* 
Rheumatoid Arthritis/ Collagen 
Vascular Diseases 
87   (7.00) 1,284  (4.56) 15.85 <0.001* 
Valvular Disease 167 (13.44) 2,087  (7.42) 60.79 <0.001* 
Weight Loss 50    (4.02) 701  (2.49) 11.18 0.0008* 
a: n(%) & the Cochran-Mantel-Haenszel statistic was used to compare categorical variables. 
*: Significant at p value 0.05 as derived from Chi-square 
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Table 3.4: Prevalence of Micro and Macrovascular Diabetes Complications and 
Other Contributing Diseases  Stratified by the Presence of Serious Hypoglycemic 
Events 
Diabetes Complications 
Hypoglycemia 
(n=1,243) 
No 
Hypoglycemia 
(n=28,128) 
Chi Sq. 
Value 
P value 
Macrovascular  
Arrhythmia 196 (15.77) 2,016   (7.17) 126.45 <0.001* 
Congestive Heart Failure 262 (21.08) 1,911   (6.79) 354.51 <0.001* 
Coronary Artery Disease 411 (33.07) 5,269 (18.73) 156.77 <0.001* 
Peripheral Vascular 
Disease 
451 (36.28) 4,334 (15.41) 380.37 <0.001* 
Stroke  94    (7.56) 765   (2.72) 98.32 <0.001* 
Microvascular  
Acute Renal Failure   195 (15.69) 919   (3.27) 503.27 <0.001* 
Amputation  9    (0.72) 61   (0.22) 12.87 0.0003+ 
Chronic Renal 
Pathophysiology  
131 (10.54) 951   (3.38) 171.89 <0.001* 
Dialysis  7    (0.56) 66   (0.23) 5.18 0.0228+ 
End Stage Renal Disease  3    (0.24) 12   (0.04) 9.24 0.0024+ 
Diabetic Nephropathy 71    (5.71) 574   (2.04) 74.70 <0.001* 
Diabetic Retinopathy  259 (20.84)  3,861 (13.73) 49.90 <0.001* 
Ulcer   339 (27.27) 1,508   (5.36) 969.82 <0.001* 
Other Contributing Diseases  
Addison's Disease 13   (1.05) 54   (0.19) 38.13 <0.001* 
Liver Disease 82   (6.60) 1,225   (4.36) 14.07 0.0002* 
Thyroid Disease 187 (15.04) 3,515 (12.50) 7.01 0.0081* 
a: n(%) & the Cochran-Mantel-Haenszel statistic was used to compare categorical variables. 
*: Significant at p value 0.05 as derived from Chi-square. 
+: Significant at p value 0.05 as derived from Fischer’s Exact Test. 
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Table 3.5: Concomitant Usage of Diabetic Medications Stratified by Exposure to 
Hypoglycemia 
Concomitant 
Medicationsa 
Hypoglycemia 
(N = 1243) 
No 
Hypoglycemia        
(N = 28,128) 
Chi 
Sq. 
P value 
Alpha Glucosidase 
Inhibitors  
9    (0.72) 80    (0.28) 7.61 0.0058+ 
Biguanides  528 (42.48) 12,047 (42.83) 0.06 0.8065 
Dipeptidyl Peptidase 4 
Inhibitors 
120   (9.65) 2,338   (8.31) 2.79  0.0945* 
Insulin 300 (24.14) 2,572   (9.14) 
303.2
4 
<0.001* 
Other Injectable Agents 32   (2.57) 504   (1.79) 4.06 0.0437* 
Meglitinides 29   (2.33) 232   (0.82) 30.74 <0.001* 
Sulfonylureas 516 (41.51) 7,305 (25.97) 
147.1
7 
<.001* 
Thiazolidinediones 144 (11.58) 2,737   (9.73) 4.62 0.0315* 
a: n (%) & the Cochran-Mantel-Haenszel statistic was used to compare categorical variables. 
*: Significant at p value 0.05 as derived from Chi-square. 
+: Significant at p value 0.05 as derived from Fischer’s Exact Test. 
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Table 3.6: Prevalence of Anti-diabetic Medications Stratified by Exposure to 
Hypoglycemia 
Diabetes Medications 
Hypoglycemia 
(N = 1,243) 
No Hypoglycemia        
(N = 28,128) 
No Therapy 434 (34.92) 13,175 (46.84) 
Monotherapy 
Insulin 70 (5.63) 600 (2.13) 
Sulfonylureas 102 (8.21) 1,192 (4.24) 
Biguanides 112 (9.01) 4,641 (16.50) 
Thiazolidinediones 6 (0.48) 233 (0.83) 
Alphaglucosidase Inhibitors 3 (0.24) 10 (0.04) 
Meglitinides 1 (0.08) 21 (0.07) 
Dipeptidyl Peptidase – 4 Inhibitors 3 (0.24) 90 (0.32) 
Combination Therapya,b 
Insulin + Biguanides 49 (3.24) 474 (1.69) 
Insulin + Sulfonylureas 28 (2.25) 138 (0.49) 
Insulin + Thiazolidinediones 8 (0.64) 58 (0.21) 
Biguanides +Sulfonylureas 146 (11.25) 2,871 (10.21) 
Biguanides + Thiazolidinediones   9 (0.72) 513 (1.82) 
Sulfonylureas + Thiazolidinediones 11 (0.88) 188 (0.67) 
Insulin + Biguanides + Sulfonylureas 57 (4.59) 498 (1.77) 
Biguanides + Sulfonylureas + Dipeptidyl 
Peptidase – 4 Inhibitors 
26 (2.09) 659 (2.34) 
Biguanides +Sulfonylureas + 
Thiazolidinediones  
32 (2.57) 651 (2.31) 
Others 137 (11.02) 2,116 (7.52) 
a: n (%) & the Cochran-Mantel-Haenszel statistic was used to compare categorical variables. 
b: Examples of combination therapy (use of more than one medication) might include  Glipizide/Metformin 
Hydrochloride, Glyburide/Metformin Hydrochloride, Pioglitazone Hydrochloride/Glimepiride, Pioglitazone 
Hydrochloride/Metformin Hydrochloride, Repaglinide/Metformin Hydrochloride, Rosiglitazone 
Maleate/Glimepiride, Rosiglitazone Maleate/Metformin Hydrochloride, Sitagliptin Phosphate/Metformin 
Hydrochloride. 
*: Significant at p value 0.05 as derived from Chi-square. 
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Table 3.7: Concomitant Usage of Non –Diabetic Medications Stratified by Exposure 
to Hypoglycemia 
Concomitant 
Medications 
Hypoglycemia 
(N = 1243) 
No 
Hypoglycemia        
(N = 28,128) 
Chi Sq. P-Value 
Overall Medication Frequencya 
Number of Medications 15.34 + (12.21) 10.97 + (9.63)  <0.001* 
Categorized Medication Frequencyb 
Number of Medications     
0 - 3 296 (23.81) 7881 (28.02) 
119.48 <0.001* 
4 - 7 62   (4.99) 3347 (11.90) 
8 - 10 59   (4.75) 2255   (8.02) 
More than 10 826 (66.45) 14645 (52.07) 
Medication Classesb 
ACE Inhibitors 549 (44.17) 10548 (37.50) 22.51 <0.001* 
Allopurinol 70   (5.63) 1048   (3.73) 11.80 0.0006* 
Angiotensin II Receptor 
Blockers 
120   (9.65) 2419   (8.60) 1.67 
0.1956* 
Benzodiazepines 262 (21.08) 4815 (17.12) 13.05 0.0003* 
Beta-Adrenergic Blocking 
Agents 
484 (38.94) 7404 (26.32) 96.44 
<0.001* 
Fibrates 107   (8.61) 2146   (7.63) 1.61 0.2045* 
Fluoroquinolones 411 (33.07) 6130 (21.79) 87.37 <0.001* 
Nonsteroidal Anti-
Inflammatory Drugs 
344 (27.67) 8011 (28.48) 0.37  0.5379 
Trimethoprim 4    (0.32) 92    (0.33) 0.01 0.9746 
Warfarin 158 (12.71) 1520   (5.40) 118.01 <0.001* 
a: Mean + (STD. DEV) & T test used for continuous variables. 
b: n (%) & the Cochran-Mantel-Haenszel statistic was used to compare categorical variables. 
*: Significant at p value 0.05 as derived from Chi-square. 
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Table 3.8: Independent Predictors Of Serious Hypoglycemic Eventsa 
Risk Factor Crude OR 95% CI 
Adjusted 
ORb 
95% CI 
Age Category 
18 - 34 1.00 NA  1.00  NA 
35 - 49 0.85 0.56 – 1.28 0.78 0.51 – 1.18 
50 - 64 1.05  0.72 – 1.54 0.76 0.50 – 1.13  
65 And Above 1.66  1.13 – 2.43  0.71 0.47 – 1.07  
Gender 
Female 1.00 NA 1.00 NA 
Male 1.06 0.95 – 1.19 1.04  0.92 – 1.14 
Charlson’s Comorbidity Index 
CAT 1 (0) 1.00  NA 1.00 NA 
CAT 2 (1) 1.56 1.26 – 1.93 1.38 1.11 – 1.72 
CAT 3 (2) 2.60  2.18 – 3.11 2.05 1.70 – 2.47 
CAT 4 (3 Or More) 5.00 4.30 – 5.18 2.12 1.73 – 2.59 
Congestive heart failurec 3.49 3.04 – 4.01 1.24 1.04 – 1.49 
Cardiac arrhythmiac 2.34 2.05 – 2.67  1.21 0.99 – 1.49 
Peripheral vascular disordersc 2.93 2.57 – 3.33 1.19 1.02 – 1.40 
Hypertension (uncomplicated)c 1.22 1.08 – 1.38 0.84 0.74 – 0.97 
Paralysisc 4.10 2.59 – 6.48 1.67  1.01 – 2.78 
Other Neurological Disordersc 3.06  2.53 – 3.70 1.52 1.22 – 1.89 
Hypothyroidismc  1.30  1.11 – 1.51 1.13 0.96 – 1.34 
Renal failurec 4.19 3.56 – 4.92 1.19 0.96 – 1.48 
Obesityc 1.30 1.03 – 1.65 1.30  1.01 – 1.67 
Fluid and electrolyte disordersc 3.11 2.68 – 3.62 1.31 1.09 – 1.57 
Deficiency anemiac 2.36 1.98 – 2.82 1.37 1.13 – 1.67 
Psychosesc 3.52  2.72 – 4.55 1.60 1.19 – 2.14 
Chronic renal pathophysiologyc 3.36 2.77 – 4.08 1.23 0.98 – 1.56 
Acute renal failurec 5.50 4.66 – 6.50 1.79 1.44 – 2.23 
Ulcerc 6.62  5.78 – 7.57 4.07 3.50 – 4.72 
Amputationc 3.35 1.66 – 6.77 2.73 1.26 – 5.91 
Addison’s Diseasec 5.49  2.99 – 10.09 3.17 1.64 – 6.14 
Number Of Medications 
0 - 3 1.00 NA 1.00 NA 
4 - 7 0.49 0.37 – 0.65  1.38  1.11 – 1.72 
8 - 10 0.69 0.52 – 0.92 2.05 1.70 – 2.47 
More than 10 1.50  1.31 – 1.72 2.12 1.73 – 2.59 
Insulinc 3.16 2.75 – 3.62 2.20 1.88 – 2.56 
Sulfonylureasc 2.02 1.80 – 2.27 1.71 1.49 – 1.97 
Alphaglucosidase Inhibitorsc 2.55 1.28 – 5.10 1.93 0.92 – 4.06 
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Meglitinidesc 2.87 1.94 – 4.24 1.75 1.14 – 2.70 
a: Independent predictors were identified using a conditional logistic regression model. 
b: Adjusted for all factors listed in the table. 
c: Dichotomized predictors; absence of factor is the referent group. 
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Figure 3.2: Classification For Episodes Of Inpatient Claims 
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Figure 3.3: Classification Of Episodes For Outpatient Claims 
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Table 3.9: Cost Estimates of Hypoglycemic Events, Other Diabetes-Related Events, 
and All Other Events Stratified by Setting. 
Setting Type Of Costa Encounters Mean cost per 
encounter ($) 
Total Costs ($)b 
Inpatient 
Costs 
Hypoglycemia 2,025 1,514.60 3,067,076 
Other Diabetes 27,412 232.71 6,379,256 
All Other  367,531 1,171.60 430,600,338 
Total Inpatient Costs 440,046,671c 
Outpatient 
Costs 
Hypoglycemia 2,851 142.91 407,456 
Other Diabetes 206,671 89.93 18,587,620 
All Other 1,229,828 182.63 224,610,691 
Total Outpatient Costs 243,605,766c 
a: Cost category identified using ICD-9 codes associated with the claim and creating 3 mutually exclusive groups:  
1) those identified as hypoglycemia (hypoglycemia costs). 
2) those with primary ICD-9 code 250.XX (other diabetes costs). 
3) others (all other costs). 
b: Total costs rounded to nearest dollar. 
c: Costs of hypoglycemic events, other diabetes-related events, and all other events may not sum to total costs due 
to rounding. 
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4.1 Sulfonylureas 
Sulfonylureas (SUs) have been the widely prescribed medications in the management 
of T2DM since the 1950s, with as many as 75 to 80% of patients initiated on one of 
these agents.225,226 First-generation agents such as acetohexamide, chlorpropamide, 
and tolbutamide were very popular in the 1960s.227 However, by the 1970s, many 
safety concerns arose over the use of these drugs with many observational studies 
clinical trials, most notably the UGDP (University Group Diabetes Program), providing 
inconclusive evidence regarding the detrimental effects of this class of drugs.227 The 
UGDP was intervention trial of 1027 newly diagnosed T2DM patients with the 
objective of comparing the efficacy of oral anti hyperglycemic agents, insulin and diet 
alone in the prevention of diabetes-related vascular complications. This study 
demonstrated an annual rise of approximately 1% per year in the rate of 
cardiovascular mortality of patients receiving tolbutamide (a sulfonylurea) compared 
to diet alone. Subsequently, the safer second generation of SUs (e.g., glyburide, 
glipizide, and glimepiride) emerged in the next few decades and has largely replaced 
the first generation of SUs. Even though they differ from the first generation of SUs  
with respect to their chemical composition, both groups were found to be equivalent 
in their hypoglycemic effect.90 
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4.1.1 Efficacy And Indications  
Many retrospective and prospective have focused on the efficacy of SUs. Although 
potency of effects can vary among patients, when used as a monotherapy in patients 
who cannot achieve the glycemic goals by nonpharmacologic interventions, SUs tend 
to lower A1C by 1.5 to 2.0 percentage points and fasting plasma glucose by 60 – 70 
mg/dL, when used as monotherapy at maximal doses are used.90,228,229 SUs can be 
used as the first line oral antidiabetic agents of choice in patients who fail to achieve 
adequate glycemic control using nonpharmacological measures or may also be added 
to a patients regimen if metformin monotherapy is contraindicated, not tolerated or 
does not achieve the target A1C at 3-6 months of treatment. SUs can be combined 
with other classes of OADs, excluding insulin secretagogues and combining daytime 
SUs with bedtime insulin, an increasingly popular practice lacking scientific evidence 
of potential advantages over insulin monotherapy, can help reduce can reduce 
insulin doses by half. SUs are preferred in patients who are not obese or overweight 
since weight gain is a major concern with this class of agents.227 Similarly these drugs 
are used conservatively in the geriatric population as well as patients with impaired 
renal and hepatic functions and belong to pregnancy category B or C. However, 
according to the UKPDS, despite achieving the target achieved a A1C of <7 % in the 
first 3 years, only 34 % of patients attained a HbA1c <7 % at 6 years, with this number 
further declining to 24 % at 9 years.97,230  
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4.1.2 Adverse Events With Sulfonylureas  
This class of drugs has been historically accepted as being well tolerated with only 
about 2 -5 % of patients reporting primary toxicities associated with it being 
hypoglycemia, weight gain, B cell exhaustion and adverse cardiovascular 
outcomes.231  
Previous literature attributes initiation of SU therapy to a resulting increase in body 
weight, which also accompanies many of agents, apart from metformin, that are 
used for diabetes management.232 Typically, various studies report a weight gain of 
approximately 1 – 4 kg.227,231-235 There have been concerns regarding the cardiac 
safety of the sulfonylureas class of drugs especially after research on the 
physiological effect of these drugs.99,236-238 SUs usually affect an initial increase in the 
B cell function, which is followed by a gradual and linear reduction, which goes hand 
in hand with the therapeutic failure of these drugs and the resulting progressive 
worsening of glycemic control.217,239,240  
4.1.3 Hypoglycemia with Sulfonylureas 
Even though different SUs possess different pharmacotherapeutic profiles, the major, 
most common, and potentially, the most worrisome adverse effect associated with 
this class of drugs is hypoglycemia. The risk of development of hypoglycemia 
episodes differs between different SUs with the likelihood of the prolonged 
manifestation of this side effect being greater with longer-acting agents like 
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chlorpropamide, glyburide, glibenclamide and longer acting glipizide as compared to 
the newer second generation like glimepiride (150 vs 105 episodes for glibenclamide 
and respectively).94,241,242 Similarly, other factors like timing of the drug, dose, and 
potency of the specific agent are known to affect the risk of this adverse event. 
Previous studies have attempted to characterize the risk factors for hypoglycemia in 
patients with T2DM. Among the other patient related factors, advanced age, taking 
multiple medications, inconsistent frequency of meals and physical activities as well 
as impaired organ system functions are clearly known to increase the risk of 
recurrent hypoglycemic effects of SUs.243 For example, Setzer et al., in a 
comprehensive review of 1,418 cases of severe drug-induced hypoglycemia, found 
that sulfonylurea ingestion was a factor in 65% of adult cases, 86% of cases were 
older than 50 years, and the omission of 1 or more meals was implicated in 80% of 
cases. Moreover these results should be viewed in light of the drawbacks of this 
study including lack of a control group, inclusion of patients with and without 
diabetes as well as intentional overdoses, and design flaws244.  Similarly, Asplund et al 
reported that more than 90% of the 57 type 2 diabetic patients experiencing 
glibenclamide-associated hypoglycemia were older than 60 years and more than 70% 
were older than 70 years.245 
Bonds and colleagues, in a secondary analysis of the ACCORD clinical trial data, did 
not find any association between sulfonylureas and severe hypoglycemia in both the 
intensive [Hazard ratio 1.06, 95% CI 0.88–1.28] and the standard intervention group 
[Hazard ratio 0.85, 95% CI 0.6–1.20].178 Similarly, Burge et al. in a prospective, 
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randomized, double-blind clinical trial evaluated the hypoglycemic effects of 
maximum doses of once-daily second-generation sulfonylureas in the elderly 
patients. Each patient was assigned to either glyburide or glipizide therapy and took 
part in three 23-hour fasting studies after undergoing sequential administration of 1 
week of placebo and 1 week of 10 mg and 1 week of 20 mg of the assigned 
sulfonylurea. It was observed that none of the 58 patients had and event of 
hypoglycemia during the fasting period.246 Similarly, The GUIDE study which 
randomized 845 T2DM patients to gliclazide modified release (MR) or glimepiride 
monotherapy or in combination with other treatments to HbA1c and safety by 
episodes of hypoglycemia, showed no hypoglycemia requiring external assistance for 
similar HbA1c reduction in both groups, age notwithstanding.235 
However, in contrast, many other clinical trials as well as observational studies 
implicate pharmacological effect of the SUs as the principal cause. Data from several 
clinical trials, though variable with respect to the rates of hypoglycemic events, 
attribute hypoglycemia to SU therapy. In the UKPDS, the rates of hypoglycemia 
varied from 11% to 17.7% depending on the specific agent used with the rates of 
severe episodes being less than 1% with either chlorpropamide or glibenclamide.97,232 
However, failure to provide details of the diagnosis of the hypoglycemia episode and 
considerable inter changing between agents were the principal drawbacks of this 
study which made it difficult to define and associate the hypoglycemic episode to a 
particular agent.97 However, in comparison to the Diabetes Control and 
Complications Trial (DCCT), the relative risk of hypoglycemia was much lower in the 
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UKPDS. Both, Draeger et al. and Clarke et al. compared glyburide with other 
sulfonylureas and found varying rates of hypoglycemia, with all the agents within the 
class associated with a higher risk of hypoglycemia.242,247  
Gangji et al. in a meta-analysis to glyburide with other secretagogues as well as 
insulin with respect to the potency to cause hypoglycemia and cardiovascular events 
found a 52%  and 83% greater risk of hypoglycemic events associated with glyburide 
in comparison to other secretagogues (Relative Risk (RR) 1.52 [95% CI 1.21-1.92]) and 
other sulfonylureas respectively ( RR 1.83 [95% CI 1.35-2.49]).243 Hollander et al. 
compared the effects of nateglinide, glyburide, and placebo on post meal glucose 
excursions and insulin secretion in 152 patients and as one of the outcomes found 
that nateglinide-treated patients had significantly fewer hypoglycemia events as 
compared to those treated with glyburide but more events than placebo-treated 
patients (12 vs. 53 vs. 2, respectively).248  
Van Staa et al. assessed the risk of hypoglycemia in 33,243 patients treated with 
sulfonylureas in 719 clinical practices in the UK and found that a diagnosis of 
hypoglycemia during sulfonylurea therapy was recorded in 605 people over 34,052 
person-years of sulfonylurea therapy thus amounting an annual risk of 1.8%249,250 
while in another review in Germany, the incidence rates for severe hypoglycemia was 
0.86/1000 person- therapy years and 5.6/1000 person-years for glimepiride and 
glibenclamide respectively.251 
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Jennings et al. demonstrated that up to 20% of the patients taking SUs experience 
symptoms consistent with hypoglycemia over a 6-month period with 6% of the 
patients having hypoglycemic symptoms in a month.252,253 Shorr et al. while studying 
the incidence and risk factors for developing serious hypoglycemia among older 
persons using sulfonylureas or insulin in a population-based, retrospective cohort 
study of 19932 Tennessee Medicaid enrollees, aged 65 years or older taking SUs or 
insulin identified 586 persons with a first episode of serious hypoglycemia during 
33,048 person-years of insulin or sulfonylurea use thereby giving crude rates of 
1.23/100 person years for serious hypoglycemia (95% confidence interval [CI], 1.08-
1.38) in users of sulfonylureas and 2.76100 person years (95% CI, 2.47-3.06) among 
insulin users and 3.38/100 person years in patients using both. The adjusted relative 
risk was 0.2 for tolbutamide, 0.6 for glipizide and tolazamide, and 1.0 for 
glibenclamide in comparison to chlorpropamide. The authors also reported that that 
recent hospitalization was the strongest predictor of hypoglycemia in the elderly 
population211,252. Vickova et al. reported rates of 157.1 per 10 000 person-years in 
nateglinide users and 203.2 per 10 000 person-years in repaglinide users.254,255 
Thus, it can be seen from the literature that the incidence of hypoglycemia is 
widespread in T2DM patients on SU therapy and that this has the potential to be the 
limiting factor in the attainment of the target goals for glycemic control. Thus, 
experts largely advice prudent setting of glycemic targets as well as careful selection 
and dosing of the oral diabetic agents based on various patient and other 
environmental factors. 
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4.1.4 Persistence with Sulfonylureas 
The relationship between persistence to SU therapy and health outcomes has been 
previously explored in a number of studies. Boccuzzi et al. noted that in patients who 
continuously refilled a prescription for their initial oral antidiabetic  within 1.5 times 
the days’ supply of the previous fill, the rate of discontinuation for sulfonylureas was 
less than that for metformin (11.3% vs 11.9%).109 In contrast, Dailey et al. examined 
drug use patterns among patients with T2DM to understand drug use patterns 
among Medicaid recipients and assess their persistence to different antidiabetic 
regimens. After following 37,431 patients for a year, the authors found that 85.3% of 
the sample on monotherapy was taking a sulfonylurea among whom 15% of the 
patients remained persistent in comparison to the 14% who were on metformin 
monotherapy among whom 16% remained persistent.256 Jermendy et al. compared 
the persistence of diabetic patients initiated on metformin or a SU to patients newly 
prescribed statin or clopidogrel therapy and found that the 1-year persistence of 
initial treatment with metformin, sulfonylureas or metformin/sulfonylureas 
combination was 47.7%, 45.4% and 55.8%, respectively. This though higher than 
statin therapy (26.3%), was still sub optimal.257 Similarly, Sclar et al. in a study of 
Medicaid recipients in South Carolina exhibited low treatment persistence in SU 
users, with only 39.4% of the study population obtaining atleast a 6 month supply.258 
Hertz and colleagues conducted a retrospective cohort study of 6090 newly treated 
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patients aged 18-64 years to determine adherence with pharmacotherapy for T2DM 
found that 9.7% of patients initiated on sulfonylureas were non-persistent at an early 
stage while almost 34% of the patients were non-persistent at the end of a year.259 
Grégoire et al. assessed persistence patterns with oral antidiabetic medications in a 
population-based cohort study. They found that the likelihood of continuing the with 
the initially prescribed oral antidiabetic medication over a 12 month period was 56% 
for SUs, which was about 10% less than that for metformin. In another study, 
Ligueros-Saylan and colleagues found that almost 44% of the patients on SUs 
discontinued their therapy within one year of initiation.260 The risk of medication 
discontinuation during the follow up period was significantly higher for patients who 
were prescribed sulfonylureas as compared to metformin, the likelihood of (Adjusted 
Hazard Ratio: 1.32; 95% CI 1.29–1.34) and probability of restarting the therapy after 
discontinuation was less likely (Adjusted Hazard Ratio: 0.91; 95% CI 0.89–0.93).261  
It is well understood from previous literature that persistence with medications is a 
vital factor in achieving optimal glycemic control. A large body of literature also 
points to the fact that treatment non persistence is a frequent issue related to oral 
antidiabetic medications including sulfonylureas. Cramer et al., while reviewing 
studies of patient compliance and persistence with cardiovascular or antidiabetic 
medications, suggested that even though the overall persistence rate for oral 
antidiabetics was comparable to other therapeutic classes of medications for various 
diseases, noncompliance with antidiabetic medication was still a grave issue with the 
results showing that the 12-month persistence of oral antidiabetics was 62% with 
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almost 30% of days of therapy not covered by medication and only 59% of patients 
having medication for more than 80% of their days on therapy in the year.107 It has 
also been shown in various studies that conforming to the medication regimen can 
significantly decrease the utilization of medical resources. For example, Hepke et al. 
conducted a study in a non-managed care setting and concluded that higher degree 
of medication adherence was associated with reduced use of emergency department 
and inpatient visits.262 Thus considering the association between medication 
persistence and positive health outcomes including achievement of glycemic control 
and reducing complications and hospitalizations as well as medical costs, it becomes 
necessary to explore the association between medication persistence to SUs and 
various patient related factors, one of them being hypoglycemic events. 
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4.2 Rationale And Objectives Of The Study 
Data suggests that intensive glycemic control, though beneficial in minimizing several 
complications of diabetes may sometimes act as a precursor to incidence of 
hypoglycemia.95,200,263 Recurrent hypoglycemia is associated with significant 
morbidity and often leads to negative health outcomes with respect to ideal diabetes 
management. Moreover, there is evidence that hypoglycemia may create a barrier to 
medication adherence. For example, Walz et al. evaluated the impact of symptomatic 
hypoglycemia on medication adherence, satisfaction with treatment, and glycemic 
control in patients with T2DM and reported that patients who experienced moderate 
or worse symptoms of hypoglycemia reported poorer adherence to medication (46% 
versus 67%; p-value <0.01) and were more likely to report barriers such as “bothered 
by medication side effects” (36% versus 14%; P-value <0.001) compared with 
patients with no hypoglycemia or mild symptoms of hypoglycemia.264 Similarly, Lopez 
et al. carried out a retrospective study in adults with T2DM taking antidiabetic agents 
and found that 55.7% of the patients had at least one hypoglycemic event. Among 
patients taking antidiabetic medications, 52% reported medium to low adherence 
with their medications, with almost 60% of people with medium to low adherence 
having experienced a recent episode of hypoglycemia.265 The RECAP-DM (Real-Life 
Effectiveness and Care Patterns of Diabetes Management) study, a multicentre study 
was conducted in seven countries, evaluated the association of patient-reported 
hypoglycemic symptoms with treatment satisfaction and barriers to adherence. The 
study focused on the addition of a sulfonylureas or a thiazolidinedione to ongoing 
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metformin therapy. Nevertheless, 38% of patients reported hypoglycemic symptoms 
during the previous year, patients with hypoglycemic symptoms were more likely to 
report barriers to adherence.181 
Although various aspects of medication adherence in diabetes therapy have been 
investigated, studies which have focused on evaluating the impact of hypoglycemia 
on the adherence and persistence to SU therapy have been scarce. Medication 
persistence and treatment continuation could be altered in patients on SU therapy 
who experience hypoglycemic events due to number of reasons including fear of 
hypoglycemic events, impaired physical functioning as well as the impact on the 
quality of life, social well-being and activities of daily living. Studies report 
approximately 7% of patients on SU therapy experience one or more episodes of 
severe hypoglycemia per year, with hypoglycemic episodes potentially affecting 
decisions to discontinue treatment. It is essential to understand and describe 
differences in medication persistence in patients taking SU therapy related to 
hypoglycemia.213 Therefore, the aim of this study was quantify the effect of 
hypoglycemia on persistence rates with oral SU therapy. 
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4.3 Methods  
4.3.1 Datasource 
For the purpose of our study, we used the Blue Cross and Blue Shield Of Rhode Island 
(BCBSRI) administrative claims data for the years 2009 - 2012. BCBSRI is a non-profit 
hospital service and medical service corporation covering more than 600,000 
members. In the data extract used for our analyses, all the members had at least one 
International Classification of Disease-9 (ICD-9) code for diabetes (ICD-9 250.XX) 
between 2009 and 2012. To achieve the aims of our study, we utilized three 
administrative files, including eligibility files, medical claims (inpatient and 
outpatient) and pharmacy claims. The enrollment file included age, gender as well as 
the start and end dates for enrollment in the health plan. Similarly, the outpatient 
and inpatient files include diagnosis information (ICD-9 codes), Current Procedural 
Terminology (CPT) codes, admit and discharge dates as well as cost and copayment 
information. The medication claims dataset included prescription medications 
dispensed during the study period and included the National Drug Codes (NDC), drug 
product names, prescription quantity (number of units dispensed) and days supplied 
at the time of dispensing (e.g. 30 day supply of medication). Due to the 
comprehensive nature of the claims provided in the dataset, it can be assumed that 
this dataset provides a near complete picture of an individual’s health care.  
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4.3.2. Research Design And Study Population 
Using the inpatient and outpatient medical claims, and prescription claims, we 
conducted a retrospective cohort study using a new user design (Figure 4.1).266  As 
our focus was on patients taking SU therapy, we further identified patients in the 
dataset who initiated treatment with a SU.  More specifically, we utilized the 
following inclusion and exclusion criteria: 
Inclusion Criteria: 
• At least 18 years of age. Patient age was calculated as of the date of first SU 
fill. 
• At least 1 prescription claim for an SU Oral Antidiabetic Drug (OAD). 
• Continuous enrollment in the health plan for at least 12 months after the 
initial SU fill date. 
Exclusion Criteria: 
• At least one claim for type 1 diabetes (ICD-9 250.X1 or 250.X3) or gestational 
diabetes (ICD-9-CM 648) within the baseline period. 
Since we required a continous eliglibility period of 12 months following the cohort 
entry for each patient, we constructed eligibility episodes for each unique patient by 
considering the eligibility episode separate if there was a lag of 30 or more days 
between the end date of the previous episode and the start date of the next episode. 
We only considered the eligibility episode in which the first prescription was 
recorded. Thus, after the initial identification of the patient cohort, we created the 
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cohort entry date as an indicatior of the first date of fill for a SU. We further divided 
the study period for each patient into two phases: the baseline period and the post 
baseline period (Figure 4.2). The duration of the baseline phase was 3 months from 
the date of the first SU fill. The length of the post baseline phase was 9 months from 
the end date of baseline arm of the study. Thus, we followed each identified patient 
for a total maximum duration of 12 months starting on the first date of SU fill. An 
overview of study design is presented in Figure 4.2. Further, we assessed the 
hypoglycemia exposure, demogrpahics, other diabetic medication exposure as well 
as history of comorbid conditions within the baseline arm or the first 3 months of the 
study after the first date of fill.  
4.3.3 Exposure To The Medication Class Of Interest (SUs) 
As mentioned earlier, the BCBSRI data includes information on the use of 
prescription drugs by the patients in the health plan and can be linked to the 
inpatient and outpatients medical claim files using a unque indentifier. Utilizing the 
prescription claims data, we identified the use of medications in the patient 
population by using a combination of NDC codes as well as generic and brand 
product names. NDC codes are unique, three-segment numbers, usually 10 digits in 
length, which act as a universal product identifier for drugs. Further, for verification 
purposes, we used the Redbook 2008 to link the therapeutic groups and therapeutic 
classes to the drug records in the dataset. Moreover, we excluded observations if 
patient had day of supply less than or equal to 0 as well as those patients who had 
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days of supply more than 180. Using the aforementioned methods, we identified all 
the patients who received their first prescription for SU along the duration of the 
study. It has been noted in literature that patients with T2DM are often treated with 
a variety of concomittant medication. Based on previous evidence, we established 
and outlined certain classes of drugs that were know to act as contributing factors to 
risk of hypoglycemia.  
Once we identified the eligible study population, we then evaluated exposure history 
during the baseline period to create two exposure groups: 1) those with at least one 
inpatient or outpatient claim for hypoglycemia during the baseline period; and 2) 
those without any claims for hypoglycemia during the baseline period.  Hypoglycemic 
exposure was defined as the first hypoglycemic event within the baseline period 
requiring medical attention in either the inpatient or outpatient setting. To identify 
these hypoglycemic events we used the algorithm suggested by Ginde and 
colleagues.187  This algorithm identifies an hypoglycemic event if any hospital and 
clinic visits are indicative of hypoglycemia by using standard ICD-9 codes (ICD-9: 
251.0, 251.1, 251.2, 270.3, 962.3).Further if there is absence of hypoglycmia but 
presence of diabetes with other specified manifestations (ICD–9 : 250.8) without 
other contributing diagnoses (ICD-9 : 259.8, 272.7, 681.XX, 682.XX, 686.9X, 707.1-
707.9, 709.3, 730.0-730.2 or 731.8), then such incidents are also termed as a 
hypolgycemic event. This algorithm is well validated and demonstrated an 89% 
positive predictive value (PPV) (95%CI,86–92) in accurately identifying hypoglycemia 
visits and an exhibited an estimated 97% sensitivity and > 99 specificity.187,263  It has 
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been well documented that severe episodes of hypoglycemia are often followed in 
quick succession by further hypoglycemic events. Hence, while characterizing the 
subsequent events of hypoglycmia following the first incident, we counted the events 
that occurred with a minimum gap of 7 days between them as separate event, else 
the entire hypoglycemic episode was considered as a single event. Using this 
information, we created two groups of indivuduals, those with at least one 
hypoglycemic event during the baseline period and those without.  As our interest 
was in incident discontinuation following hypoglycemia, we excluded patients with 
treatment discontinuation (n= 16) before an event of hypoglycemia within the 
baseline period. 
4.3.4 Outcome of interest : SU Treatment Discontinuation 
We followed all persons in both exposure groups for SU medication discontinuation 
until the end of the follow-up period.  We defined discontinuation as a gap of > 30 
days in SU prescription availability that occurred between consecutive prescriptions. 
Usually, the gap period allowed in various retrospective studies varies from 30 to 90 
days or 1.5x last days supply.267 Based on the clinical relevence to hypoglycemia and 
the day’s supply limts, we chose a window of 30 days to be appropriate. This period 
was considered as a period where the patients would not anticipate suboptimal or 
negative health outcomes.267,268 If another refill of the SU was filled within the 
specified window from the end date of the preceeding prescription’s days of supply, 
the patient was considered persistent.  The persistence in terms of days to 
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discontinuation was calculated for the entire SU drug class, allowing for switches 
within the same class (i.e. patients switched from one SU agent to another).  We 
followed all patients to the first of three endpoints: 1) time to discontinuation; 2) a 
subsequent hypoglycemic episode; or 3) the end of the study period.  An overview of 
outcome identification is presented in Figure 2.   
4.3.5 Demographics and Comorbidities 
We compared the demographic as well as clinical characteristics between the 
hypoglycemia exposed and the hypoglycemia non exposed cohorts during the initial 
baseline period of the study. This process was carried out to characterize the 
potential confouding effects of certain patient related factors of interest like age and 
gender on the the risk of discontinuing the SU therapy. Since age was recorded as the 
age at the end of the enrollement period,  we re-calculated the age at the date of the 
first fill of SU for all the patients in the study. 
We used the inpatient as well as outpatient claims records for characterising rhe 
presence of comorbidities in patients. We identified the ICD-9 codes in these files to 
ascertain the presence of certain macro- and microvascular complications of diabetes 
as well as other conditions like Addison’s disease and hypothyroidism which are 
associated with diabetes by employing methodologies that have been applied in 
other studies. We calculated a overall point estimate of comorbidity by application of 
the Deyo adaptation of the Charlson’s Comorbidity Index.263,269 As a part of this 
comorbidity index,  scores from a minimum of 1 to a maximum of 6 were assigned 
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with different weights, to each of the 19 selected  medical conditions based on their 
adjusted relative risks and were then summed into a composite score for each 
individual patient. In addition to the overall comorbidity score, we also evaluated the 
individual comorbidities that might have an association with hypoglycemia. This was 
done by using the Quan H. ‘s enhanced ICD-9 codes of the Deyo’s adaptation of the 
Elixhauser Comorbidity Index. The performance and validity  of the Charlson and 
Elixhauser comorbdity indices in predicting health outcomes has been previously 
evaluated in a vareity of population studies where they have been consistent as 
prognostic measures of outcomes.270 The presence of each comorbidity were 
recorded as a categorical dichotomous variable. 
Similar to the SU identification, we also characterized the use of other medications in 
the baseline arm of the study by using a combination of NDC codes, product names 
as well the threpautic classes and groups. The specific classes of drugs that we were 
interested in evaluating were angiotensin converting enzyme (ACE) inhibitors, 
angiotensin 2 receptor blockers (ARB), allopurinol, benzodiazepines, beta-blockers, 
fibrates, fluoroquinolones, non-steroidal anti-inflammatory drugs (NSAIDs), 
trimethoprim and warfarin.190,208 The presence of each drug class were recorded as a 
categorical dichotomous variable. We also created a continous variable to identify 
the total number of unique medications that were used by each patient since it is a 
known factor affecting medication persistence. 
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4.3.6 Statistical Analyses 
In our initial phase of analyses, we compared demographic and clinical characteristics 
between the two exposure groups to determine group comparability.  Differences 
between exposure and non exposure group were assessed using the Pearson's chi-
square test or Fisher exact test in case of  the categorical variables and Student t-test 
or Mann Whitney U test for the continous variables. We also conducted a descriptive 
analysis of the outcome variable and computed the total time to discontinuation SU 
therapy by hypoglycemia exposure status thereby reporting the mean time to 
discontinuation in both groups. 
Since there would be a certain lag between the first prescription of SU to the first 
instance of hypoglycemia in the hypoglycemia exposed cohort, a certain degree of 
immortal time bias was introduced due to the fact that hypoglycemia exposed cohort 
would not experience the discontinuation outcome prior to exposure (Appendix 
4.12).  To account for this phenomena,  we adjusted for during immortal time in the 
exposed group during our statistical analysis.271-273 The schematic representation of 
immortal time bias is shown in Figure 3. We adjusted for this immortal time bias in 
our statistical analyses by moving the start of follow-up or exposed time to the end of 
the immortal period while accounting for the time between cohort entry and 
exposure date as unexposed time. 
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At this stage we had outlined the individual variables which were identified as 
potential confounders during bivariate analyses based on either their clinical 
relevence or their independent bivariate association with hypoglycemic exposure. To 
identify the impact of the hypoglycemia exposure on the persistence of SU therapy in 
terms of time to discontinuation, we developed a time varying Cox proportional-
hazards model that was based upon the estimates of the descriptive bivariate 
analyses in the first phase of analytical process. The anti-log transformation of 
coefficients derived from this model were utilized to calculate Hazard Ratios (HR) 
comparing the relative hazard of discontinuing medication in the hypoglycemia 
exposure group compared to the hypoglycemia non-exposure group while adjusting 
for the immortal time bias in the hypoglycemia exposed group. In the general form of 
the time-varying Cox-Proportional Hazards model is274 
 h(t|X) = h(t) exp(X1β1 + • • • + Xp βp). 
The dependent variable in our model was the time from the first date of SU 
precription to the date of discontinuation of the therapy which was the date on 
which the days of supply of the last prescription ended. The independent variable of 
interest was hypoglycemia exposure, and operationalized as time varying 
(1=hypoglycemia exposure, 0=Hypoglycemia Unexposure). We used the method 
suggested by Suissa et al. in order to define the time varying nature of the 
hypoglycemia exposure. The status of a patient was considered unexposed from the 
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date of the cohort entry until the date of the hypoglycemic event and thereafter 
exposed until the end of follow-up.271,273 
Other confoudning variables that were found significantly associated with 
hypoglycemic were eligible for entry into the model if they had atleast a 10% 
difference between the hypoglycemia exposed and hypoglycemia unexposed groups 
during bivariate anlyses. We then fitted sequential models in a nested manner by 
means of a manual non-computer generated forward stepwise approach. We 
assessed the B-coefficient for the hypoglycemia exposure group from the model at 
each step when the confounding factor was added. If there was a 10% change in the 
B-coefficient for hypoglycemia exposure in the model in comparison to the model 
without the added confounding factor then it warranted the inclusion of the 
confounding factor and it was retained in the model. These stepwise iterations were 
continued until the most parsimonious model was fitted according to the proposed 
criteria.   
Once the preliminary model was fitted, we assessed the mulitcollinearity in the 
retained variables using variance inflation factor (VIF) and the Condition Index (CX).  
If the value of VIF exceeded  5, we considered that there was a high degree of 
multicollinearity between two covariates and warranted one to be removed from the 
model based on the p-value and clinical importance. We further evaluated two-way 
interactions between biologically and clinically plausible variables that were retained 
in the preliminary model. The interaction terms were sequentially added and the 
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model with the interaction term was compared to the model without the interaction 
term by means of likelihood ratio tests. Lastly, we also examined the model for any 
violations of the proportional hazards assumption by visual inspection of the survival 
curves.152,153 We used Akaike Information Criterion (AIC) at all steps of building the 
final model, since AIC is asymptotically equivalent to cross-validation and the 
bootstrap, two most popular validation methods. Also a likelihood test was 
conducted to evaluate the final model. We estimated and reported crude and 
adjusted hazard ratios (HR) and 95% confidence intervals (CI) from the crude and 
final models. 
We also performed a power and sample size calculation based on the rate of 
medication discontinuation. We considered two-sided alpha level constant at 0.05 
and based on our analyses, set the rate of medication discontinuation at 0.60. We 
considered a that a 5% change in the rate of medication discontinuations between 
groups is a clinically meaningful difference thereby setting the regression coefficient 
at 0.05. Since there are no sample size estimations available that take into account 
for the time-varying nature of the exposure for a Cox proportional-hazards model, we 
estimated the power of our study based on time fixed methods. 
All statistical tests were conducted with a two-tailed alpha level of 0.05, and all 
statistical analyses in this study were performed using SAS software (SAS Institute 
Inc., Cary, NC, Version 9.3). Sample size calculations were conducted using using PASS 
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software (2014 version; NCSS, Kaysville,UT). This study was reviewed and approved 
as exempt by the University of Rhode Island’s Institutional Review Board. 
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4.4 Results 
Cohort Identififcation   
The study sample was comprised of 36,954 individuals.  Figures 4.3 and 4.4 give an 
detialed explanation of the patient selection process. During the study period, 9,686 
patients were initiated on SU therapy. Among SU users, 8,229 (85.0%) patients were 
given a 30 day supply of medication while 1,153 patients were given a 90 day supply 
(11.9%). Out of the study sample taking SUs, a  total of 5,390 (55.7%) patients 
recorded only one episode of SU drug use which might indicate complete persistence 
or discontinuation after a single episode of SU use. In contrast about 4.9% of the 
patients on SU therapy recorded more than 5 drug use episodes over the course of 
the study. In this eligible sample of patients, 5,442 (56.2%) patients did not persist to 
their medication and discontinued it at some point during the study follow up period. 
The incidence of discontinuation is presented in Table 4.1. Overall, 2,016 patients 
(34.0%) discontinued their medication. Within the unexposed cohort, 1,996 patients 
(34.0%) discontinued their SU therapy at some point during the post baseline period, 
while 20 patients (36.4%) of the exposed cohort discontinued their medication 
(Χ2=0.14,; p-value: 0.70). 
According to inpatient records in the dataset, a total of 1,295 patients had an 
inpatient hypoglycemic events requiring medical attention occured and 2,368 
patients had an outpatient visits for hypoglycemia occured.  Within the baseline 
period, 139 had a hypoglycemic episode for an overall risk of 0.37% over 3 months.  
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Table 4.2 presents the basic demographic characteristics of the final study sample. 
Age was comparable in the two exposure groups with a mean age (SD) at the index 
date of first SU prescription of 64.9 years [11.21] and 64.5 [12.48] in the 
hypoglycemia group and unexposed group, respectively. Gender distribution was 
similar across the two cohorts with 56.4% of the hypoglycemia-exposed cohort (31 
patients) and 57.2% (3,363 patients) of the patients in the exposed and unexposed 
cohorts respectively being female (Χ2=0.01; p-value: 0.90). Nine patients (16.4%) in 
the exposed cohort were using insulin in the baseline period in contrast to the 533 
patients in the unexposed cohort (9.1%;  Χ2=3.49; p-value: 0.06).  
The prevalence of the comorbidities stratified by hypoglycemic exposure is 
summarized in Table 4.3. The average Charlson’s comorbodity scores (SD) were 
observed to be higher in the hypoglycemic cohort (3.78 [2.82]) as compared to the 
hypoglycemia unexposed cohort (2.45 [2.43]; p value 0.001). Prevalence of all these 
conditions was observed to be notably higher in the hypoglycemia exposed group. 
Chronic pulmonary disease was diagnosed in 14.6% of patients with hypoglycemia in 
contrast to the 4.5% in patients who did not experience hypoglycemia (Χ2=12.68; p 
value=0.0004). Similarly, congestive heart failure was seen 9.1% of the hypoglycemia 
exposed cohort and 3.6% of the hypoglycemia unexposed cohort (Χ2=4.75; p value: 
0.02). Moreover, in the hypoglycemia group, 80% had a diagnosis of uncomplicated 
diabetes and 72.7% were diagnosed with complicated diabetes (Χ2: 3.51, p value: 
0.06). As opposed to the exposed cohort, the unexposed cohort had a lower 
frequency of both diabetes with and without complications (896, 15.24% and 3545, 
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60.30% respectively) (Χ2: 171.41, p value: <0.001). Other factors are presented in 
Table 3 and were consistently higher in the hypoglycemia group versus the non-
exposed group.   
The overview of the microvascular and macrovascular complications associated with 
diabetes is displayed in Table 4.4. Congestive heart failure was much more prevalent 
in the diabetic patients who had an event of hypoglycemia with 9.1% being 
diagnosed with this disorder compared to the 2.7% in the unexposed cohort (Χ2=8.55 
p value: 0.003). Similarly, the patients in the exposed cohort had a higher prevalence 
of coronary artery disease (16.1% vs 10.3%; Χ2=2.33 p-value=0.12). Patients with 
hypoglycemia events had a higher prevalence of diabetic retinopathy (10.9% vs 5.0%, 
Χ2= 29.22; p value=0.04) ulcer (7.3% vs 1.8%; Χ2= 76.89; p value=0.002) and thyroid 
disease (7.3% vs 2.8%; Χ2= 90.17; p value=0.02) in contrast to those who did not 
experience any hypoglycemia events. 
Table 4.5 outlines a brief overview of the other medications that were concomitantly 
used during the baseline period. Of those who exposed an event of hypoglycemia, 
the average number of unique medications used was (8.63 +/- 3.84) which was 
higher than drug use by the patients who did not experience an event of 
hypoglycemia (7.16 +/- 3.67) during the baseline period. Notably, the use of 
benzodiazepines were higher in the hypoglycemia group (14.6%) than in the 
unexposed group (9.0%; Χ2=2.03; p value=0.1535). With respect to other 
medications that were considered for analyses, the unexposed group was found to 
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be using these medications to a higher degree. For example, with in case of warfarin, 
5.9% in the unexposed group and 3.6% in the hypoglycemia group were using this 
medication (Χ2=0.51; p-value=0.47). 
Table 4.6 summarizes the use of other oral antidiabetic medications by the patients 
during the baseline period. 37 patients (67.27%) within the exposed cohort were 
using the biguanide class of oral antidiabetic medications simultaneously during the 
baseline period as compared to 3639 patients (61.90%) in the hypoglycemia 
unexposed group (Χ2= 0.66, p value= 0.41). Similarly, the frequency of use of TZDs 
was higher in the hypoglycemia exposed group with 11 patients (20%) using these 
medications as opposed to the 950 patients (11.11%) in the hypoglycemia unexposed 
group (Χ2=0.59, p value=0.44). The use of alpha glucosidase inhibitors and 
meglitinides was also higher in the hypoglycemia exposed group as compared to the 
hypoglycemia unexposed group (1.82% vs 0.27%, 1.82% vs 0.19% respectively)( Χ2 
4.55, p value=0.03 and Χ2= 7,18, p value= 0.0074 respectively). The frequency of 
using DPP 4 inhibitors was identical in both cohorts with 5 and 505 patients (9.09% 
and 8.59% respectively) in the exposed and unexposed cohort using this medication ( 
Χ2 =0.01, p value= 0.89). 
Estimates for the accrued person time by both the study cohorts as well as the crude 
and adjusted hazards ratios are presented in Table 4.7. Patients in the hypoglycemia 
exposed cohort accrued 12,908 person days of follow up (Mean=234.69) during the 
course of the study period while patients in the hypoglycemia unexposed cohort 
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accrued 1,789,222 days of follow up (Mean=304.31). The misclassified immortal time 
contributed by the patients from the exposed cohort that had to be accounted for as 
unexposed time was estimated to be 2,250 person days of follow-up.  
The results of the Cox Proportional Hazards model are presented in Table 4.7. Age 
and gender were included in the model irrespective of their significance during 
bivariate analyses because of their biological importance. The crude HR for 
discontinuation of SU medication was 1.47 (95% CI: 0.94 – 2.28). After adjusting for 
effects of all the covariates under consideration, the HR for discontinuation of SU 
medication was 1.32 (95% CI: 0.82 – 2.11). Thus, in both unadjusted analyses and 
analyses that adjusted for relevant confounding variables, it could be seen that there 
was a 47% and 32% elevation in the rate of medication discontinuation. Based on our 
sample size, our study had approximately 82% power to detect a hazard ratio of 1.05.
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4.5 Discussion 
Our current study sought to determine the impact of severe hypoglycemic episodes 
requiring medical intervention on the persistence of the oral SU therapy. According 
to our findings, though the patients who experience an event of hypoglycemia in the 
baseline period are approximately 30% more likely to discontinue their medication, 
this association was not statistically significant. To our knowledge, there have been 
no previous studies that have specifically evaluated the impact of hypoglycemia on 
the time to discontinuation of SU medications following hypoglycemic exposure using 
a new user design.  
We utilized an incident user design while conducting this study. This design was 
preferred since it enabled us to capture all the hypoglycemia events that occurred 
soon after initiation of the SU therapy. Ray et al. while reviewing the new user 
designs, clearly state that even with medications, rate of outcomes, both beneficial 
as well as adverse, varies with time since the initiation of therapy with the probability 
of the outcome being the maximum immediately after the start of the medication 
regimen.266 Hence using this design ensured that we accounted for even those 
patients that were more susceptible to hypoglycemic  effects of this medication 
regimen as opposed to other designs that might have been incapable of selecting 
these patients.275 For example, in a study to assess the risk of venous 
thromboembolism (VTE), associated with newer oral contraceptives, Suissa et al. did 
not distinguish between new users, repeaters and switchers and thereby found an 
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excess risk of VTE associated with the use of third generation oral contraceptives. The 
authors recognized the bias in this study and attributed it to the non-differentiation 
between the three different user groups.276 In addition, this type of study design also 
helps alleviate the need to methodically adjust for covariates that lie in the casual 
pathway.266,277  
Though the risk of hypoglycemia is widely recognized in the treatment of Type 1 
Diabetes, there is increasing recognition of this issue in T2DM. Seaquist and 
Associates reported that many trials like the ACCORD and ADVANCE  have suggested 
that T2DM patients might be at a greater risk of adverse events associated with 
instances of hypoglycemia, including mortality.278 Mitchell et al. in an online survey of 
1,329 T2D patients in United Kingdom (UK), found that 23% of patients who used oral 
glucose lowering medications in absence of insulin experienced hypoglycemic 
events.279 Leckie and colleagues conducted a prospective 12-month survey of 243 
employed people to examine the frequency and consequences of hypoglycemia. 
They found the rate of severe hypoglycemic events to be 0.14 episodes per person 
per year  and concluded that this rate was lower than the rates of 1.1–1.7 episodes 
per patient per year that have been reported in previous Northern European 
studies.224   
Our decision to choose the SUs as the drug class of interest was based on the fact 
that it has been traditionally established in various propective and retrospective 
studies that among all the oral antidiabetic medications, SUs are associated with a 
 157 
 
higher propensity to cause hypoglycemic episodes. In our study we found that among 
the 26.2% of patients who were initiated on an oral SU regimen, 3.9% of the patients 
had at least one event of hypoglycemia. In our final study sample, 0.9% of patients 
experienced a hypoglycemic event. Our study indicated a clear evidence of 
recurrence of hypoglycemic events, with patients experiencing multiple 
hypoglycemic incidents requiring medical attention.  
Other studies have reported varying rates for the incidence of hypoglycemic episodes 
with SUs. For example, In the UKPDS, the mean rate of severe hypoglycemic events 
was 18% at the end of 10 years of follow-up. In a study conducted by the UK 
Hypoglycemia Study Group, 39%  of the patients on SU medication reported severe 
hypoglycemic events.213 Miller et al. evaluated the prevalence and risk factors for 
hypoglycemic in 1055 patients with T2DM and found that only 5 patients (0.5%) 
suffered from severe hypoglycemia and that all these patients were insulin users.195 
Van Staa et al., using the UK General Practice Research Database, reported that 1.8% 
users of SUs suffered from an incident of hypoglycemia with patients using 
glibenclamide being at the highest risk.249 Jennings et al. investigated the prevalence 
of hypoglycemia in patients treated with oral hypoglycemic agents and reported that 
20% of patients treated with sulfonylureas had symptoms of hypoglycemia during the 
previous 6 months.253 Bodmer et al. in a case control study to compare the risk of 
lactic acidosis and hypoglycemia among patients with type 2 diabetes using oral 
antidiabetic drugs found the rate of mild/moderate or severe hypoglycemia was 60 
per 100,000 person years for sulfonylureas.197 Thus, in the context of the pertinent 
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issue, the rates that were found in our study are clinical significant findings 
considering the number of patients that receive SU, either alone or as part of 
combination therapy every year even though previous literature has documented a 
relatively low risk of severe hypoglycemia in patients with T2DM. In addition, our 
results could not be satisfactorily compared to these previous studies owing to the 
differences in make-up of the study population, study designs, and definitions of the 
hypoglycemic events. 
We observed the persistence rates to oral SU medications from the cohort entry date 
to the end of follow up period, which was a time span of 1 year. We observed that 
the rate of medication discontinuation in our study was about 34.0%, with almost 
one third of the patients in the exposed cohort discontinuing their medication within 
the 9 month follow-up period. The principal finding of our study indicates that the 
after adjusting for all relevant covariates, patients who are exposed to hypoglycemic 
episodes are approximately 30% more likely to discontinue their medication regimen 
than those who do not experience hypoglycemia, although this finding does not 
attain statistical significance.  
Cramer et al., in their review of literature, reported that the overall average 
persistence rate for oral antihyperglycemic agents was 62.3% with the rate dropping 
to 51.1% for studies conducted in the US.107 It has to be noted however that the 
review failed to take into consideration the potential misclassification of studies as 
well as the class differences in the medications under consideration. In another 
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review investigating adherence to diabetic medications, Cramer et al. noted that the 
rate of people continuing with their medications varied from 16% to 80% during a 
treatment time of 6–24 months while the time to discontinuation of medications was 
83–300 days.108 Similarly, Grégoire et al. found the persistence rates in newly 
initiated SU therapy to be 56% and concluded that in comparison to metformin, SUs 
displayed a poorer persistence profile. However, it was unclear in this study whether 
the discontinuation was due to lack of clinical efficacy, adverse events, or any other 
causes.261 Similarly, Sclar et al., Skaer et al, and Bocuzzi et al. demonstrated rates of 
44%, 58% and 60% respectively for SU therapy during the first year.109,258,280 
Rathmann and colleagues, in a study to investigate therapy persistence and other 
factors in DPP-4 inhibitors and SUs, found the rate of discontinuation with the SUs to 
be 49%, which was 10% higher than that for DPP-4 inhibitors.281 Moreover, it should 
be seen that this study did not take into account the validity of the type of diabetes 
the patients were suffering from as well as the prescribed daily dosages of the 
medications281. In another European study, Jeremendy et al. found that the rate of 
SU persistence was only about 49%.257 
Our estimates should be viewed in light of some important differences with other 
studies. A variety of definitions of persistence have been used in various studies. 
Similarly, it is vital to understand that simply refilling the drug doesn’t necessarily 
indicate persistence and that there are very few suitable means to evaluate the 
actual medication taking behavior of people. Further, in studies of medication 
compliance, it can be seen that the follow up times as well as the defined gap in 
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medication refill in terms number of days can vary largely. In contrast to other 
studies, we regarded a switch to other oral medications as a discontinuation of SU 
therapy, potentially accounting for variation in rates between our study and 
previously published studies.   
While our study was intended to principally analyze the impact of hypoglycemia on 
medication discontinuation, we found some other factors that were significantly 
associated with discontinuation of medication namely age, number of concomitant 
medications as well as use of insulin in the baseline period. It could be seen that the 
increase in age was significantly associated with better persistence to medications. 
This is in agreement with previous studies that have investigated the relationship of 
age and persistence. For instance, Guénette et al. reported that patients aged 54 
years or above were more likely to be persistent to their antidiabetic medications as 
compared with those aged from 18 to 53 with people over the age of 75 being more 
than 44% more likely to persist with their meducations.110 Similarly, Hertz et al. 
demonstrated that younger age was significantly associated with discontinuation of 
medication with patients between ages 17 – 24 being much more likely to have 
discontinued therapy (HR=2.44, 95% CI 1.89 – 3.15) as compared to patients between 
ages 50 and 64.259 One possible explanation for this finding would be greater 
realization of the dependency of their health on therapy as compared to people who 
are younger. Our finding that treatment with insulin was associated with higher 
likelihood of medication discontinuation is supported by previous studies. Catalan et 
al. reported that elderly patients with previous insulin use were 1.59 times less likely 
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to persist with acarbose drug regimen as compared to those who had not received 
insulin.282 Moreover, addition of insulin to SU might exacerbate the risk of having a 
hypoglycemic event thereby increasing the risk of discontinuation. In context of the 
progression of diabetes, poly-pharmacy to meet treatment goals is unavoidable. 
Hence, an interesting finding in our study was an increase in likelihood of continuing 
with therapy when the number of concomitant medications increased. There have 
been contrasting results with respect to polypharmacy and hence treatment 
complexity potentially being a cause of decreased therapy persistence with 
medications. For example, Dailey et al., Donnan et al., and Venturini et al. reported 
decreased compliance with increase in the number of medications.256,283,284 On the 
other hand, Guénette et al. and Hertz et al. reported an increase in the persistence 
rate with higher number of concomitant medications.110,259 Grant el at. found no 
association between multiple medications and sub optimal treatment adherence but 
suggested  rather that side effects of certain drugs caused the non-adherent 
behavior.285  
There is a plethora of literature that provides evidence that complex multifactorial 
relationship between achievement of glycemic objectives, medication compliance, 
and adverse events like hypoglycemia that might in turn affect them. There might be 
a range of clinical and behavioral aspects like adverse events, severity of illness and 
frequency of dosing that might be responsible for a person to adhere to the 
medication regimen. Moreover, with the oral antidiabetic medications, 
hypoglycemia, and fear of hypoglycemia are known limiting factors affecting the 
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rates of medication compliance. Medication tolerability issues like hypoglycemia 
might in turn affect an individual’s perception to perform certain self-care behaviors 
that are essential in the management of diabetes, adhering to medications being one 
of them265. Certain studies have demonstrated that the additional burden placed on 
the patients as a consequence of the physical and psychological distress that is 
associated with incidence of hypoglycemia and its management might prompt them 
to make decisions in order to balance the unpleasant effects with achievement of 
glycemic goals.190 In many cases it has been observed that blood glucose levels are 
eventually compromised in this process.286 Shui et al. in a cross sectional study to 
investigate the fear of hypoglycaemia among 120 insulin-treated patients noted that 
15% of respondents reported high fear with 19.2% of the patients compromised on 
their blood glucose levels.287,288 Leiter and colleagues conducted a study to assess the 
influence of hypoglycemia and fear of future hypoglycemic episodes on patients with 
type 1 or insulin-treated type 2 diabetes. The authors found that among the 133 
insulin-treated type 2 diabetes patients, 29.9% and 84.2% patients reported an 
increased fear of future hypoglycemia following a mild and severe episode of 
hypoglycemia respectively. The authors also suggested that this subsequently 
changed the patient’s willingness to continue with therapy. in a Swedish study of 309 
patients above the age of 35, Lundkvist et al. found that in patients who had 
incidents of hypoglycemia there was lower control of diabetes, worse general health 
and that these patients were more anxious about future hypoglycemic events than 
those without hypoglycemia. The authors concluded such patients exhibited a 
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greater degree of avoidance behavior289. Severity of the hypoglycemic episode often 
leads to reduced satisfaction to diabetes medication regimen, which in turn might 
result in a greater degree of medication discontinuation.290 Although not all the 
aspects of the relationship between fear of hypoglycemia and compliance with the 
medication regimen are entirely clear, it is plausible that it acts as a major barrier to 
patient’s medication taking behavior and thus the management of diabetes.  
.However, since this was a retrospective cohort study using a medical claims 
database, some inherent limitations need to be taken into consideration. With 
respect to the diagnosis of hypoglycemia, it vital to understand that many of the 
hypoglycemia episodes resolve by themselves or get treated without a visit to any 
medical facility. Hence, our estimates of hypoglycemia might represent only a 
fraction of the true extent of this adverse event associated with diabetes therapy. 
Secondly, due to the nature of the datasource, examination of the clinical measures 
of glycemic control and disease severity were not possible and hence the impact of 
these measures on the likelihood of medication discontinuation could not be 
ascertained. Moreover, since the patients might have been on SU medications while 
in other insurance plans, using the incident user design does not necessarily 
guarantee that all the patients in the final sample are newly prescribed SU therapy. 
Our analysis was primarily based on the data from pharmacy drug dispensing. Hence, 
even though we considered failure of the patients to refill their medications as being 
a marker of discontinuation of therapy, in reality, there are no plausible methods to 
understand if this reflected the true use of medications, which might be 
 164 
 
overestimated in case of patients who filled their prescriptions but did not take their 
medications. Also, extending our selection of a 3 month period as a baseline period, 
might have added to the capability to examine a higher number of hypoglycemia 
events. However, it has been seen in previous studies of chronic disease medication 
persistence that majority of events occur within the initial period of medication 
initiation. In addition to this consideration, the nature of hypoglycemia episodes in 
patients as well as the issue of repeated hypoglycemia events was instrumental in 
choosing a baseline period of 3 months.  
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4.6 Conclusions 
Hypoglycemia is a known barrier to optimal use of oral antidiabetic medications, 
especially SUs. Even though we found no statistical association between the 
incidence of hypoglycemia and subsequent persistence to SUs, it is important to take 
into account the implications of hypoglycemic episodes on medication adherence. 
Optimal diabetes management requires timely examination of blood glucose levels 
and reduction in the risk of side effects like hypoglycemia when on therapy. This 
might be beneficial in the long-term well-being as well as the improvement in the 
Quality of Life (QOL) of patients. Further research must be directed towards 
exploring the association between hypoglycemia and other risk factors that might 
have an impact on medication adherence and persistence. This might provide 
invaluable insights into selection of an appropriate medication regimen that would 
provide effective glycemic control and reduction in the risk of sub optimal health 
outcomes. 
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Figure 4.1 Overview of Cohort Study Design: Exposure To Severe Hypoglycemia With An 
Outcome Of Medication Discontinuation 
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Figure 4.2: Detailed Overview Of Study Timeline 
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Figure 4.3: Detailed Cohort Selection of BCBSRI Enrollees 
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Figure 4.4: Characterization Of The Association Between A Hypoglycemia Event 
And Medication Discontinuation 
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Table 4.1: Frequency Of Patients Who Were Persistent/Non-Persistent with Sulfonylurea 
Therapy Stratified By Exposure To Hypoglycemia 
Hypoglycemia 
Outcome 
Non Discontinued Discontinueda Total (%) 
No Hypoglycemia 3,883 1,996 5,879 (99.08) 
Hypoglycemia 35 20 55     (0.92) 
TOTAL 3,918 2,016 5,934 
a: Discontinuation: Defined as a gap of > 30 days between the end of day’s pf supply of the preceding prescription 
and refill of the next prescription. 
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Table 4.2: Demographics Stratified by Exposure to Hypoglycemia 
Demographic 
Characteristics 
Hypoglycemia 
(N = 55)  
No Hypoglycemia 
(N = 5879) 
P Value 
 Mean +/- STD.DEV  
Age (Years)a 64.87  +/-   11.21 64.46  +/-  12.48 <0.001* 
    
Genderb N (%)  
Male 31 (56.36) 3363 (57.20%) 0.900 
Female 24 (43.64) 2516 (42.80%)  
a:  Mean + Std. Dev & the T Test were used to compare continuous variables. 
*: Significance at p value 0.05 as derived from T Test. 
b:  n (%) & Cochran-Mantel-Haenszel statistic was used to compare categorical variables. 
+:Significance at p value 0.05 as derived from Fischer’s Exact Test. 
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Table 4.3: Prevalence of Comorbidities Stratified by Exposure to Hypoglycemia 
Comorbidity  
Hypoglycemia 
(n=55) 
No 
Hypoglycemia 
(n=5879) 
P-Value 
Charlson’s Comorbidity Index 
Charlson’s Comorbidity Scorea  3.78    +/-   2.82  2.45  +/-  2.43 <0.001
^
 
Elixhauser Comorbidity Indexb 
AIDS/HIV 0 (0.00)   4 (0.07) 0.8466 
Alcohol Abuse 0 (0.00) 12 (0.20) 0.7373 
Blood Loss Anemia 0 (0.00) 21 (0.36) 0.6570 
Cardiac Arrhythmias 1 (1.82)      364 (6.19) 0.1791+ 
Chronic Pulmonary Disease   8 (14.55)      263 (4.47) 0.0004+ 
Coagulopathy 1 (1.82) 18 (0.31) 0.0482+ 
Congestive Heart Failure 5 (9.09)      210 (3.57) 0.0292+ 
Deficiency Anemia 2 (3.64) 95 (1.62) 0.2395+ 
Depression 3 (5.45)      235 (4.00) 0.5835 
Diabetes Complicated 44 (80.00)      896 (15.24) <0.001* 
Diabetes Uncomplicated 40 (72.73)    3,545 (60.30) 0.0607* 
Drug Abuse 0 (0.00)  11 (0.19) 0.7481 
Fluid And Electrolyte Disorders 1 (1.82)  58 (0.99) 0.5361 
Hypertension, Complicated 1 (1.82)         60 (1.02) 0.5594 
Hypertension, Uncomplicated   9 (16.36) 1,248 (21.23) 0.3795 
Hypothyroidism 4 (7.27) 155 (2.64) 0.0341+ 
Liver Disease 2 (3.64)   71 (1.21) 0.1039+ 
Lymphoma 0 (0.00)   24 (0.41) 0.6349 
Solid tumor without metastasis 3 (5.45) 276 (4.69) 0.7910 
Metastatic Cancer 0 (0.00)   10 (0.17) 0.7595 
Obesity 0 (0.00)   30 (0.51) 0.5953 
Other Neurological Disorders 1 (1.82)   40 (0.68) 0.3106 
Paralysis 0 (0.00)    6  (0.10) 0.8126 
Peptic Ulcer Disease Excluding Bleeding 0 (0.00)    2 (0.03) 0.8912 
Peripheral Vascular Disorders   6 (10.91)       247 (4.20) 0.0143+ 
Psychoses 0 (0.00) 24 (0.41) 0.6349 
Pulmonary Circulation Disorders 1 (1.82) 29 (0.49) 0.1679+ 
Renal Failure 5 (9.09) 110 (1.87) 0.0001+ 
Rheumatoid Arthritis/ Collagen Vascular 
Diseases 
1 (1.82)  77  (1.31) 0.7418 
Valvular Disease 0 (0.00) 104 (1.77) 0.3197 
Weight Loss 0 (0.00)     8 (0.14) 0.7843 
a: Mean + (Std. Dev) & the T test was used to compare overall Charlson’s Index. 
^: Significance at p value 0.05 as derived from T Test. 
b: n (%) & the Cochran-Mantel-Haenszel statistic / Fischer’s Exact Test were used to compare categorical variables. 
*: Significance at p value 0.05 as derived from Chi-square. 
+:  Significance at p value 0.05 as derived from Fischer’s Exact Test due to smaller sample sizes. 
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Table 4.4: Prevalence of Micro and Macrovascular Diabetes Complications, Other 
Contributing Diseases  Stratified by Exposure to Hypoglycemia 
Diabetes Complications Hypoglycemia 
(n=55)  
No Hypoglycemia 
(n=5879) P-Value 
Macrovasculara 
Arrhythmia 1   (1.82) 259   (4.41)  0.3508 
Congestive Heart Failure 5   (9.09) 159   (2.70) 0.0034+ 
Coronary Artery Disease 9 (16.13) 603 (10.26) 0.1383+ 
Peripheral Vascular Disease 7 (12.73) 725 (12.33) 0.9293 
Stroke 0   (0.00) 27     (0.46) 0.6144 
Microvasculara 
Acute Renal Failure   1   (1.82) 39 (0.66) 0.2975 
Amputation  0   (0.00) 2   (0.03) 0.8912 
Chronic Renal Pathophysiology  1   (1.82) 33   (0.56) 0.2190 
Dialysis  0   (0.00) 9     (0.15) 0.7755 
End Stage Renal Disease  0   (0.00) 0     (0.00) NA^ 
Diabetic Nephropathy 0   (0.00) 41   (0.70) 0.5343 
Diabetic Retinopathy  6 (10.91) 293 (4.98) 0.0455+ 
Ulcer   4   (7.27) 104 (1.77) 0.0024+ 
Other Contributing Diseasesa 
Addison's Disease 0 (0.00) 2     (0.03) 0.8912 
Liver Disease 1 (1.82) 52   (0.88) 0.4638 
Thyroid Disease 4 (7.27) 146 (2.78) 0.0243+ 
a:  n (%) & the Fischer’s Exact Test were used to compare categorical variables due to smaller sample sizes. 
+: Significance at p value 0.05 as derived from Fischer’s Exact Test. 
^: No p value calculated due to 0 sample size. 
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Table 4.5: Concomitant Usage of Non-Diabetic Medications Stratified by Exposure to 
Hypoglycemia 
Medications 
Hypoglycemia 
(N = 55) 
No Hypoglycemia        
(N = 5879) 
P-Value 
Overall Medication Usea 
Number Of Medications 8.63 +/- 3.84 7.16 +/- 3.37 <0.001* 
Use Of Other Non-Diabetic Medication Classesb 
ACE Inhibitors 25 (45.45) 2958 (50.31) 0.4730 
Allopurinol 3     (5.45) 222    (3.78) 0.5165 
Angiotensin II Receptor Blockers 
(ARBs) 
1    (1.82) 174    (2.96) 0.6184 
Benzodiazepines 8  (14.55) 529    (9.00) 0.1535+ 
Beta-Adrenergic Blocking 
Agents 
22 (40.00) 2149 (36.40) 0.5809 
Fibrates 9  (16.36) 608 (10.34) 0.1453+ 
Fluoroquinolones 6  (10.91) 320  (5.44) 0.0766+ 
Nonsteroidal Anti-Inflammatory 
Drugs 
8  (14.54) 624  (10.61) 0.3468 
Trimethoprim 0    (0.00) 3    (0.05) NA^ 
Warfarin 2    (3.64) 348   (5.92) 0.4744 
a:  Mean + Std. Dev  & the T Test was used to compare continuous variables. 
*: Significance at p value 0.05 as derived from T Test. 
b:  n (%) & the Fischer’s Exact Test were used to compare categorical variables.  
+: Significance at p value 0.05 as derived from Fischer’s Exact Test. 
^: No P value calculated due to 0 sample size in hypoglycemia group. 
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Table 4.6: Usage of Other Oral Diabetic Medications Stratified by Exposure to 
Hypoglycemia 
Concomitant Medicationsa 
Hypoglycemia 
(N = 55) 
No Hypoglycemia        
(N = 5879) 
P-Value 
Insulin 9  (16.36) 533     (9.07) 0.0060+ 
Biguanides 37  (67.67) 3639   (61.90) 0.4139 
Thiazolidinediones 11  (20.00) 950   (16.16) 0.4415 
Alpha Glucosidase Inhibitors 1    (1.82)  16     (0.27) 0.0327+ 
Meglitinides 1    (1.82) 11     (0.19) 0.0074+ 
Dipeptidyl Peptidase 4 Inhibitors 505    (8.50)  5     (9.09) 0.8950 
a:  n (%) & the Fischer’s Exact Test were used to compare categorical variables.  
+:Significance at p value 0.05 as derived from Fischer’s Exact Test. 
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Table 4.7: Descriptive Statistics Of Follow-Up Time, Stratified By Exposure To Hypoglycemia 
And The Effect Of Hypoglycemia On Sulfonylurea Medication Discontinuation 
 
Hypoglycemia 
Status 
S. 
Size 
Person 
Days Of 
Follow Up 
Discont’d 
Patients 
Crude HR 
(95% CI) 
Adjusted HR 
(95% CI) 
No 
Hypoglycemia 
5,879 1789147* 1996 1.00 (REF)  1.00 (REF) 
Hypoglycemia 55 12908** 20 
1.47  
(0.94 2.11)
 +
 
1.32 
(0.82 1.88)
++
  
*Includes Time From Cohort Entry To Sooner Of Date Of Discontinuation, Date Of Hypoglycemia Or End 
Of Study Period. 
**Includes Time From Cohort Entry To Date Of Hypoglycemia Exposure. 
+ Derived From A Time-dependent Exposure Cox Proportional-hazards Model With SU  Medication 
Discontinuation As The Outcome Variable And Exposure Status As The Time-dependent Independent 
Variable. 
++Derived From A Time-dependent Exposure Cox Proportional-hazards Model Adjusted For Age, Gender, 
Number Of Medications, Insulin Use, Congestive Heart Failure, Cardiac Arrthymia, Pulmonary Circulation 
Disorder, Peripheral Vascular Disorder, Diabetes (Complicated And Uncomplicated), Hypothyroidism, 
Renal  Failure, Liver Disease, Coagulopathy, Deficiency Anemia, Depression, Retinopathy, Ulcer, 
Fluoroquinolones,  Fibrates , Benzodiazepines, Biguanides, Tzd, Alphaglucosidase  Inhibitors, Meglitinides. 
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Appendix 1: Population Characteristics Of The Respondents With Diabetes Within  
The MEPS 2008-2011 
Variables  Unwtd Freq 
 (4668) 
Wtd % 
Age   
18-34 204 4.37 
35-49 816 17.48 
50-64 1777 38.07 
65 And Above 1631 34.94 
Missing 240 5.14 
   
Gender   
Male 2065 44.24 
Female 2603 55.76 
   
Marital Status   
Married 2619 56.11 
Widowed/Divorced/Separated 1535 32.88 
Never Married 514 11.01 
   
Income Level   
Poor/Near Poor 1170 25.06 
Low Income 782 16.75 
Middle Income 1413 30.27 
High Income 1303 27.91 
   
Education Level   
Less Than High School 1381 29.58 
High School 2068 44.30 
Advanced Education 831 17.80 
Others 370 7.93 
Missing 18 0.39 
   
Race/Ethnicity   
Hispanic 1042 22.32 
White Non Hispanic 2221 47.58 
Black Non Hispanic 1026 21.98 
Others 379 8.12 
   
Percieved Health Status   
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Excellent/Very Good 1133 24.27 
Good 1839 39.40 
Fair/Poor 1696 36.33 
   
Insurance Coverage   
Any Private 2624 56.21 
Public Only 1562 33.46 
Uninsured 482 10.33 
   
Insulin Use   
Yes 1363 29.20 
No 770 70.44 
Missing 4 0.36 
   
MSA Status   
NON MSA 833 17.84 
MSA 3835 82.16 
   
Employment Status   
Employed 2065 44.24 
Not Employed 2599 55.68 
Missing 4 0.09 
   
BMI Status   
Under /Normal 646 13.84 
Over 3923 84.04 
Missing 99 2.12 
   
Smoking Status   
Yes 647 13.86 
No 3930 84.19 
Missing 91 1.95 
   
Primary Care Provider   
Yes 4299 92.10 
No 342 7.33 
Missing 27 0.58 
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Appendix 2 : Sample Panel Design For MEPS 
 
 
 
Quality AfHRa. Medical Expenditure Panel Survey, Household Component, MEPS-HC Panel Design and Data Collection 
Process. 2013; http://meps.ahrq.gov/mepsweb/survey_comp/hc_data_collection.jsp. Accessed 01 September, 2014. 
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Appendix 3: List of Product Names For Sulfonylurea Medications 
 
AMARYL 
AVANDARYL 
CHLORAL HYDR 
CHLORAMPHEN 
CHLORPROMAZ 
CHLORPROPAM 
DIABETA 
GLIMEPIRIDE 
GLIPIZIDE 
GLIPIZIDE ER 
GLIPIZIDE XL 
GLUCOTROL 
GLUCOTROL XL 
GLUCOVANCE 
GLYBURID MCR 
GLYBURIDE 
METAGLIP 
TOLBUTAMID 
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Appendix 4: Frequency OF Drug Episodes For The Study Population 
Number of Drug Episodesa Frequency Percentage(%) 
1 5408 55.72 
2 2107 21.71 
3 953 9.82 
4 467 4.81 
5 297 3.06 
6 172 1.77 
7 114 1.17 
8 75 0.77 
9 51 0.52 
10 25 0.25 
11 17 0.17 
12 11 0.11 
13 5 0.05 
15 2 0.02 
a: Separate episodes are defined by a gap of > 30 days between the end of days pf supply of the 
preceding prescription and refill of the next prescription   
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Appendix 5: Ginde and Colleagues‐Algorithm to Identify Cases of Hypoglycemia 
 
 
Ginde AA, Blanc PG, Lieberman RM et al.  Validation of ICD-9-CM coding algorithm for 
improved identification of hypoglycemia visits. BMC Endocr Disord. 2008;8:4
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Appendix 6: Total Number Of Patients With First Episodes Of Hypoglycemia Within The Study 
Period Stratified By The Baseline And Post Baseline Timeline 
 
Study Timeline period  Hypoglycemia Frequency Percentage(%) 
Baseline Perioda 139 36.68 
Post-Baseline Periodb 240 63.32 
a: Baseline Period : 90 days starting from the first prescription of a sulfonylurea. 
b: Post baseline period : 9 months starting from the end of baseline period until the end of study period. 
 
Appendix 7: Frequency For Discontinuation Of Sulfonylurea Medication In The Eligible 
Sample Population 
Discontinuation Outcome  Frequency Percentage(%) 
Discontinuationa 5442 56.08 
No Discontinuation 4262 43.92 
a: Discontinuation : Defined as a gap of > 30 days between the end of days pf supply of the preceding prescription 
and refill of the next prescription   
 
 
Appendix 8: Frequency For Outcomes During The Study Timeline In The Eligible Sample 
Population 
Outcome  Frequency Percentage(%) 
Discontinuationa 5442 56.08 
Censoredb 184 1.89 
End Of Study Periodc 4078 42.03 
a: Discontinuation : Defined as a gap of > 30 days between the end of days pf supply of the preceding prescription 
and refill of the next prescription  
b: Censored : Defined as an event of hypoglycemia occurring in the post baseline period. 
c: End of study period : Patients who were followed till the end of study period were free of the outcome of 
discontinuation or exposure to hypoglycemia within the post baseline period. 
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Appendix 9: Charlson’s Comorbidity Index 
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining Comorbidities in ICD-
9-CM and ICD-10 administrative data. Med Care. 2005 Nov; 43(11): 1130-9. 
 
Myocardial Infarction:  410.X, 412.X 
Congestive Heart Failure:   398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 425.4-
-425.9, 428.X 
Peripheral Vascular Disease:   093.0, 437.3, 440.X, 441.X, 443.1--443.9, 447.1, 557.1, 557.9, V43.4 
Cerebrovascular Disease:   362.34, 430.X--438.X 
Dementia:   290.X, 294.1, 331.2 
Chronic Pulmonary Disease:   416.8, 416.9, 490.X--505.X, 506.4, 508.1, 508.8 
Rheumatic Disease:   446.5, 710.0--710.4, 714.0--714.2, 714.8, 725.X 
Peptic Ulcer Disease:   531.X--534.X 
Mild Liver Disease:   070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 070.6, 070.9, 570.X, 571.X, 573.3, 573.4, 
573.8, 573.9, V42.7 
Hemiplegia Or Paraplegia :  334.1, 342.X, 343.X, 344.0--344.6, 344.9 
Renal Disease:   403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 582.X, 583.0--583.7, 
585.X, 586.X, 588.0, V42.0, V45.1, V56.X 
Any Malignancy, Including Lymphoma And Leukemia, Except Malignant Neoplasm Of Skin:    140.X--172.X, 174.X--
195.8, 200.X--208.X, 238.6 
Moderate Or Severe Liver Disease:   456.0--456.2, 572.2--572.8 
Metastatic Solid Tumor:   196.X--199.X 
AIDS/HIV :  042.X--044.X
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Appendix 10: Elixhauser Comorbidity Index 
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining Comorbidities in ICD-9-CM and 
ICD-10 administrative data. Med Care. 2005 Nov; 43(11): 1130-9.  
Peptic Ulcer Disease Excluding Bleeding:  531.7, 531.9, 532.7, 532.9, 533.7, 533.9, 534.7, 534.9  
AIDS/H1V:  042.x‐‐044.x 
Lymphoma: 200.x‐‐202.x, 203.0, 238.6 
Metastatic Cancer:  196.x‐‐199.x 
Solid Tumor without Metastasis:  140.x‐‐172.x, 174.x‐‐195.x 
Rheumatoid Arthritis/Collagen Vascular Diseases:  446.x, 701.0, 710.0‐‐710.4, 710.8, 710.9, 711.2, 
714.x, 719.3, 720.x, 725.x, 728.5, 728.89, 729.30 
Coagulopathy:   286.x, 287.1, 287.3‐‐287.5 
Obesity:   278.0 
Weight loss:   260.x‐‐263.x, 783.2, 799.4 
Fluid and Electrolyte Disorders:   253.6, 276.x 
Blood Loss Anemia:   280.0 
Deficiency Anemia :  280.1‐‐280.9, 281.x 
Alcohol Abuse:   265.2, 291.1‐‐291.3, 291.5, 291.9, 303.0, 303.9, 305.0, 357.5, 425.5, 535.3, 571.0‐‐
571.3, 980.x, V11.3 
Drug Abuse:   292.x, 304.x, 305.2‐‐305.9., V65.42 
Psychoses:   293.8, 295.x, 296.04, 296.14, 296.44, 296.54, 297.x, 298.x 
Depression:   296.2, 296.3, 296.5, 300.4, 309.x, 311 
Congestive Heart Failure:   398.91, 402.01, 402.11. 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 
404.93, 425.4-425.9, 428.x 
Cardiac Arrhythmias:   426.0, 426.13, 426.7, 426.9, 426.10, 426.12, 427.0-427.4, 427.6-427.9, 785.0, 
996.01, 996.04, V45.0, V53.3 
Valvular Disease:   093.2, 394.x-397.x, 424.x, 746.3-746.6, V42.2, V43.3 
Pulmonary Circulation Disorders:    415.0, 415.1, 416.x, 417.0, 417.8, 417.9 
Peripheral Vascular Disorders:   440.x, 441.2, 441.4, 441.7, 441.9, 443.1, 443.9, 447.1, 557.1, 557.9, 
V43.4 
Hypertension, Uncomplicated:   401.x 
Hypertension, Complicated:   402.x-405.x 
Paralysis:   334.1, 342.x, 343.x, 344.0 344.6, 344.9 
Other Neurological Disorders:  331.9, 332.0, 332.1, 333.4, 333.5, 333.92, 334.x-335.x, 336.2, 340.x, 
341.x, 345.x, 348.1, 348.3, 780.3, 784.3 
Chronic Pulmonary Ddisease:  416.8, 416.9, 490.x-505.x, 506.4, 508. 1, 508.8 
Hypothyroidism:   240.9, 243.x, 244.x, 246.1, 246.8 
Renal Failure:   403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 585.x, 586.x, 
588.0, V42.0, V45.1, V56.x 
Liver Disease:   070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 070.6, 070.9, 456.0-456.2, 570.x, 
571.x, 572.2-572.8, 573.3, 573.4, 573.8, 573.9, V42.7
 191 
 
Appendix 11: Diabetes Complications 
 
Meduru P, Helmer D, Rajan M, Tseng CL, Pogach L, Sambamoorthi U. Chronic illness with complexity: 
implications for performance measurement of optimal glycemic control. J Gen Intern Med. 2007;22 
Suppl 3:408-18. PMCID: 2150612. 
 
Diabetes-related complexity 
 
Macrovascular complications 
 
Coronary artery disease:  410, 410.0, 410.00, 410.01, 410.02, 410.1, 410.10, 410.11, 410.12, 410.2, 
410.20, 410.21, 410.22, 410.3, 410.30, 410.31, 410.32, 410.4, 410.40, 410.41, 410.42, 410.5, 410.50, 
410.51, 410.52, 410.6, 410.60, 410.61, 410.62, 410.7, 410.70, 410.71, 410.72, 410.8, 410.80, 410.81, 
410.82, 410.9, 410.90, 410.91, 410.92, 411.0, 411.1, 411.8, 411.81, 411.89, 412, 413, 413.0, 413.1, 
413.9, 414, 414.0, 414.00, 414.01, 414.02, 414.03, 414.04, 414.05, 414.1, 414.10, 414.11, 414.19, 
414.8, 414.9 
Congestive heart failure:  402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 428, 428.0, 428.1, 428.9 
Arrhythmia 423, 423.0, 423.1, 423.2, 423.8, 423.9, 427.31 
Stroke 431, 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91 
Peripheral vascular disease:  250.7, 250.70, 250.71, 250.72, 250.73, 440.2, 440.20, 440.21, 440.22, 
440.23, 440.24, 440.29, 440.8, 440.9, 442.2, 442.3, 443, 443.0, 443.1, 443.8, 4438.1, 443.89, 443.9, 
444.22, 444.81 
 
Microvascular complications 
 
Chronic renal pathophysiology:  274.1, 274.10, 274.11, 274.19, 403.10, 403.90, 404.10, 404.11, 404.90, 
404.91, 581, 581.0, 581.1, 581.2, 581.3, 581.8, 581.9, 582, 582.0, 582.1, 582.2, 582.4, 582.8, 582.81, 
582.89, 582.9, 583, 583.0, 583.1, 583.2, 583.4, 583.6, 583.7, 583.8, 583.81, 583.89, 583.9, 583, 583.0, 
583.1, 583.2, 583.4, 583.6, 583.7, 583.8, 583.81, 583.89, 583.9, 590.0, 590.00, 590.01, 593.6, 593.9, 
753.12, 753.13, 753.14 
Diabetic nephropathy:  250.4, 250.40, 250.41, 250.42, 250.43 
Acute renal failure:  403.00, 403.01, 404.00, 404.01, 404.02, 404.03, 405.01, 453.3, 584, 584.5, 584.6, 
584.7, 584.8, 584.9, 580, 580.0, 580.4, 580.8, 580.81, 580.89, 580.9, 590.1, 590.10, 590.11, 590.2, 
590.3, 590.8, 590.80, 590.81, 593.81, 866, 866.0, 866.00, 866.01, 866.02, 866.03, 866.1, 866.10, 
866.11, 866.12, 866.13 
End-stage renal disease:  V56.xx, 458.21, E87.91, V45.1 
Dialysis:  389.5, 392.7, 394.2, 394.3, 399.5, 549.8 
Diabetic retinopathy:  362.0, 362.01, 362.02, 250.50, 250.51, 250.52, 250.53 
Ulcer:  700, 681.10, 681.11, 682.7, 707.1, 730.76, 730.77 
Amputation:  841.1, 841.2, 841.3, 841.4, 841.5, 841.6, 841.7, 841.8, 841.9 
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Appendix 12: Testing the Proportionality Assumption 
 
 
 
 
 
In the above figure, the curves do not cross each other thereby indicating that the 
assumption of proportionality is not violated. A time varying exposure variable was created 
in order to confirm this assumption and it could be seen that it reiterated the satisfaction of 
this assumption since it was insignificant.(a significant variable would indicate violation).
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Appendix 13: Observed Scenarios For Medication Refill And Persistence Patterns 
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Appendix 14: Description Of Hypoglycemia Exposed And Unexposed Patients As An Example 
Of Classifying Immortal Time Bias As Unexposed Time. 
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